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1.1 The eye
The eye is a sensory organ that is responsible for capturing and processing visual 
information. The eye can be divided into an anterior part and a posterior part. The anterior 
part of the eye consists of the cornea, anterior chamber, conjunctiva, pupil, ciliary body 
and lens. The posterior part of the eye is formed by the vitreous body, choroid, retina and 
optic nerve. Light enters the eye via the pupil and goes through the cornea and the lens 
to the back of the eye where it reaches the retina. Here, light is converted into an electrical 
signal that leaves the eye via the optic nerve to visual centers in the brain (Figure 1.1).
Figure 1.1. Anatomy of the eye. 
The anterior segment of the eye contains the cornea, conjunctiva, pupil, ciliary body and lens. The 
posterior segment consists of the vitreous body, retina, choroid and optic nerve.
1.2 Anatomy of the retina
The retina, that lines the inner surface of the eye, is a layered structure with highly 
specialized cells that together are responsible for converting light into an electrical signal. 
Basically, the retina consists of an outer pigmented layer and an inner layer, which is called 
the neural retina. The retina is composed of ten primary layers that are formed by multiple 
different cell types (Figure 1.2).
The most posterior layer of the retina is formed by a monolayer of pigmented cells, called 
the retinal pigment epithelium (RPE). The RPE separates the neural retina from the 
choroid, and is involved in the transport of nourishing components from the choroid to 
the neural retina. Furthermore, the RPE supports the adjacent photoreceptor cells, such 
that they can function properly. Most importantly, RPE cells play an important role in 
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1,2 The photoreceptor cell layer 
is the outer most layer of the neural retina and consists of the outer segments of rod and 
cone photoreceptor cells. The third layer is the external limiting membrane, also called 
outer limiting membrane, which is made of adherens junction and tight junction proteins, 
and serves to support the maintenance of the retinal structure through mechanical 
strength.3,4 The cell bodies of the photoreceptor cells are forming the outer nuclear 
layer. Cone pedicles or rod spherules form synapses with the dendrites of bipolar cells 
and processes of horizontal cells in the outer plexiform layer. The synaptic interactions 
that take place in the outer plexiform layer play a role in increasing contrast and thereby 
enhancing the ability to detect objects.5 The sixth layer contains cell bodies of the amacrine, 
bipolar and horizontal cells, and is called the inner nuclear layer. Bipolar cells receive 
synaptic input from the photoreceptor cells and transmit this to the ganglion cells. Two 
types of bipolar cells can be distinguished: on-center bipolar cells and off-center bipolar 
cells. Photoreceptors are depolarized in the dark and release glutamate, which activates 
off-center bipolar cells. Light triggers the release of glutamate by the photoreceptor cells, 
thereby activating on-center bipolar cells.6 Horizontal cells are laterally oriented neurons, 
which integrate and regulate the information from photoreceptor cells. In the inner 
plexiform layer, axons of the bipolar cells connect with the dendrites of ganglion cells. 
Amacrine cells form the connection between bipolar cells and ganglion cells. The ganglion 
cell layer is the eighth layer of the retina and contains cell bodies of ganglion cells and 
some displaced amacrine cells. The axons of the ganglion cells form the next layer: the 
nerve fibre layer. The axons of the ganglion cells are collected in a bundle of fibres by the 
optic nerve. Ganglion cells collect information from amacrine cells and bipolar cells and 
transfer this to the optic nerve, via which the electrical signal is send to the brain. Finally, 
the tenth layer, closest to the vitreous body and called the inner limiting membrane, is 
composed of astrocytes and terminations of the Müller cells. Astrocytes originate from 
the brain and enter the retina along the developing optic nerve. They are important for 
the maintenance of the blood-retina barrier, form nutritive service to the neurons, and 
play a role in ionic homeostasis.7,8 The major role of Müller cells is to give structural and 
functional support to other retinal cells. They regulate uptake of neurotransmitters, are 
involved in phagocytosis of neural debris, control homeostasis by taking up extracellular 
K+, and play a role in the storage and breakdown of glycogen.9,10 In addition, Müller cells 
play a role in the recycling of chromophore in the alternative retinal cycle that involves 
cones.11
1.3 Photoreceptor cells
There are two types of light-sensitive photoreceptors, namely rods and cones. Humans 
have approximately 130 million photoreceptor cells, with twenty times more rods than 
cones.12 Rods are mainly located in the mid-periphery of the retina and are stimulated by 
dim light, whereas cones are stimulated by bright light. Therefore, rods are responsible 
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for peripheral vision and vision under dim light conditions, whereas cones are mainly 
responsible for central vision, colour vision and allow high visual acuity.12,13 In the human 
retina, three cone subtypes can be distinguished: S-, M- and L-cones or blue, green and 
red cones respectively. The S-cones are dispersed through the entire retina, whereas the 
M- and L-cones cluster in the fovea. The S-cones are sensitive to supra-frequency photons 
(λmax~415–430 nm), the M-cones to middle-frequency photons (λmax~530–537 nm), 
and the L-cones to low-frequency photons (λmax~555–565 nm).14 The center of the 
human retina contains an area enriched with cone photoreceptors, called the fovea, which 
has the highest visual acuity of the retina.15,16 Both rods and cones have an outer and 
inner segment, a cell body that contains the nucleus, and a synaptic end (Figure 1.3).17 The 
outer segment of the photoreceptor is in direct contact with RPE cells, while the synapses 
of the photoreceptors are connected to bipolar cells, horizontal cells and amacrine cells. 
The inner segment is the place where protein synthesis occurs and the outer segment 
is responsible for the actual phototransduction, i.e. capturing photons and producing 
electrical responses. The inner segment is linked to the outer segment by the connecting 
cilium (CC), a microtubule-based structure that is important for transport of proteins from 
the inner segment to the outer segment. The outer segment consists of disks that are 
formed by invaginations of the plasma membrane.13 Outer segments therefore have a 
high density of membranes that contain visual pigments responsible for capturing light. 
The outer segment disks are constantly renewed. Around 10% of the photoreceptor disks 
are shed and phagocytized by the RPE every day. Simultaneously, new membrane disks 
Figure 1.2. Anatomy of the retina. 
The retina is a multi-layered structure composed of different cell types: retinal pigment epithelium 
(RPE), photoreceptor cells (rods and cones), horizontal cells, bipolar cells, Müller cells, amacrine cells 
and ganglion cells. All together, these cells are responsible for converting light into an electrical 
signal that goes to the brain. This picture was kindly provided by Rozan Vrooman.
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function and homeostasis.18,19
Figure 1.3. Schematic representation of the photoreceptor cells. 
Both rod (left panel) and cone (right panel) photoreceptor cells are composed of an outer segment, 
a cell body that contains the nucleus, and an inner segment. The inner segment is connected with 
the outer segment by the connecting cilium (CC). BB: basal body of the connecting cilium. Adapted 
from Slijkerman et al.20
1.3.1 The phototransduction cascade
Phototransduction takes place in the outer segment of the photoreceptor cells. In rods, 
the phototransduction cascade is initiated by rhodopsin. Basically, the absorption of light 
by rhodopsin activates a G-protein cascade that results in an electrical signal at the plasma 
membrane of the rod photoreceptor.21 Rhodopsin consists of two components, a light-
sensitive G-protein coupled receptor called opsin and a chromophore, 11-cis-retinal.22 
When a photon is absorbed by the photoreceptor cell, the chromophore isomerizes 
from 11-cis-retinal to all-trans-retinal, which in turn changes rhodopsin to its active 
state.23 Activated rhodopsin catalyses the exchange of GDP for GTP, thereby activating 
the G-protein transducin.12 The α-subunit of transducin dissociates and then activates 
cGMP-phosphodiesterase, which in turn hydrolyses cGMP in the cytoplasm. In response 
to decreased cGMP concentrations, cGMP-gated ion channels in the plasma membrane 
will close. This leads to hyperpolarisation of the cells and a decrease in the release of the 
neurotransmitter glutamate to the synapse with the bipolar cells.23 Glutamate activated 
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bipolar cells transfer the signal to the ganglion cells, which in turn transfer the signal in the 
form of action potentials via the optic nerve to visual centers in the brain.
1.4 Inherited retinal diseases
Inherited retinal diseases (IRDs) are a group of blinding disorders generally characterized 
by a progressive degeneration of retinal cells. They affect approximately 1 in 2,000 
individuals worldwide.24 IRDs are genetically heterogeneous and have been associated 
with mutations in more than 250 genes (RetNet http://www.sph.uth.tmc.edu/Retnet). The 
large majority of IRDs are monogenic disorders, and are caused by mutations in genes that 
are expressed in photoreceptor cells or RPE cells. IRDs can follow all modes of Mendelian 
inheritance, i.e. autosomal dominant (ad), autosomal recessive (ar) and X-linked, and can 
be divided into different subtypes with varying clinical hallmarks, degree of progression, 
and age of onset. A few examples of digenic inheritance have been reported.25,26 The 
distinction between different forms of IRDs can be very subtle, due to overlap in clinical 
symptoms and genetic causes. Retinal diseases can either present as a clinical phenotype 
restricted to the eye (non-syndromic IRD), or manifest together with other disorders 
located elsewhere in the body (syndromic IRD). Usher syndrome, Joubert syndrome and 
Bardet-Biedl syndrome are examples of syndromic types of IRD. Non-syndromic IRDs can 
be further divided in subgroups based on the disease progression and region of the retina 
that is affected. Progressive conditions affecting exclusively the central retina (macula), 
leading to central vision loss, are known as macular dystrophies, of which Stargardt 
disease is the most common form. Progressive conditions that affect the retina more 
widely can be classified based on the type of photoreceptor that initially degenerates. 
In cone dystrophy (CD) or cone-rod dystrophy (CRD), the cones are first affected, leading 
to a decrease of visual acuity and blind/blurry spots in the center of the visual field. In 
contrast, in rod-cone dystrophies, the rods are first affected, which initially leads to night 
blindness and subsequently peripheral vision loss. The most common example is retinitis 
pigmentosa (RP). The clinical hallmarks of RP will be described in more detail in the next 
section. The most severe form of IRD is Leber congenital amaurosis (LCA), affecting both 
photoreceptor cell types and/or the RPE and Müller cells, with a very early age of onset (1 
year) and leading to complete blindness.27
1.4.1 Retinitis pigmentosa
Retinitis pigmentosa is a retinal disorder characterized by progressive degeneration of 
photoreceptor cells. The prevalence of RP is approximately 1 in 4,000 individuals worldwide 
and, like other IRDs, the disease can be inherited in an autosomal dominant, autosomal 
recessive, or X-linked manner.28,29 In most RP cases, there is initial degeneration of rods 
followed by degeneration of cones.30 Retinitis pigmentosa mainly affects rods, however, 
in advanced stages of RP cones are also affected due to the co-dependence of rods and 
cones. In addition, rods secrete an inactive thioredoxin, rod-derived cone viability factor 
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31,32 There is a high variability in the 
clinical manifestation of RP; some patients suffer from vision loss in childhood whereas 
others do not have symptoms until (late) adulthood. The majority of the patients show a 
classic pattern of symptoms, namely night blindness in adolescence followed by loss of 
mid-peripheral vision in young adulthood. When the disease progresses, patients develop 
tunnel vision and finally lose central vision around the age of 60 years. In early stages 
of disease, a clinical diagnosis is difficult to establish, especially when there is no family 
history of RP. In later stages of RP, a clinical diagnosis is possible by fundus examination 
that shows the presence of pigmented deposits, narrowing of the arterioles, and a waxy 
pallor of the optic disc.28 Visual field constriction or tunnel vision can be shown using visual 
field measurements. This test is often used to classify the severity of the disease, and to 
monitor progression, since it can quantitatively show photoreceptor degeneration as well 
as the degree of functional impairment. Other detailed ophthalmic examinations include 
fundus autofluorescence, full-field (ff) or multi-focal (mf) electroretinography (ERG), and 
spectral-domain or swept-source optical coherence tomography.33
1.5 Eyes shut homolog
Retinitis pigmentosa is both genetically and clinically heterogeneous, with 62 causal genes 
identified for autosomal recessive RP (arRP) to date (RetNet, https://www.sph.uth.tmc.edu/
RetNet/). Mutations in Eyes shut homolog (EYS) account for approximately 5-10% of all 
arRP cases in the European population and are the leading cause of arRP in the Japanese 
population.34,35 The EYS gene consists of 44 exons, whereby exon 42 is alternatively spliced 
and does not reside in most of the EYS transcripts. Depending on its splicing, EYS encodes 
for a 3,165 or 3,144 amino acids long EYS protein which is predominantly expressed in the 
retina.36,37 Eyes shut homolog consists of 28 epidermal growth factor (EGF)-like domains 
and five laminin A G-like (LamG) domains (Figure 1.4), which are conserved among 
different species. An EGF domain is defined by the presence of six cysteine residues that 
are able to form disulfide bonds, and form two beta-sheets connected to each other by a 
loop. It has been described that EGF domains are important for intracellular signaling and 
cell adhesion.38 The LamG domain is found in many different proteins and is, as seen for 
EYS, often located at the C-terminus. Proteins harboring LamG domains can have a wide 
variety of functions, such as cell adhesion, migration and signalling.39
The Drosophila ortholog of EYS, also known as spam or spacemaker, is located in the inter-
rhabdomere space of the compound eye of the fly. Here, it is shown to play a major role 
in proper formation of the inter-rhabdomere lumen, since in eys mutant flies, the inter-
rhabdomere space was completely absent.40 In zebrafish, it was recently shown that eys 
localizes near the photorecptor connecting cilium.41 Furthermore, eys knock-out zebrafish 
models show degeneration of the retinal architecture and visual impairment.41,42
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Since EYS is specifically expressed in the retina, and supported by the fact that Eys is absent 
from several rodent species,36 still very little is known about the exact function of EYS and 
the pathogenic mechanism underlying EYS-associated RP.
Figure 1.4. Exonic structure and protein domain structure of eyes shut homolog 
(EYS). 
(A) Eyes shut homolog consists of 44 exons of which exon 42 is alternatively spliced. (B) Protein 
domain structure of EYS and its orthologs in Drosophila and zebrafish. Note the conservation of the 
order of EGF-like and laminin A G-like domains between the different species.
1.6 Models for IRDs
1.6.1 Animal models for IRDs
The role of animal models in the IRD field has not only been shown to be important 
for understanding the pathogenic mechanisms underlying the disease, but also in the 
development of novel therapies. 
The zebrafish retina is morphologically similar compared to the human retina, meaning 
that all major cell and tissue layers that can be found in humans are also found in 
zebrafish. The zebrafish retina contains four cone subtypes which by far outnumber the 
rod photoreceptors.20 Their cones are sensitive to the same three color wavelengths as 
cones in humans and, in addition, a fourth UV-sensitive cone is present. Other advantages 
of the zebrafish as a model are: they produce a large number of offspring, have relatively 
short generation time, and are easy genetically modified. However, a drawback of the 
zebrafish is its capacity to regenerate the retina after damage.43
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retina of mouse and rat contains sensitive rods and cones that are not evenly distributed 
over the retina and it does not contain a cone-rich area.20 In general, rodents are a good 
model to study IRDs, because of their genetic similarity to human and there are some 
naturally occurring retinal degeneration models described. However, Eys is not present in 
mouse and rat,36 which excludes it for the use as a research model for this particular gene.
Since the pig is a diurnal animal, its retina is cone-rich with the highest density of cones 
in the central retina. This makes the pig a good model to study retinal dystrophies in 
which cones are affected. Disadvantages of using pig as a research model are the poorly 
annotated genome and the large space needed for housing. To overcome the latter, mini-
pigs are widely used.
The dog retina is rod-dominated in most parts of the retina, but it does contain an area 
in the center of the retina that is cone-rich. Like for mice, many naturally occurring dog 
models have been identified and used for research. For example, in dogs with an RPE65 
mutation, gene therapy successfully restored vision.44 Drawbacks of using dog as a model 
for IRDs are housing, long regeneration time, and ethical aspects.
1.6.2 Cellular models for IRDs
Vertebrate animal models all have their limitations in their use as a model for IRDs, such as 
their evolutionary distance from humans, differences in retinal morphology compared to 
humans, and, for large animal models, slow reproduction rate and high costs for housing. 
In addition, there are ethical issues surrounding the use of animal models for IRDs. 
Therefore, the search for alternatives is increasing. Over the last few years, technological 
development resulted in the ability to differentiate human derived induced pluripotent 
stem cells (iPSCs)45 into retinal cells,46 which makes it possible to study retinal degeneration 
in vitro. Since these cells contain the exact same genetic code as in the human subjects, 
specific consequences of mutations can be studied in these cells. Using gene editing 
techniques, the effect of correcting genetic defects can be studied in these cells as well. 
Developing disease models via differentiation of human-derived iPSCs involves several 
key elements: selection of the somatic cell type, a reprogramming strategy and choice of 
the differentiation protocol.
While selecting the somatic cell type for iPSC generation, it is important to take into 
account that these cells have epigenetic memory. This might influence the differentiation 
of iPSCs towards a lineage different than its origin.47 Most reported cellular RP models 
use dermal fibroblasts as somatic cell type source. In addition, some studies showed that 
RPE and photoreceptors can also be generated from keratinocytes48 or T-lymphocytes.49 
Blood cells are a convenient source for the generation of iPSCs, since it is less invasive 
to get them and the source is almost unlimited.50 Another advantage of blood-derived 
human iPSCs is that they are identical to human embryonic stem cells with respect to 
morphology, DNA methylation, expression of surface antigens and transcription factors 
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associated with pluripotency, and their differentiation capacity.51 Another somatic cell 
source is urine, which can be collected noninvasively and at multiple timepoints without 
any risks.52 Besides the above mentioned somatic cell sources, adipose tissue, periodontal 
ligament, pancreatic islet beta cells, and mesenchymal stromal cells (wisdom teeth) are 
also reported suitable for reprogramming cells into iPSCs.53-56
For studying RP, there are models using a single cell type approach and models that 
are more mimicking the complete multi-layered retinal structure. In the single cell type 
approach, photoreceptors or RPE cells are generated from iPSCs in two-dimensional (2D) 
cultures. For this, specific signaling molecules are added to the culture medium and often 
this is combined with the use of matrices on which the cells are cultured.57-59 It is easier to 
obtain RPE cells from iPSCs compared to photoreceptors. This can partly be explained by 
the tendency of iPSCs to differentiate towards ectoderm upon fibroblast growth factor 
withdrawal.60 
The group of Takahashi was the first that successfully differentiated iPSCs derived from RP 
patients with mutations in RP1, RP9, PRPH2 or RHO towards photoreceptor-like cells.57,61 
These cells expressed photoreceptor-specific markers, such as recoverin and rhodopsin. 
In addition, they showed a decrease in rod viability and increase in endoplasmic reticulum 
stress markers, similar to what is observed in RP patients.
A big advantage of the 2D cultures is that molecular events can be studied in a 
homogeneous cell population, as in case of RPE cells, which can be manually selected, 
excised and enriched. In case of other retinal cell types, the drawback is that the generated, 
not well-organized, cell layers often contain a mixture of different cell types.48,62
In addition to the generation of 2D culture models, different groups have shown that 
it is also possible to differentiate iPSCs into three-dimensional (3D) retinal structures. 
Nakano et al. were the first who described that pluripotent cells have the self-organizing 
capacity to form organoids.63 Several other groups adapted this approach and, with small 
changes in the differentiation strategy, in some cases even photoreceptor outer segments 
could be generated.64-66 It is amazing that spheres of iPSCs can differentiate into perfectly 
organized 3D retinal organoids containing layered retinal cells: photoreceptors, ganglion 
cells, Müller cells, horizontal cells, amacrine cells and bipolar cells. These organoids or optic 
cups can serve as a powerful tool to study retinal development and disease mechanisms. 
Furthermore, it might also be a potential therapeutic tool for cell and organ replacement.
An example of a step towards clinical application is the study by Wiley et al.67 They 
generated iPSCs from a large RP cohort according to Good Manufacturing Practice (GMP) 
by establishing common criteria for cellular identity and sterility. All iPSC lines were able 
to differentiate into 3D organoids and did not induce tumor formation after injection 
into mice. Phillips et al. modeled VXS2-associated microphthalmia, by comparing optic 
cups from a patient and a healthy person.68 Patient-derived cells showed a delay in 
photoreceptor maturation, which was rescued by expression of exogenous VSX2 early 
in the differentiation process. Human derived optic cups were also used to study gene 
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Disruption of this specific isoform in rod photoreceptors can cause retinal disease.69 
Parfitt et al. generated optic cups from iPSCs derived from an LCA patient with an intronic 
mutation in CEP290, that encodes a protein expressed in the connecting cilium. They 
showed that a pseudoexon was more prominently present in the mRNA of optic cups 
compared to fibroblasts. Expression of the full length CEP290 was restored by blocking 
aberrant splicing, which in turn restored cilia function.70
These examples show that the use of optic cups is a good tool to mimic retinal 
development and disease. However, the generation of these 3D retinal organoids remains 
very challenging. The production process takes at least several months and it is highly 
dependent on manual manipulation and subjective selective criteria at initial stages. In 
addition, there can be high variability among different iPSC lines.71
1.6.3 Genetic modifications of IRD models
Homologous recombination is a mechanism naturally used by cells to repair double-
stranded breaks in the DNA. However, it can also be used to introduce DNA into the genome 
of a host cell, for instance embryonic stem cells. For this, two flanking homologous arms 
are used to facilitate a targeted way of integration. With this method, DNA up to several 
kilobases (kb) can be introduced or exchanged.72 Homologous recombination can also be 
used to generate knock-out or knock-in animals. Since the homology arms are sequence 
specific, the ability of targeting some loci is very low.
One of the first approaches of targeted gene modifications made use of zinc fingers, 
peptides that can recognize and bind 3 base pair DNA motifs. These zinc fingers can be 
fused with the endonuclease enzyme FokI, creating a zinc finger nuclease (ZFN) complex 
which can mediate targeted DNA cleavage. The cleaved DNA ends will be repaired by the 
cellular non-homologous end-joining (NHEJ) pathway, whereby sometimes mutations 
such as insertions and/or deletions are introduced.73 Critical for the use of ZFNs is the 
nucleotide specificity, since off-target effects can interfere with the phenotype of interest. 
Furthermore, targeting options with this technique are limited to its DNA restriction 
motifs. To increase the restriction possibilities, a transcription activator-like (TAL) effector 
DNA-binding domain can be fused to a general cleavage domain. Hereby, a wide range of 
possible restriction motifs is estimated to be present once in every 35 base pairs of DNA.73 
When a TAL effector is combined with a nuclease, resulting in so-called transcription 
activator-like effector nucleases (TALEN), DNA can be cut at specific locations. It has been 
shown that TALEN are suitable for gene editing in zebrafish, mouse, rat or human derived 
embryonic stem cells and induced pluripotent stem cells.74-77
It has been recently discovered that prokaryotic immune components known as clustered 
regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated nucleases 
such as Cas9 are also able to mediate genome editing in mammalian cells.78-80 The Cas9 
nuclease cleaves double-stranded DNA at a specific target in the genome using guide 
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RNAs (gRNA). These double-strand breaks are repaired by either the NHEJ pathway or by 
the homology-directed repair (HDR) pathway. In case no template is present, insertions 
and/or deletions will be introduced when using NHEJ. The HDR pathway allows precise 
genome editing using a donor DNA template for repair. The CRISPR/Cas9 system has 
been adapted for efficient use in cells as well as a wide variety of organisms, including 
zebrafish, mouse, rat, pig, sheep and human.81-83 The most important advantages of the 
use of CRISPR/Cas9 over other genome editing strategies are its efficiency and simplicity. 
The system can be easily adjusted by changing the gRNA sequence to any DNA sequence 
of interest, which makes that target options are enormous.
1.7 Therapeutic strategies for IRDs
Currently, there is no therapy available for RP patients that has been proven to prevent the 
development or progression of the disease or can restore visual function. Drugs currently 
used in the treatment of RP are focused on slowing down the progression of the disease 
or target secondary complications. Research for new therapies, such as gene therapy, cell 
therapy and prosthesis, are ongoing.17,84
1.7.1 Gene therapy
The retina is an accessible and immune-privileged structure, which makes it a suitable 
target for gene therapy.17 Here, we will discuss gene replacement or augmentation 
therapy, meaning the replacement of a mutated gene that causes disease with a 
healthy copy of the gene or cDNA (Figure 1.5A). Due to the genetic heterogeneity of 
IRDs, including RP, it is not possible to design a common gene therapy for all genetic 
subtypes. Therefore, different therapeutic strategies are required depending on the causal 
gene, type of mutation and pattern of inheritance. For instance, recessive and X-linked 
mutations are more susceptible for gene augmentation therapy, because it leads to 
absence of the protein or to production of a null protein. In these cases, gene replacement 
or augmentation therapy could overcome the disease symptoms. 
Currently, the two main approaches for delivery of therapeutic transgenes to the target 
cell type in the retina are viral or non-viral.85 Viral vectors are mostly used in studies on 
gene therapy for RP, such as adeno-associated virus (AAV), adenovirus and lentivirus. 
The standard way of delivering viral vectors to the retina is via subretinal injection. The 
advantage of adenovirus and lentivirus is that they have large packaging capacity, up to 
37 kb and 8 kb, respectively.86 However, they are not very efficient in targeting retinal cells, 
partly due to their large size. The most commonly used viral vectors for pre-clinical and 
clinical studies are AAVs, since they are easy to manipulate and safe. There are different AAV 
subtypes, of which AAV2/5, AAV2/7, AAV2/8 and AAV2/9 have been shown to efficiently 
target both photoreceptors and RPE cells.87-90 A huge drawback of the use of AAVs is 
their low packaging load of maximum 4.7 kb.86 Liposomes, polymers, polypeptides and 
nanoparticles are examples of non-viral vectors. They have some advantages over viral 
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Of course the use of non-viral vectors also has drawbacks, such as lack of long-term gene 
expression, degradation and inefficient transport into the cell.84,86
Successful clinical trials for inherited retinal dystrophy have first been reported for RPE65-
related LCA. Mutations in RPE65 account for approximately 6% of all the LCA cases.27 
From 2008, results have been reported for three phase 1 clinical trials of AAV-mediated 
RPE65 gene therapy for LCA (ClinicalTrials.gov identifiers: NCT00643747, NCT00481546, 
NCT00516477). In 2017, the results of a phase 3 clinical trial using LUXTURNATM (voretigene 
neparvovec, AAV2-hRPE65v2) for the treatment of patients with vision loss due to bi-
allelic RPE65-associated IRD were published by Spark Therapeutics Inc. (NCT00999609). 
The read-out was the 1-year improvement of multi-luminance mobility testing (MLMT) 
scores, which measures functional vision at specific light levels. The MLMT change score 
was significantly higher in the treated group versus the control group. No adverse events 
or immune responses were reported. LUXTURNATM was recently approved by the US Food 
and Drug Administration (FDA), for the treatment of visual impairment due to RPE65 
mutations.
1.7.2 Gene therapy for RP
To date, several studies reported the successful use of gene therapy in animal models, 
resulting in delayed progress of RP or restored vision. For instance, the delivery of AAV 
vectors to replace mutated CNGB1 or MERTK in animal models of arRP showed the 
restoration of protein expression and ERG activities, respectively.92,93 Two other studies 
reported restored and preserved photoreceptors in murine and canine models of X-linked 
RP after gene therapy using an AAV loaded with the RPGR gene.94,95 The promising results 
of these preclinical studies establish a scientific basis for application in human subjects. 
Currently, phase 1/2 clinical trials to treat RLBP1-, PDE6B-, RPGR-, or MERTK-associated RP 
with gene therapy are ongoing (ClinicalTrials.gov identifiers: NCT03374657, NCT03328130, 
NCT03116113, NCT03316560, NCT03252847, NCT01482195). These studies all involve 
subretinal injection of an AAV-vector containing a copy of the wild-type gene of interest.
1.7.3 Microgene therapy
As described above, the most commonly used way of delivering therapeutic transgenes is 
via AAV vectors. As mentioned before, one of the most important drawbacks of AAV is the 
limiting cargo capacity of approximately 4.7 kb. For large genes, for which the cDNA size 
exceeds 4.7 kb such as EYS, packaging the complete cDNA into an AAV is not possible and 
other strategies are required. To overcome this problem, the use of microgenes might be 
a possible solution (Figure 1.5B). A microgene is a smaller version of the gene of interest, 
containing the most important functional domains. This idea, amongst others, is based 
on the fact that in other species, smaller version of the same gene are still functional. 
For example, EYS orthologs in Drosophila and zebrafish are smaller than human EYS with 
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less EGF-like or LamG domains, but still maintain proper function (Figure 1.4). A study by 
Zhang et al. reported the delivery of a miniCEP290 gene into a mouse model of LCA. Mice 
injected with miniCEP290 significantly improved photoreceptor morphology, survival and 
function compared to control injected mice.96 The potential of the microgene strategy 
has also been shown in studies outside the IRD field. Duchenne muscular dystrophy 
(DMD) is caused by mutations in the DMD gene, encoding the dystrophin protein. Several 
studies showed that AAV-mediated micro-dystrophin expression in different mutant 
mouse models with DMD lead to a milder form of muscle disease.97-99 A study by Chen 
et al. showed that a type VII collagen microgene construct retained the function and 
characteristics of full length type VII collagen in vitro. Dystrophic epidermolysis bullosa 
(DEB) keratinocytes treated with the VII collagen microgene could produce a population 
of phenotypically corrected DEB cells, which showed the same characteristics as normal 
human keratinocytes.100
1.7.4 Antisense oligonucleotide therapy
Another therapeutic strategy for IRDs that has emerged over the last years is the use of 
antisense oligonucleotides (AONs).70,101-106 These are small DNA or RNA molecules that 
are complementary to the pre-mRNA region of interest. Binding of AONs to their target 
can result in modulation of pre-mRNA splicing or degradation of the target transcript, 
depending on their chemistry. Redirection of pre-mRNA splicing is a commonly used 
application of AONs. As a consequence of the binding of AONs to their target, splice-
regulating factors are no longer able to bind, and changes in splicing can occur.107 In 
this way, AONs can be used to block mutations or regulatory sequences within the pre-
mRNA, which eventually will induce inclusion or skipping of exons, block the recognition 
of pseudo-exons, or influence alternative splicing. For example, exons in which many 
different disease-causing mutations are found can be skipped using AONs to remove the 
mutations from the gene (Figure 1.5C). Two requirements for skipping regular exons as 
a potential therapy are that the skipping of the respective exon results in an in-frame 
transcript and that the exon does not encode a crucial domain for the structure or function 
of the protein.
In the first example of the successful use of AONs for IRD, AONs were used to target a 
deep-intronic variant in CEP290 (c.2991+1655A>G) that leads to LCA.108 This mutation 
creates a new splice donor site in intron 26, leading to the insertion of a pseudo-exon, 
resulting in a frameshift and premature termination of protein synthesis.108 In patient-
derived lymphoblastoid cells or fibroblasts, insertion of this pseudo-exon could be 
prevented by the administration of AONs targeting the pseudo-exon region.102,103 Parfitt 
et al. treated patient-derived optic cups with AONs, which blocked aberrant splicing and 
restored expression of full length CEP290, leading to normal trafficking of ciliary proteins.70 
Intraocular injections of AONs to a humanized transgenic mouse model, in which part 
of the human CEP290 gene (including the deep-intronic mutation) was inserted into the 
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Figure 1.5. Therapeutic approaches for inherited retinal diseases. 
(A) Gene therapy replaces the mutated gene with a healthy copy of the gene. Adeno-associated 
virus (AAV) vectors are most commonly used for retinal delivery. ITR: inverted terminal repeats; pA: 
PolyA tail. (B) Microgene therapy: the delivery of smaller versions of the gene of interest, containing 
the most important functional domains. (C) Antisense oligonucleotides (AONs) mediated correction 
of mRNA. SF: splice factors.
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mouse Cep290 gene, resulted in a significant decrease of aberrant Cep290 transcripts.104,109 
Recently, Albert et al. successfully used AONs for the rescue of splice defects in 
photoreceptor precursor cells caused by two neighboring deep-intronic mutations 
in ABCA4.110 Proof-of-concept studies for the use of AONs to correct splicing were also 
published for two other deep-intronic mutations, one in USH2A (c.7595-2144A>G) and 
one in OPA1 (c.610+364G>A).105,111 These studies demonstrate the potential of AON-based 
splice correction for IRDs.
Besides targeting deep-intronic variants, AONs can also be used for the skipping of 
regular exons that contain frameshift mutations. Exon skipping is currently one of 
the most promising therapeutic tools for DMD, and a successful first-in-man trial has 
recently completed. For DMD, AONS have been designed for numerous exons or 
combination of exons (double exon skiping).112 Cysteine altering missense mutations in 
NOTCH3 cause cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy, or CADASIL, a hereditary cerebral small vessel disease. Rutten et al. 
used AON-mediated exon skipping to accomplish NOTCH3 cysteine correction.113
In addition, AONs have also been developed for the inclusion of exons. Spinal muscular 
atrophy (SMA) is a neuromuscular disorder caused by mutations in the SMN1 gene. In 
humans, a second gene, SMN2, is present which is identical to SMN1 apart from five 
nucleotides. One of these changes, a C to T substitution in exon 7, is critical and leads to 
skipping of exon 7 in 90% of the produced mRNA, which in turn leads to a non-functional 
protein. As a therapy for SMA, an AON was designed to target the inhibitory intron splicing 
silencer N1, thereby promoting exon 7 inclusion in SMN2 leading to the production of 
functional protein.114
1.7.5 Other therapeutic approaches
When RPE cells or photoreceptors are still intact, gene therapy seems to be a promising 
strategy. However, gene therapy is not an option when RPE cells or photoreceptors are 
fully degenerated, and alternative therapeutic strategies need to be employed. With 
stem cell transplantation, the patient receives healthy stem cells that can start to develop 
into normal retinal cells. So far, the most promising sources of cells for human retinal 
transplantation are embryonic stem cells (ESC) and iPSCs.46,115,116 In more advanced stages 
of retinal degeneration, optogenetics is a promising therapeutic approach to restore vision. 
Optogenetics is a type of gene therapy, that renders light responsiveness to surviving 
retinal cells, such as cones, bipolar cells and ganglion cells that are not photosensitive 
anymore by their own.117 Retinal prosthesis will be the optional therapy to treat patients 
without any functional photoreceptors. These devices will trigger neural activity in the 
remaining cells in the retina. The therapeutic approaches mentioned in this section will 
not be further discussed in this thesis.
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The aim of this thesis is to unravel the pathogenic mechanism underlying EYS-associated 
retinitis pigmentosa, which will serve as the basis for the development of therapeutic 
approaches for the disease. 
Chapter 2 provides an overview of all the 271 reported and 26 novel EYS variant in 
patients with retinitis pigmentosa. All these variants were classified according to their 
pathogenicity using the ACMG guidelines. In addition, future prospects on how to 
experimentally assess the true causality of EYS variants are discussed in this chapter.
Chapter 3 describes the spectrum of retinal disease and the course of visual function 
in a cohort of 30 patients carrying biallelic EYS variants. Intriguingly, two siblings that 
were diagnosed with macular dystrophy were found to carry compound heterozygous 
EYS variants: c.1299+5_1299+8del and c.6050G>T. In addition, we show that the 
c.1299+5_1299+8del variant affects splicing using an in vitro minigene splice assay.
In Chapter 4, we report the identification of eys in zebrafish and the generation of a 
zebrafish eys knock-out model using CRISPR/Cas9 technology to be able to study the 
function of Eys. This chapter shows that Eys is important for maintenance of photoreceptor 
morphology and visual function in zebrafish.
Chapter 5 presents the development and in vitro testing of three different EYS microgenes 
that can be used as a potential therapeutic approach for the treatment of EYS-associated 
retinal dystrophies. We show that two out of three EYS microgenes encode stable 
microgene proteins.
In Chapter 6, AONs were designed for skipping EYS exon 26 as a therapeutic approach 
for retinal dystrophy caused by mutations in this exon. Patient-derived iPSCs were 
differentiated towards photoreceptor cells to test this approach in a cellular model. We 
observed downregulation of pluripotency markers in differentiated cells, whereas some 
retinal genes were upregulated, although expression levels were quite low. Furthermore, 
we show that EYS without exon 26 encodes a stable protein and that a combination of two 
AONs targeting exon 26 are able to skip the complete exon, supporting the therapeutic 
potential of AON-mediated skipping of this exon.
Chapter 7 provides the general discussion of this thesis. We highlight our main findings 
and discuss future directions and challenges for the development of therapeutic 
approaches for EYS-associated retinal dystrophies.
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Abstract
Mutations in Eyes shut homolog (EYS) are one of the most common causes of autosomal 
recessive (ar) retinitis pigmentosa (RP), a progressive blinding disorder. The exact 
function of the EYS protein and the pathogenic mechanisms underlying EYS-associated 
RP are still poorly understood, which hampers the interpretation of the causality of 
many EYS variants discovered to date. We collected all reported EYS variants present 
in 377 arRP index cases published before June 2017, and uploaded them in the Leiden 
Open Variation Database (www.LOVD.nl/EYS). We also describe 36 additional index 
cases, carrying 26 novel variants. Of the 297 unique EYS variants identified, almost half 
(n=130) are predicted to result in premature truncation of the EYS protein. Classification 
of all variants using the American College of Medical Genetics and Genomics guidelines 
revealed that the predicted pathogenicity of these variants cover the complete spectrum 
ranging from likely benign to pathogenic, although especially missense variants largely 
fall in the category of uncertain significance. Besides the identification of likely benign 
alleles previously reported as being probably pathogenic, our comprehensive analysis 
underscores the need of functional assays to assess the causality of EYS variants, in order 
to improve molecular diagnostics and counseling of patients with EYS-associated RP.
Key words: 
EYS, in silico assessment, LOVD, retinitis pigmentosa (RP)
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2.1 Introduction
Eyes shut homolog (EYS; MIM# 612424) is one of the most frequently mutated genes 
in patients with retinitis pigmentosa (RP; MIM# 26800), a group of inherited retinal 
dystrophies. Retinitis pigmentosa is the most common form of retinal degeneration, with 
a prevalence of approximately 1 in 4,000 individuals, and is characterized by progressive 
degeneration of rod photoreceptor cells causing constriction of the visual field and 
eventually, often, total blindness.1 Different modes of inheritance including autosomal 
recessive (ar), autosomal dominant, and X-linked, have been observed in the disease.1 To 
date, 58 causal genes for arRP are known (RetNet, http://www.sph.uth.tmc.edu/RetNet/), 
most of them only being responsible for 1-2% of all the cases. However, a few genes are 
mutated in a larger number of patients, including EYS, accounting for approximately 
5-10% of all arRP cases.2-4
EYS encodes the 3,144 amino acids long protein eyes shut homolog (EYS) and is 
predominantly expressed in the retina.5,6 Loss of EYS protein function is thought to be 
the molecular mechanism underlying EYS-associated RP. The EYS protein consists of 28 
epidermal growth factor-like (EGF) domains and five laminin A G-like (LamG) domains, 
which are highly conserved (Supp. Figure S1). EGF domains are defined by six cysteine 
residues which are able to form disulphide bonds, and form two beta-sheets connected to 
each other by a loop. The exact role of EGF-domains in proteins is not yet clear, but it has 
been described to be important in intracellular signaling and cell adhesion.7 The LamG 
domain is found in many different proteins and is often located at the C-terminus of the 
protein, as is seen for EYS. A wide variety of roles is described for proteins harboring LamG 
domains, like cell adhesion, migration and signalling.8
EYS is an ortholog of the Drosophila spacemaker (spam) protein, which plays a major role 
in maintenance of the photoreceptor morphology.9 Recently, two independent groups 
reported retinal degeneration in different Eys knockout zebrafish.10,11 Yu, et al. revealed 
that Eys is located near the connecting cilium and is required for maintaining the ciliary 
pocket.10 The study by Lu et al. showed mislocalization of the outer segment proteins 
red opsin, UV opsin and rhodopsin in the absence of Eys.11 Due to its retina-specific 
expression, and supported by the fact that the Eys locus is lacking in several rodent species 
(mouse, rat, guinea pig)5, still very little is known about the exact function of EYS and the 
pathogenic mechanism underlying EYS-associated RP, which hampers the interpretation 
of the causality of many EYS variants discovered to date.
In this study, we performed a systematic analysis of all 271 reported EYS variants reported 
in patients with RP. Therefore, we collected all EYS variants published up to June 2017 
that were associated with arRP or allied diseases. We also report 26 novel EYS variants 
not reported previously. All variants were uploaded into the Leiden Open source Variant 
Database (LOVD) for EYS, and were classified according to their pathogenicity based on 
the American College of Medical Genetics and Genomics (ACMG) guidelines.12 In addition, 
we discuss future prospects on how to experimentally assess the true causality of EYS 
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variants. With that, we aim to facilitate a better interpretation of the pathogenicity of EYS 
variants in relation to arRP.
2.2 Materials and methods
2.2.1 Literature search
We collected all publications from before June 2017 in which EYS variants (NM_001142800.1) 
were reported in patients with arRP. Variant combinations, age of onset, and disease 
phenotype were collected. Obvious duplicates were removed. 
2.2.2 Subjects
This study was approved by the institutional review boards of the Radboud University 
Medical Center an adhered to the tenets of the Declaration of Helsinki. Sanger sequencing 
of EYS, Multiplex Ligation-dependent Probe Amplification (MLPA, MRC-Holland) of 
EYS, microarray chip based on APEX technology (Asper Biotech, Tartu, Estonia) and/or 
whole exome sequencing was requested at the genome diagnostic laboratory of the 
Radboudumc to determine the genetic cause in patients with visual impairment. We 
extracted all homozygous and (possible) compound heterozygous variants in the EYS 
gene that were reported to the patients, as well as individuals with one (potentially) 
pathogenic allele. In addition, in 11 index patients, EYS variants were identified through a 
targeted sequencing approach which was based on molecular inversion probes (Khan, MI 
et al., manuscript in preparation). 
2.2.3 Variant analysis
For numbering of the cDNA, the A of the ATG translation initiation codon in the EYS 
reference sequence (NM_001142800.1) was numbered as +1 and the initiation codon as 
codon 1. Frequencies of the variants present in controls were extracted from the Exome 
Aggregation Consortium (ExAC) database Version 0.3.1, which gives access to exome data 
of more than 60,000 individuals from all over the world (http://exac.broadinstitute.org).
The majority of the reported EYS variants in patients were identified in either non-Finnish 
Caucasian individuals or East-Asian (Chinese and Japanese) individuals. Statistical analysis 
was performed to assess whether EYS variants were enriched in the EYS patient group 
vs. the ExAC database. To increase the power and specificity, this analysis was performed 
separately for non-Finnish Caucasians and East-Asians. We used the Fisher’s exact test 
as implemented in R (http://www.R-project.org) to compare EYS variants found in the 
Caucasian index patients in the EYS-LOVD dataset to non-Finnish European controls 
in ExAC, and did the same for the East-Asian population. To select only true statistical 
significant findings, a correction by the false discovery rate (FDR) of Benjamini-Hochberg, 
classical one stage method13 was performed with an error margin of 5% on the total data. 
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In case a certain genomic position was not listed in ExAC, the allele number of the closest 
variant was used for statistical analysis.
2.2.4 In silico predictions
We obtained Combined Annotation Dependent Depletion (CADD), Grantham and PhyloP 
scores for all missense variants reported in EYS. CADD scores were obtained from the 
website http://cadd.gs.washington.edu/home14 and Grantham scores were obtained from 
the paper by Grantham in 1974.15 PhyloP scores were obtained from the table browser 
tool provided by the UCSC Genome Browser (http://genome.ucsc.edu/). We used the 
Cons 46-way track and the Vertebrate PhyloP Conservation table for GRCh37/hg19 (clade: 
Mammal, genome: Human, assembly: Feb. 2009 (GRCh37/hg19), group: Comparative 
Genomics, track: Cons 46-way, table: Vertebrate Cons (phyloP46wayAll)). To compare 
the average PhyloP score of EYS to that of all genes in the human genome, conservation 
scoring by PhyloP and genomic positions of coding exons were downloaded from UCSC 
genome browser (http://hgdownload.cse.ucsc.edu/downloads.html). Bedtools and in-
house scripts were used to generate gene average PhyloP scores, based on the scores 
of all base-pairs within the coding regions of each gene. Software available via Alamut 
Visual version 2.7 (Interactive Biosoftware, Rouen, France) was used to obtain splicing 
scores. The following software programs were used: SpliceSiteFinder-like, MaxEntScan, 
NNSPLICE, Genesplicer, and Human Splice Finder.
2.2.5 Variant pathogenicity classification
The predicted pathogenicity of all EYS variants was assessed according to the ACMG 
guidelines,12 allowing to classify all variants into one of the five following categories: 
pathogenic, likely pathogenic, benign, likely benign, or uncertain significance. First, 
we scored the variants based on the evidence of pathogenicity in different categories 
published in the guidelines. These categories are as follows:
• pathogenic, very strong (PVS), for example, this variant is protein truncating,
• pathogenic, strong (PS), for example, this variant leads to the same amino acid change 
as a previously described pathogenic variant,
• pathogenic, moderate (PM), for example, this variants is located in a mutational hot 
spot and/or well-established functional domain,
• pathogenic, supporting (PP), for example, all computational evidence support the 
variant to be pathogenic.
After scoring the variants for the different categories, the ACMG guidelines combine these 
scores to come to the final classification in one of the five pathogenicity categories as 
further described in Supp. Table S1. 
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2.2.6 LOVD submission
All the 271 collected published and 26 novel EYS variants, together with patient data 
such as a description of the phenotype, age of onset and segregation information, 
when available, were uploaded in the Leiden Open Variation Database (LOVD). In case of 
multiplex families, affected relatives were also uploaded to the LOVD. Scores given to all 
variants in the column ID_pathogenic, were based on the pathogenicity assessment that 
was performed as described in the previous section.
2.3 EYS Variants
2.3.1 The spectrum of EYS mutations
In total, we collected information of 377 RP patients described in 43 papers2-6,16-53, in which 
630 alleles with EYS variants were reported. In addition, we identified 26 novel variants 
found in 36 index patients that were not published previously (Table 2.1). From the in 
total 413 index patients, 129 patients had homozygous EYS variants, 187 patients had 
compound heterozygous variants, and 97 patients carried only one variant. The total 
amount of 698 alleles represent 297 unique EYS variants (Table 2.1, Supp. Table S2), with 
protein-truncating variants as the most common type (130 variants), followed by missense 
variants (116 variants) (Figure 2.1A, Table 2.2). All the collected published variants and the 
26 novel variants together with a description of the phenotype and segregation analysis, 
when available, were uploaded in the LOVD (www.LOVD.nl/EYS).
To analyze whether variants were significantly enriched in the LOVD dataset, Fisher’s 
exact tests were performed separately for the Caucasian population and the East-Asian 
population. We did this analysis in two different ways. First, we analyzed which EYS 
variants were enriched in the RP patients carrying EYS mutations. In addition, we were also 
interested in the enrichment of EYS variants in the complete RP population. For the latter, 
we have taken into account that approximately fifty percent of the RP patients have arRP 
and that of these arRP patients, five percent can be explained by mutations in EYS. This 
was done for variants present in all index cases, relatives with the same mutations were 
excluded from this analysis. Large deletions and duplications were not tested, because 
copy number variants are not listed in ExAC.
The first analysis revealed that in the non-Finnish European population, 60 variants were 
significantly enriched in the EYS-LOVD (Fisher’s exact test, P<0.05, FDR of 5%) compared to 
controls in ExAC. The majority of these variants were protein-truncating mutations (n=29). 
The other variants were missense (n=18), splice site (n=5), in-frame indels and synonymous 
variants (n=3), and variants in the 5’-UTR (n=5). In the East-Asian individuals, 11 variants 
were significantly enriched in East-Asian patients in the EYS-LOVD (Fisher’s exact test, 
P<0.05, FDR of 5%) compared to the East-Asian control population in ExAC. These were 
comprised of 5 missense variants and 6 protein-truncating variants. Interestingly, two 
variants, p.(Cys2139Tyr) and p.(Trp2640*), were significantly enriched in the EYS-LOVD 
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in Caucasian as well as in East-Asian patients. After performing the corrections for the 
percentage of arRP cases and the proportion of RP caused by mutations in EYS, only the 
p.(Ile1451Profs*3) variant was significantly enriched (Fisher’s exact test, P<0.05, FDR of 5%) 
in the Caucasian population.
Table 2.2. 
Distribution of the EYS variants found in arRP patients.
Variant type Unique variants Total number of alleles
Missense 116 222
Protein truncating 130 399
Splice site 27 42
In-frame indels 7 8
Synonymous 12 17
5’ UTR 5 7
Complex alleles - 3
Total 297 698
2.3.2 Complex alleles
Three unique complex alleles have been reported, p.[Gln1751*; Tyr3059*], p.[Cys2139Tyr; 
Ile1698Thr], and p.[His1302Gln; Tyr3135*]. The p.[Gln1751*; Tyr3059*] variant has been 
reported heterozygously in two patients. Both p.(Gln1751*) and p.(Tyr3059*) are protein-
truncating variants and thus predicted to be pathogenic. None of the two variants has ever 
been reported without the other. The p.(Cys2139Tyr) variant present in the complex allele 
p.[Cys2139Tyr; Ile1698Thr] however also occurred as a standalone variant in 14 patients. 
Moreover, this was the most frequently reported missense variant and classified as likely 
pathogenic. Lastly, of the complex allele p.[His1302Gln; Tyr3135*], the p.(Tyr3135*) variant 
is found in ten patients and is classified as pathogenic since this is a protein-truncating 
variant and absent from controls. The p.(His1302Gln) variant was not reported as a 
standalone variant and was classified as being of uncertain significance. For the complex 
alleles, the pathogenicity of each variant was assessed at the individual level.
2.3.3 Frequent EYS variants
The most frequently reported variant in arRP patients is p.(Ser1653Lysfs*2), which was 
found in 79 index patients. Interestingly, this variant was mainly found in Japanese 
patients as well as three Korean patients. The majority of patients (63/79) were compound 
heterozygous for this mutation. Of these, 21 individuals (all Japanese) carried another 
recurrent mutation p.(Tyr2935*) on the other allele. This p.(Tyr2935*) variant was reported 
in 37 patients and thereby the second most frequent mutation in the Japanese population. 
In the Caucasian population, the most frequently reported variant is p.(Ile1451Profs*3), 
reported in 12 arRP patients, three of which carried the variant in homozygous state. 
Besides the above mentioned frequent variants, a few other variants were also reported 
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more often (p.(Trp2640*), p.(Tyr3135*), p.(Cys2139Tyr) and p.(Gly2186Glu)). In general 
however, the vast majority of variants (276/297) were reported in only one or a few index 
cases, demonstrating the tremendous allelic heterogeneity of EYS-associated RP. 
2.4 Pathogenicity assessment of all EYS variants 
We classified all the EYS variants according to the ACMG guidelines as described in the 
Methods section. Based on our analysis, we have classified 144 variants as pathogenic, 11 
variants as likely pathogenic, 17 variants as likely benign, 6 as benign, and 119 as being of 
uncertain significance.
2.4.1 Protein-truncating variants
Most of the EYS variants reported in patients with arRP were protein-truncating variants. In 
total, 399 protein-truncating alleles were reported, corresponding to 57% of all reported 
EYS alleles (n=698) (Supp. Table S2). Of the 130 unique protein-truncating variants, 51 were 
nonsense mutation and 79 were causing a frameshift (including large deletions). Most of 
the truncating variants are rare, since only 10 out of these 130 variants were present in 
the ExAC database. Protein-truncating variants were classified as pathogenic if the variant 
leads to a termination of the protein before the amino acid position 3135, since it has 
been described repeatedly that this p.(Tyr3135*) variant is disease-causing 2,6,39. It thus 
appeared that all protein-truncating variants could be classified as pathogenic.
2.4.2 Splice site variants
Mutations that affect the canonical di-nucleotides of the splice acceptor (AG) or splice 
donor (GT) site were considered pathogenic. For all the non-canonical splice site variants, 
we assessed splice scores using five different splice prediction tools in Alamut Visual. 
Variants are considered probably pathogenic in case an increase or decrease of >10% of 
the splice prediction score was predicted by all five programs. Based on this assessment, 
only the c.1299+5_1299+8del mutation was classified as likely pathogenic. All other 
non-canonical splice variants were classified as of uncertain significance. Five splice 
site variants were enriched in the Caucasian EYS-LOVD, one of which was a canonical 
splice variant, whereas the other four were non-canonical splice variants, including the 
c.1299+5_1299+8del mutation.
2.4.3 Missense variants
In total, 116 unique missense variants in EYS were reported in arRP patients. Prior to the 
classification of the missense variants according to the ACMG guidelines, we obtained 
CADD, Grantham and PhyloP scores for all missense variants and used this for the 
computational evidence. To be supporting evidence (PP3), the threshold for these in 
silico predictions for a variant to be pathogenic were set at CADD >15, Grantham >80, 
and PhyloP >2.8. Next to that, we assessed the distribution of the missense variants over 
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the protein to be able to identify mutational hotspots or frequently mutated domains. 
To obtain the protein domains and their location, we used the SMART prediction tool 
from http://smart.embl-heidelberg.de/. The EYS protein consists of 28 EGF- and EGF-like 
domains, mainly clustered at the N-terminus of the protein, and 5 LamG domains located 
at the C-terminal part of the protein that are separated by one or two EGF domains (Figure 
1C). We could not identify clear mutational hotspots, although we could observe that 
there are slightly more missense variants located at the C-terminus of the protein (Figure 
1C). Moderate evidence (PM) for a variant to be pathogenic was counted if the variant 
affects the number of cysteines in an EGF domain or if the variant is located in a LamG 
domain. EGF-domains are conserved domains that are found to be present in a variety of 
proteins and might play a role in intracellular signaling and cell adhesion. An important 
component of these domains are the six cysteine residues that form disulphide bonds. 
Therefore, variants that affect the number of cysteines in an EGF domain are likely to 
disrupt the structure of the domain. The C-terminus of the EYS protein contains five LamG 
domains that are highly conserved. Proteins containing LamG domains appear to have 
roles in cell adhesion, migration and signaling. Therefore, we counted moderate evidence 
for pathogenicity when the variant is affecting an amino acid residue that is located in a 
LamG domain.
Finally, we combined all this information in the pathogenicity assessment. Of all missense 
variants, three were classified as benign, seven as likely benign, and nine as likely 
pathogenic (Table 2.3, Figure 2.1B). The majority of the missense variants (n=96) had to be 
classified as of uncertain significance, mainly due to insufficient criteria for these variants 
to be able to classify them otherwise. For instance, for the p.(Cys2396Ser), p.(Cys2668Phe), 
p.(Cys2890Tyr) and p.(Gly2907Glu) variants, some evidence points towards a likely 
pathogenic variant, however additional moderate (PM1-6) or supporting (PP1-5) evidence 
was lacking.
There were 18 missense variants significantly enriched in the Caucasian EYS-LOVD. 
Three of these, p.(Gly2017Val), p.(Cys2139Tyr) and p.(Gly2945Glu), were classified as 
likely pathogenic. All other variants were classified as being of uncertain significance. 
The pathogenic evidence for these variants is very limited, so even when taking into 
account that the variants are enriched is not enough to classify them as likely pathogenic. 
Interestingly, p.(Cys2139Arg) was not enriched in the Caucasian EYS-LOVD, however it 
was classified as likely pathogenic due to its absence in controls, its location in an EGF 
domain and the fact that another variant affecting this amino acid is disease-causing as 
well. In the East-Asian patients, five missense variants were statistically enriched (Fisher’s 
exact test, P<0.05, FDR of 5%) compared to the East-Asian control population. Of these 
variants, p.(Cys2139Tyr) and p.(Gly2186Glu) were classified as likely pathogenic whereas 
the other three (p.(Glu47Asp), p.(Gly843Glu) and p.(Ile2188Thr) were classified as of 
uncertain significance. Taken into account that these variants are significantly enriched 
in the East-Asian EYS-LOVD, p.(Gly843Glu) and p.(Ile2188Thr) shifted towards the likely 
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pathogenic category. For p.(Glu47Asp), even when adding the enrichment data, the 
evidence was still not sufficient for classification into the likely pathogenic category. After 
applying corrections for the percentage of arRP cases and the proportion of arRP caused 
by mutations in EYS, it appeared that none of the missense variants was significantly 
enriched in either the Caucasian or the Asian RP population.
Table 2.3.
Likely pathogenic missense mutations.
DNA variant Protein variant Homozygous Heterozygous Domain
c.2510G>T p.(Cys837Phe) - 1 EGF, cysteine
c.6050G>T p.(Gly2017Val) 3 2 LamG
c.6415T>C p.(Cys2139Arg) - 1 EGF, cysteine
c.6557G>A p.(Gly2186Glu) 2 9 LamG
c.8236G>C p.(Asp2746His) - 1 LamG
c.8236G>T p.(Asp2746Tyr) 1 - LamG
c.8288T>G p.(Leu2763Arg) - 3 LamG
c.8834G>A p.(Gly2945Glu) - 2 EGF, no cysteine
c.8861T>C p.(Phe2954Ser) - 1 LamG
Figure 2.1. 
(A) Distribution of the unique EYS variants found in patients with retinitis pigmentosa. (B) Pie-chart 
representing the distribution of the missense variants over the different pathogenicity classes (C) 
Schematic representation of the localization of all 116 missense variants in EYS. Likely pathogenic 
missense variants are depicted in red, benign and likely benign variants in green, and variants of 
uncertain significance in blue.
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2.4.4 New insights into previously reported pathogenic variants
In a number of cases, evaluation of the pathogenicity of a variant resulted in contradictory 
outcome. For example, the p.(Gly618Ser) variant was reported to be pathogenic by Audo 
et al.20 However, Gonzalez-del Pozo et al. reported this variant as unlikely pathogenic, 
because it did not segregate with the disease in the family.28 In our pathogenicity 
assessment this variant was classified as likely benign.
Another example is the p.(Val834Ile) variant that was reported in compound heterozygous 
state in two patients, one by Littink et al.4 and the other one by Audo et al.20 In the paper 
by Littink et al. this variant was classified as probably pathogenic, mainly because it was 
excluded in 180 controls. In this patient, it was found in conjunction with a protein-
truncating variant. Moreover, recently a third variant was found to be present in this 
patient. This was a large deletion (c.(-448+1_-332-1)_(748+1_749-1)del) which together 
with the protein-truncating mutation is most probably the cause of RP in this patient, thus 
rendering the p.(Val834Ile) variant being most likely benign, similar to the classification by 
Audo et al. In our in silico analysis, this variant was also classified as likely benign, because 
it is found in the ExAC database (AF=0.001072) and the bio-informatic predictions for this 
variant met the criteria for supporting evidence (BP4) to be benign.
Furthermore, there were also a few variants that were reported as pathogenic, however, 
were classified as likely benign upon our pathogenicity assessment. The p.(Leu302Phe) 
variant was reported in a compound heterozygous state in two patients by Xu et al. and 
Ge et al.50,52 In both papers, the variant is not explicitly discussed, although they are listed 
in tables with “causative” or “pathogenic” variants. Xu et al. detected this variant in 1/314 
patients versus 0/192 controls,52 which could be their main reason to classify this variant 
as pathogenic. We classified the variant as likely benign, because the allele frequency 
of 0.0003051 in ExAC is higher than expected in controls (cut-off value = 0.00005) for 
a pathogenic variant and the in silico predictions of CADD, PhyloP and Grantham all 
point towards this variant being benign. Ge et al. also reported another variant as being 
pathogenic, p.(Thr1084Pro), which we classified as likely benign for the same reason as 
p.(Leu302Phe). The p.(Thr1084Pro) variant reported by Ge et al. was found homozygously 
in a patient which also had the p.(Leu302Phe) variant and the p.(Phe2954Leu) variant.50
2.4.5 Genotype-phenotype correlation
Of all reported arRP patients that carried one or more EYS variants, we collected 
information about disease phenotype and age of onset, when available. These data were 
used to evaluate if there was any genotype-phenotype correlation between the EYS 
variant and the manifestation of the disease. However, unfortunately, for many patients 
phenotypic details were not available. Moreover, reporting of the disease manifestation is 
not always consistent and the methods used for diagnosing patients is variable between 
medical centers. Therefore, we could not draw any conclusions regarding the relationship 
between EYS variants and disease phenotype, nor were there obvious indications that 
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individuals with protein-truncated variants had a more severe phenotype compared 
to patients with missense variants. However, for almost all patients with bi-allelic EYS 
mutations, night blindness was reported as the initial symptom. Furthermore, all these 
patients had hallmark RP symptoms including bone-spicule pigmentation, attenuated 
retinal arterioles and low visual acuity. Pale optic disc was not reported for all patients, 
however was a frequently described phenomenon. The age of disease onset was highly 
variable, ranging from 13 to over 50 years.
2.5 Future directions
2.5.1 Expanding molecular diagnostics
From the 413 index patients, 97 patients carried only one EYS variant. It is possible that 
a second EYS mutation in these patients is not present; however, it is more likely that a 
second mutation was not detected using the sequencing methods that were used. Most 
likely, the reason for this would be that the second mutation is not located in the region 
that is targeted by the mutation detection approach. For instance, with whole exome 
sequencing that is commonly used to date, variants in intronic regions are missed. To be 
able to detect these type of variants, techniques such as whole genome sequencing or 
targeted molecular inverted probe (MIP) sequencing of the complete gene can be used. 
The use of such approaches will most likely lead to the identification of more variants, but 
at the same time will make the interpretation of these variants more challenging.
2.5.2 Improvement of in silico analysis
For the classification of the missense variants we obtained CADD, Grantham and PhyloP 
scores as computational evidence. The PhyloP is a measure for the conservation of a 
nucleotide at a certain position. Since EYS is not present in certain rodent species (mouse, 
rat, guinea pig), there is a probability that scores obtained for PhyloP are lower compared 
to other genes. Therefore, we calculated the average PhyloP score of all coding nucleotides 
of 19640 protein-coding genes in the human genome. Indeed, the average PhyloP score 
of EYS was 0.887, compared to an average PhyloP score of 1.72 for all other genes. This 
calculation suggests that the 2.8 cut-off of the PhyloP score for a variant to be probably 
pathogenic might be too high for some genes in the human genome, including EYS. As 
a result, there could be an underestimation of the missense variants that are classified 
as likely pathogenic. Thus, caution has to be taken by using these in silico scores for the 
classification of the variants.
2.5.3 Experimental assessment of variants of unknown significance
The majority of the missense mutations had to be classified as being of uncertain 
significance, mainly because the available evidence was not sufficient to robustly meet 
the criteria of one of the four pathogenicity categories. Also a number of intronic variants 
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and variants in the 5’-UTR region were classified as of uncertain pathogenicity. Additional 
experimental evidence would definitely help to classify these missense variants, however, 
these data are not available at the moment. To our opinion, there are three main reasons 
that limit a (large-scale) experimental assessment of the pathogenicity of EYS variants. 
First, the Eys gene is absent in the genome of several rodent species, including mouse and 
rat, species that are widely used to study gene and protein function in vision research.54 
Second, the expression of EYS is restricted to the retina, thus preventing the use of easily 
accessible (patient) cells to study EYS function. Third, the cDNA size of EYS (9.4 kb) is 
considerable, thereby complicating cellular transfections studies. However, depending on 
the mutation, there are some possibilities to assess the effect of a certain variant.
For example, to determine whether a variant has an effect on EYS pre-mRNA splicing, one 
ideally would make use of patient-derived cells, by extracting RNA and study EYS mRNA 
composition and levels. Given the retina-specific expression of EYS, one would have to 
make use of induced pluripotent stem cell (iPSC) technology, i.e. reprogram somatic cells 
to pluripotency, and differentiate the iPSC cells into retinal cells.55 This is however very 
labor-intensive and time-consuming. A more manageable approach would be to use 
minigene splice assay, as described previously.56 This is an in vitro assay in which HEK293T 
cells are transfected with either a wild type minigene or a minigene carrying a (splice 
site) variant of interest. These minigenes are plasmids in which a fragment of the gene of 
interest is cloned between Rhodopsin exon 3 and Rhodopsin exon 5 under the control of 
the CMV promoter. Forty-eight hours post-transfection, cells can be harvested to assess 
potential splice defects via RT-PCR analysis. 
For the classification of missense variants, again patient-derived iPS cells could be used. 
For this, the phenotype of iPSCs derived from patients can be compared with iPSCs derived 
from healthy individuals, although a difference in cellular morphology between control 
and patient-derived cells does not necessarily mean that EYS is indeed the causal gene. 
Therefore, dedicated assays such as western blot analysis or immunolocalization studies 
would be necessary to reveal whether EYS function is compromised. Another possibility 
is to study the effect of EYS variants in an in vivo situation, using zebrafish as a model 
organism. Recently, two independent groups demonstrated that targeted disruption of 
Eys in zebrafish leads to retinal degeneration.10,11 With genome editing methods such as 
the CRISPR/Cas9 system available,11,57 it is possible to introduce specific Eys mutations into 
the zebrafish genome, of which the effect can then be studied by a variety of molecular 
and/or functional assays. However, the use of iPSCs as well as of zebrafish models are 
very time- consuming, labor intensive and expensive, thus rendering the in vitro or in vivo 
assessment of EYS variant still very challenging.
As described in this manuscript, the assessment of the pathogenicity of many EYS variants 
remains very challenging, yet this analysis occurs at the single variant level. Given that 
EYS-associated RP is a strictly autosomal recessively inherited disorder, there are always 
two pathogenic alleles needed to molecularly confirm this diagnosis. Thus, even in case 
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there is one clear pathogenic allele, the uncertainty of the second allele complicates 
molecular diagnostics. In such cases, segregation analysis in available relatives can shed 
further light on this. However, experimental evidence would be necessary to provide a 
clear molecular diagnosis.
2.6 Concluding remarks
Taken together, we have uploaded all the reported EYS variants in the LOVD for EYS, 
which thus far only included a small number of EYS variants. This is a first step towards a 
complete overview of all EYS variants in one big database. As the identification of EYS was 
less than ten years ago, we expect more EYS variants to be identified in the near future. 
Furthermore, data of already identified EYS variants is probably still missing from the 
EYS LOVD, since not all variants have been published. Adding genetic data of additional 
patients to this dataset can aid the classification of more pathogenic variants. Next to that, 
it may support the identification of genotype-phenotype correlations for which the data 
available so far were not sufficient to draw any conclusions on this.
In conclusion, our comprehensive analysis resulted in the in silico classification of all 
reported EYS variants. Furthermore, our study underscores the need of functional assays 
to assess the causality of EYS variants that are now classified as being of uncertain 
significance, in order to improve molecular diagnostics and counseling of patients with 
EYS-associated RP.
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    Human     (1) --MTDKSIVILSLMVFHSSFINGKT-CRRQLVEEWHPQPSSYVVNWTLTENICLDFYRDCWFLGVN-TKIDTSGNQAVPQ 
  Macaque     (1) --MTDKSIIILSLMVFHSSFINGKT-CRRELVEEWHPQPSSHVVNWTLTENICLDYYRDCWFLGVN-TKIDTSGNQVVPQ 
      Pig     (1) --MTNKLNTLVTLVVLHSMLINGKTTCKRHLVEEWRTQPSSYVVNWTLTENICLGVYGDCWFGDVN-AKINTSENHVVPQ 
  Chicken     (1) --MTPKSTVHMVVCFLQLCIVKGQIICERQIIAEWRVEPKHVLIEWTLRKNICTDFYSECWNVNKN-ATREDKN-LSVPQ 
Zebrafish     (1) MRNPKLAIIVFLLSCVIYGPVYSQVTCRRATSREWHTQPKNISVRWTLMENTCSSLTQCWSSFAETNGHFWTTGPYHFPQ 
                  -----Signal peptide ------------------------------------------------------------ 
 
    Human    (77) ICPLQIQLGDILVISSEPSLQFPEINLMNVSETSFVGCVQNTTTEDQLLFGCRLKGMHTVNSKWLSVGTHYFITVMASGP 
  Macaque    (77) ICPLQIQLGDILVISSEPSLQFPEINLMNVSETSFIGCVQNTTTEDQLLFGCRLKGMHTVNSKWLSVGTHYFITVMASGP 
      Pig    (78) ICPLQIQLGDILVISSEPSLEYPEINLMNVSEASFIDCLQNTTTEDQLLFGCKLKGMHIINSHWLSVGTHYFITVMANGK 
  Chicken    (77) ICPVQLQLGDTLFISSEPSFQSYGMNLVNVSKEEFINCPKIGFLQEQQIFVCQIRGLHQVDSTWLGVGTHYFAELHKRGP 
Zebrafish    (81) LCPLELQLGDLLFVSADGTLEQHGVQLIKVSKEEFDKCAILEPRKEQLVFASSINGTLQVESKWLMSGLNYFTIINRGSS 
                  -------------------------------------------------------------------------------- 
 
    Human   (157) SPCPLGLRLNVTVKQQFCQESLSSEFCSGHGKCLSEAWSKTYSCHCQPPFSGKYCQELDACSFKPCKNNGSCINKRENWD 
  Macaque   (157) SPCPLGLRLNVTVKQQFCQESLSSEFCSGHGKCLSEAWSKTYSCHCQPPFSGKYCQELDACSFKPCKNDGSCINKRGNWD 
      Pig   (158) SLCQLGLRLNVTVKEQFCQEYQSSELCSGHGKCLTEVWSKTYSCHCQGPYSGKYCQELDPCSYKPCKHNGSCINKGETWN 
  Chicken   (157) YLCNMGLRLNVTVKQQFCQETPNAPLCSKHGRCLSRVWEKQYSCHCFSQYSGKFCQKFNVCSTKPCHNNASCTEKLEGIR 
Zebrafish   (161) HLCRFGLRIAVLVKPQLCQSSPLLRLCSGKGECRTTLKDDSFTCRCHKHFSGRYCENVDGCYEQPCLNGGTCLSEGSAYT 
                  -------------------------    EGF domain------------------------- EGF domain ---- 
 
    Human   (237) EQ-AYECVCHPPFTGKNCSEIIG-QCQPHVCFHGNCSNITSNSFICECDEQFSGPFCEVSAKPCVSLLFWKRGICPNSSS 
  Macaque   (237) EQ-GYECVCHPPFTGKNCSEIIV-QCQPHVCFHGNCSNITSNSFICECDEQFSGPFCEVSTKPCVSLLCWKRGICPNSSS 
      Pig   (238) KQ-GYECICYPPFTGINCSEIIG-KCQPHIHFHGNCSNVTSNSFICECEEPFSGSLCEESLECCCLEGFFS--------- 
  Chicken   (237) N--SYECTCPPEFSGKNCTEIVG-QCQPHTCFNGNCSNVTPNTFLCECDKGFTGPFCEEPGDPCASQPCLNRGVCQYNQS 
Zebrafish   (241) DLPPYTCLCPAPFTGVNCSEIIGNQNCSKWCKEGACLKVSSTSYRCECFTGYTGTYCERKRLFCDSNPCRNDGRCEETAN 
                  -   EGF domain---------------------- EGF domain -------------------------------- 
 
    Human   (315) AYTYECPKGSSSQNGETDVSEFSLVPCQNGTDCIKISNDVMCICSPIFTDLLCKSIQTSCESFPLRNNATCKKCEKDYPC 
  Macaque   (315) AYTYECPKGPSSQNGETDVSECSLILCENGTDGIKISNDVMCICSPIFTDLLCKSFQTSCESFPLKNNATFKKCEKDYHC 
      Pig   (307) -----QN-------YETDVNVCSPNPCQNGTDCIDIPKDIMCMCLPIFTDKLCKHLQTPHEAFPCKTKATDMKYEENYHC 
  Chicken   (314) GYICDCPAGFLGQDCEVDINECSSRPCQNRGTCIDLPNDVSCSCLPLFTGKFCERILNPCELLPCLNNATCVSEQQNYKC 
Zebrafish   (321) GYVCTCPGGFTGLNCETTAEADSYCKS-SGCQLDEACATDKLNATCICVDPECLEQAEVCGTLPCLNGGICVVPNGQYHC 
                  --------------------- EGF domain ----------------------------EGF-like domain---- 
 
    Human   (395) SCISGFTEKNCEKAIDHCKLLSINCLNEEWCFNIIGRFKYVCIPGCTKNPCWFLKNVYLIHQHLCYCG------------ 
  Macaque   (395) SCMSGFTGKNCEKVIDHCKLLSINCLNEEWCFNIIGRFKYVCIPGCTKNPFWFLKNVHLIHLHPCYYG------------ 
      Pig   (375) SFMPGFTGKNCEKVIDHCRLLTINCLNEGWCFNIIGRFRYICTPGHTRNSCWFVKNACFFHLYPCYCG------------ 
  Chicken   (394) RCMPGFTGKNCEEVIDYCKLLSINCLNEGLCLNIIGGFTCLCAPGWTGEFCQVAENACLIYPKSCSNGSTCIDMSQLGEQ 
Zebrafish   (400) RCRQGFSGKNCEEIIDFCKLLNINCLNEGLCLNRVGGYNCLCAPGWTGEFCQYLENACLAYPNRCLNGATCISMSQTTAP 
                  -----------------    -------EGF-CA domain - ------------------------------------ 
 
    Human   (463) ---------------------VTFHGICQDKGP--AQFEYVWQLGFAGSEGEKCQGVIDAYFFLAANCTEDATYVNDPED 
  Macaque   (463) ---------------------ITFHGICQDKGP--AHFEYVWQLGFTGSEGEKCQGVIDAYFFLTANCTEDAIYVNNPED 
      Pig   (443) ---------------------AISHNICQAEDASPPQFKYVWRLGLTGSEGQKCEVFTGDYFFLIANCTKDTVCVNQPEA 
  Chicken   (474) PLFQCLCPHGFTGEFCKVQIDNCNSNLCENGGTCVNYEDHFKCICPMGFEGERCELDIDVCLFYNISCAPGAVCMNKSHG 
Zebrafish   (480) PHYMCTCLPGYTGPYCEAEVNECDSSPCQHQGTCTDFVGYYKCTCPSGYTGIDCEIDINSCWLPNATCPPETLCVDLPGD 
                  -------------------------------------------------------------------------------- 
 
    Human   (520) NNSSCWFPHEGTKEICANGCSCLSEEDSQEYRYLCFLRWAGNMYLENTTDDQENECQHEAVCKDEINRPRCSCSLSYIGR 
  Macaque   (520) NNSSCSFPCEGTKEICANGCSCLSEEDNQEYRYLCFLRWTSNMYLENITDDQENKSQHEAICEDEINRPRCSCSLSYIGR 
      Pig   (502) LGHVCWFLHEGKREMSVNGCRCLTEENNKRYQCLCIPTWLCKMYLENTTDYEENRCQQEDNYEDEINIPRCRYSLGRIDR 
  Chicken   (554) FNYTCLSPCIGKTEVCANGGSCFYDEGNQRSHCVCAHGWTGQTCLENINDCEINQCQHGATCEDEVNKYRCICPLGYTGT 
Zebrafish   (560) QLFKCHTPCPHYLQPCANGGHCVLHN-ITSYSCVCAPGWTGATCLVNINECVQHRCQNRATCVDEVGGYSCLCGHGYTGV 
                  ---------------------------------------------------EGF domain------------------- 
 
    Human   (600) LCVVNVDYCLGNHSISVHGLCLALSHNCNCSGLQRYERNICEIDTEDCKSASCKNG------------------------ 
  Macaque   (600) LCVVNVDYCLGNQSISVHGLCLALSHNCNCSDLQKYEGNICEIDIEDCKSVSCKNG------------------------ 
      Pig   (582) FYMLSVEDCLGSQNTSMHGLCLVHLHGCNFTCPQRCERHICEIETEDGEPAPCNNG------------------------ 
  Chicken   (634) FCEIDIDNCIGN-QCSEYGFCQDHLHNYSCICMLGYGGPFCEVEINECSSSPCKNGGICMNLIGSFSCHCAEGFKGETCT 
Zebrafish   (639) HCELDFCSGHQC---SEHAVCVDQQHNYTCRCMLGYEGTLCELETDECKSAPCTNNATCIDLVAGYQCLCAPGFKGRTCS 
                  -------------------------------------------------------------------------------- 
 
    Human   (656) -------------------------------------------------------------------------------- 
  Macaque   (656) -------------------------------------------------------------------------------- 
      Pig   (638) -------------------------------------------------------------------------------- 
  Chicken   (713) AHVNECLDRPCWNGGTCEEDINGFKCNCPLGFEGLNCEINFDECTYGFCKNNSTCLDLIA--DYSCVCPPGFTDKNCSTD 
Zebrafish   (716) ESMNECWSRPCNNGGSCIDLVNDYICNCPLGFTGHDCSMPATGCTSNPCNTKGTSMCEEQQDGFKCVCHHGYTGLFCETS 
                  -------------------------------------------------------------------------------- 
 
    Human   (656) -------------------------------------------------------------------------------- 
  Macaque   (656) -------------------------------------------------------------------------------- 
      Pig   (638) -------------------------------------------------------------------------------- 
  Chicken   (791) IDECAFKPCQNGGHCHNLIGEFYCSCLPGFTGQFCEADVAACLSQPCGASSICKDMSDGYVCFCAPGFIGNNCEIEVDEC 
Zebrafish   (796) INHCVEGLCHHGSECVDLTKGFMCECLPGLRGRLCEVNIDDCLDKPCGALSICKDGINAYDCFCAPGFVGNNCEIEVNEC 
 
                  -------------------------------------------------------------------------------- 
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  Chicken     (1) --MTPKSTVHMVVCFLQLCIVKGQIICERQIIAEWRVEPKHVLIEWTLRKNICTDFYSECWNVNKN-ATREDKN-LSVPQ 
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  Chicken    (77) ICPVQLQLGDTLFISSEPSFQSYGMNLVNVSKEEFINCPKIGFLQEQQIFVCQIRGLHQVDSTWLGVGTHYFAELHKRGP 
Zebrafish    (81) LCPLELQLGDLLFVSADGTLEQHGVQLIKVSKEEFDKCAILEPRKEQLVFASSINGTLQVESKWLMSGLNYFTIINRGSS 
                  -------------------------------------------------------------------------------- 
 
    Human   (157) SPCPLGLRLNVTVKQQFCQESLSSEFCSGHGKCLSEAWSKTYSCHCQPPFSGKYCQELDACSFKPCKNNGSCINKRENWD 
  Macaque   (157) SPCPLGLRLNVTVKQQFCQESLSSEFCSGHGKCLSEAWSKTYSCHCQPPFSGKYCQELDACSFKPCKNDGSCINKRGNWD 
      Pig   (158) SLCQLGLRLNVTVKEQFCQEYQSSELCSGHGKCLTEVWSKTYSCHCQGPYSGKYCQELDPCSYKPCKHNGSCINKGETWN 
  Chicken   (157) YLCNMGLRLNVTVKQQFCQETPNAPLCSKHGRCLSRVWEKQYSCHCFSQYSGKFCQKFNVCSTKPCHNNASCTEKLEGIR 
Zebrafish   (161) HLCRFGLRIAVLVKPQLCQSSPLLRLCSGKGECRTTLKDDSFTCRCHKHFSGRYCENVDGCYEQPCLNGGTCLSEGSAYT 
                  -------------------------    EGF domain------------------------- EGF domain ---- 
 
    Human   (237) EQ-AYECVCHPPFTGKNCSEIIG-QCQPHVCFHGNCSNITSNSFICECDEQFSGPFCEVSAKPCVSLLFWKRGICPNSSS 
  Macaque   (237) EQ-GYECVCHPPFTGKNCSEIIV-QCQPHVCFHGNCSNITSNSFICECDEQFSGPFCEVSTKPCVSLLCWKRGICPNSSS 
      Pig   (238) KQ-GYECICYPPFTGINCSEIIG-KCQPHIHFHGNCSNVTSNSFICECEEPFSGSLCEESLECCCLEGFFS--------- 
  Chicken   (237) N--SYECTCPPEFSGKNCTEIVG-QCQPHTCFNGNCSNVTPNTFLCECDKGFTGPFCEEPGDPCASQPCLNRGVCQYNQS 
Zebrafish   (241) DLPPYTCLCPAPFTGVNCSEIIGNQNCSKWCKEGACLKVSSTSYRCECFTGYTGTYCERKRLFCDSNPCRNDGRCEETAN 
                  -   EGF domain---------------------- EGF domain -------------------------------- 
 
    Human   (315) AYTYECPKGSSSQNGETDVSEFSLVPCQNGTDCIKISNDVMCICSPIFTDLLCKSIQTSCESFPLRNNATCKKCEKDYPC 
  Macaque   (315) AYTYECPKGPSSQNGETDVSECSLILCENGTDGIKISNDVMCICSPIFTDLLCKSFQTSCESFPLKNNATFKKCEKDYHC 
      Pig   (307) -----QN-------YETDVNVCSPNPCQNGTDCIDIPKDIMCMCLPIFTDKLCKHLQTPHEAFPCKTKATDMKYEENYHC 
  Chicken   (314) GYICDCPAGFLGQDCEVDINECSSRPCQNRGTCIDLPNDVSCSCLPLFTGKFCERILNPCELLPCLNNATCVSEQQNYKC 
Zebrafish   (321) GYVCTCPGGFTGLNCETTAEADSYCKS-SGCQLDEACATDKLNATCICVDPECLEQAEVCGTLPCLNGGICVVPNGQYHC 
                  --------------------- EGF domain ----------------------------EGF-like domain---- 
 
    Human   (395) SCISGFTEKNCEKAIDHCKLLSINCLNEEWCFNIIGRFKYVCIPGCTKNPCWFLKNVYLIHQHLCYCG------------ 
  Macaque   (395) SCMSGFTGKNCEKVIDHCKLLSINCLNEEWCFNIIGRFKYVCIPGCTKNPFWFLKNVHLIHLHPCYYG------------ 
      Pig   (375) SFMPGFTGKNCEKVIDHCRLLTINCLNEGWCFNIIGRFRYICTPGHTRNSCWFVKNACFFHLYPCYCG------------ 
  Chicken   (394) RCMPGFTGKNCEEVIDYCKLLSINCLNEGLCLNIIGGFTCLCAPGWTGEFCQVAENACLIYPKSCSNGSTCIDMSQLGEQ 
Zebrafish   (400) RCRQGFSGKNCEEIIDFCKLLNINCLNEGLCLNRVGGYNCLCAPGWTGEFCQYLENACLAYPNRCLNGATCISMSQTTAP 
                  -----------------    -------EGF-CA domain - ------------------------------------ 
 
    Human   (463) ---------------------VTFHGICQDKGP--AQFEYVWQLGFAGSEGEKCQGVIDAYFFLAANCTEDATYVNDPED 
  Macaque   (463) ---------------------ITFHGICQDKGP--AHFEYVWQLGFTGSEGEKCQGVIDAYFFLTANCTEDAIYVNNPED 
      Pig   (443) ---------------------AISHNICQAEDASPPQFKYVWRLGLTGSEGQKCEVFTGDYFFLIANCTKDTVCVNQPEA 
  Chicken   (474) PLFQCLCPHGFTGEFCKVQIDNCNSNLCENGGTCVNYEDHFKCICPMGFEGERCELDIDVCLFYNISCAPGAVCMNKSHG 
Zebrafish   (480) PHYMCTCLPGYTGPYCEAEVNECDSSPCQHQGTCTDFVGYYKCTCPSGYTGIDCEIDINSCWLPNATCPPETLCVDLPGD 
                  -------------------------------------------------------------------------------- 
 
    Human   (520) NNSSCWFPHEGTKEICANGCSCLSEEDSQEYRYLCFLRWAGNMYLENTTDDQENECQHEAVCKDEINRPRCSCSLSYIGR 
  Macaque   (520) NNSSCSFPCEGTKEICANGCSCLSEEDNQEYRYLCFLRWTSNMYLENITDDQENKSQHEAICEDEINRPRCSCSLSYIGR 
      Pig   (502) LGHVCWFLHEGKREMSVNGCRCLTEENNKRYQCLCIPTWLCKMYLENTTDYEENRCQQEDNYEDEINIPRCRYSLGRIDR 
  Chicken   (554) FNYTCLSPCIGKTEVCANGGSCFYDEGNQRSHCVCAHGWTGQTCLENINDCEINQCQHGATCEDEVNKYRCICPLGYTGT 
Zebrafish   (560) QLFKCHTPCPHYLQPCANGGHCVLHN-ITSYSCVCAPGWTGATCLVNINECVQHRCQNRATCVDEVGGYSCLCGHGYTGV 
                  ---------------------------------------------------EGF domain------------------- 
 
    Human   (600) LCVVNVDYCLGNHSISVHGLCLALSHNCNCSGLQRYERNICEIDTEDCKSASCKNG------------------------ 
  Macaque   (600) LCVVNVDYCLGNQSISVHGLCLALSHNCNCSDLQKYEGNICEIDIEDCKSVSCKNG------------------------ 
      Pig   (582) FYMLSVEDCLGSQNTSMHGLCLVHLHGCNFTCPQRCERHICEIETEDGEPAPCNNG------------------------ 
  Chicken   (634) FCEIDIDNCIGN-QCSEYGFCQDHLHNYSCICMLGYGGPFCEVEINECSSSPCKNGGICMNLIGSFSCHCAEGFKGETCT 
Zebrafish   (639) HCELDFCSGHQC---SEHAVCVDQQHNYTCRCMLGYEGTLCELETDECKSAPCTNNATCIDLVAGYQCLCAPGFKGRTCS 
                  -------------------------------------------------------------------------------- 
 
    Human   (656) -------------------------------------------------------------------------------- 
  Macaque   (656) -------------------------------------------------------------------------------- 
      Pig   (638) -------------------------------------------------------------------------------- 
  Chicken   (713) AHVNECLDRPCWNGGTCEEDINGFKCNCPLGFEGLNCEINFDECTYGFCKNNSTCLDLIA--DYSCVCPPGFTDKNCSTD 
Zebrafish   (716) ESMNECWSRPCNNGGSCIDLVNDYICNCPLGFTGHDCSMPATGCTSNPCNTKGTSMCEEQQDGFKCVCHHGYTGLFCETS 
                  -------------------------------------------------------------------------------- 
 
    Human   (656) -------------------------------------------------------------------------------- 
  Macaque   (656) -------------------------------------------------------------------------------- 
      Pig   (638) -------------------------------------------------------------------------------- 
  Chicken   (791) IDECAFKPCQNGGHCHNLIGEFYCSCLPGFTGQFCEADVAACLSQPCGASSICKDMSDGYVCFCAPGFIGNNCEIEVDEC 
Zebrafish   (796) INHCVEGLCHHGSECVDLTKGFMCECLPGLRGRLCEVNIDDCLDKPCGALSICKDGINAYDCFCAPGFVGNNCEIEVNEC 
 
                  -------------------------------------------------------------------------------- 
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    Human   (656) ----------------------------------------------TTSTHLRGYFFRKCVPGFKGTQCEIDIDECASHP 
  Macaque   (656) ----------------------------------------------TTSIHLRGYFFYKCVPGFKGTRCEIDLDECALHP 
      Pig   (638) ----------------------------------------------TTGIHLSGYFFANCFPSFQGARYEINVDNYASHL 
  Chicken   (871) LSDPCHSGATCIDHLNGFSCICQGGFQGTTCETNINECHSSPCLHNATCADFVGGYECICLPGFTGTRCETDIDECASSP 
Zebrafish   (876) LSQPCQNGASCSDELNSFSCLCLAGTTGSLCEINIDECQSSPCMNNGTCLDLSDGFKCICPSGFSGPECSMDINECVSYP 
                  -------------------------------------------------------------------------------- 
 
    Human   (690) CKNGATCIDQPGNYFCQCVPPFK--------------------------------------------------------- 
  Macaque   (690) CKSGATCIDQPGNYFCQCGPPFK--------------------------------------------------------- 
      Pig   (672) CTNRATCNDQAGSYSCQYVAPFS--------------------------------------------------------- 
  Chicken   (951) CKNGATCIDQPGNYFCQCMAPFKGLNCEFRPCEASNPCENGAVCTEEMNLDAFPLGFQCQCVKGFAGPRCEINVNECSSN 
Zebrafish   (956) CKNGGSCIDQPGNYYCRCLAPFKGLNCELLPCEAVNPCDNGAECVEEADLVLFPLGFQCRCRKGFTGPRCEVNIDECSSN 
                  - EGF-CA domain------- --------------------------------------------------------- 
 
    Human   (713) ---------VVDGFSCLCNPGYVGIRCEQDIDDCILNACEHNSTCKDLHLSYQCVCLSDWEGNFCEQESNECKMNPCKNN 
  Macaque   (713) ---------VVDGFSCLCNPGYVGTRCEQNIDNCILNAFEHNSTYKDLHLSYQCVCLSGWEGNFCEQESNECKMNPCKNN 
      Pig   (695) ---------VVDSFSCLHSLGSAGLRCEQDIEDCVLNAHESNSTCKYLHLNYQCVCFSGWERHFCERESSTCQKNPCKNN 
  Chicken  (1031) PCLHGYCYDIVNGFYCLCNPGYAGLTCEQDIDDCINNACEHNSTCVDLHLRYQCVCLPGWEGTFCEYESNECDSEPCRNN 
Zebrafish  (1036) PCLNGFCYDAVDGFYCLCNPGYAGVRCEQHINDCASNMCENNSTCVDLHLSYNCLCLPGWEGEYCQRETNECLSNPCKNN 
                  -------------------------------------- EGF-CA domain ----- --------------------- 
 
    Human   (784) STCTDLYKSYRCECTSGWTGQNCSEEINECDSDPCMNGGLCHESTIPGQFVCLCPPLYTGQFCHQRYNLCDLLHNPCRNN 
  Macaque   (784) STCTDLYKSYRCECTSGWTGQNCSEEINECDSDPCMNGGLCHESTIPGQFVCLCPPLYTGQFCHQRYNPCDLLNNPCRNN 
      Pig   (766) STCTDLDSSYRCECTFGWTGQNCSEEINECDSDPCMNGALCHESSIPGQFVCLCPPFYTGKFCHQHYNPCDPPNDPCQNN 
  Chicken  (1111) GTCTDLFNSYRCLCTAGWTGPDCSEDINECDSEPCLNGATCYESVKQGQFVCICPPFYTGDFCHQRFSPCELPYNPCINN 
Zebrafish  (1116) ATCTDLLNAYRCVCPQGWTGLDCDEDVKECSSSPCLNGAHCVESDTPGEFSCTCPPFFTGPLCEQPYDPCELQRNPCLHN 
                  - ---EGF-CA domain----- --------------EGF domain-------------------------------- 
 
    Human   (864) STCLALVDANQHCICREEFEGKNCEIDVKDCLFLSCQDYGDCEDMVNNFRCICRPGFSGSLCEIEINECSSEPCKNNGTC 
  Macaque   (864) STCLALVDGNQHCICREEFEGKHCEIDVKECLFLSCQDYGDCEDMVNNFRCICRPGFSGSLCEIEINECSSEPCKNNGTC 
      Pig   (846) STCLTLVDGNYHCLCRQGFKGQHCEINMSACLFLPCQSYADHKDGVKNFRCVFRPRLSGPLCENEINEGSCKPYKNSGVS 
  Chicken  (1191) STCLAQADGNPMCICKTGYEGTYCEVNSDECISHPCQNEGLCVDGINSYRCFCQHGFTGTLCEVEINECLSRPCKNNGTC 
Zebrafish  (1196) STCRAQSDGTALCVCPVGFEGTRCEIDSDDCVSRPCQNRGICVDGVNSYSCFCEPGFSGLHCEEDINECASNPCQNQAVC 
                  -----EGF domain-----------------------EGF domain-------------------------------- 
 
    Human   (944) VDLTNRFFCNCEPEYHGPFCELDVNKCKISPCLDEENCVYRTDGYNCLCAPGYTGINCEINLDECLSEPCLHDGVCIDGI 
  Macaque   (944) VDLTNRFFCNCEPGYHGPFCELEVNKCKISPCLDEENCVYRTDRYNCLCAPGYTGINCEINLDECLSEPCLHDGVCIDGI 
      Pig   (926) VDLTNKLVCHCEPEYHGYFCELNINEHETSPCPDGENVVNRTGGYICLCAPGYSGIDCEVNIDKCLSKAYFHGGTCIDGI 
  Chicken  (1271) LDLINRFICNCAPGYYGSLCEIDINECETLPCLNGGSCINRLGGYQCFCSPGFTGDRCETNTDECISTPCLNNGSCIDDI 
Zebrafish  (1276) QDLVNGFQCSCVPGYFGPHCNLDVNECDSSPCLHESVCINKPGGFACVCSAGFSGKWCELNVDECKSNPCRNNGSCIDGL 
                  -- EGF-CA domain ---------------- - EGF domain----------------- EGF-CA domain – 
 
    Human  (1024) NHYTCDCKSGFFGTHCETNANDCLSNPCLHGRCTELINEYPCSCDADGTSTQCKIKINDCTSIPCMNEGFCQKSAHGFTC 
  Macaque  (1024) NHYTCDCKSGFFGTHCETNANDCLSNPCLHGRCTEPINEYPCSCDADGTSIQCKIKINDCTSMPCMNEGFCQKSAHGFTC 
      Pig  (1006) NHYACDCKSGFSRRHCEANANDCISNPCPQGRCIEFTDEHQCSCDAEWTSAKCEIKINDCTSILSTNEGFCQKAAHSFPC 
  Chicken  (1351) NSYKCHCRSGFIGTNCETNVNECWPEPCLHGRCIDLIDGYQCSCEAGWTSSRCEININECESVPCINGGSCQDLVNEFAC 
Zebrafish  (1356) NGYQCVCSRGFMGDHCERNTDECSSGPCVHGSCLDEIDAFSCQCEVGWTGHRCQININECEAHPCLNGGSCVDLLDKYAC 
                  ---------------------------EGF-like domain---------------------EGF domain------- 
 
    Human  (1104) ICPRGYTGAYCEKSIDNCAEPELNSVICLNGGICVDGPGHTFDCRCLPGFSGQFCEININECSSSPCLHGADCEDHINGY 
  Macaque  (1104) ICPRGYTGAYCEKSIDNCAEPELNSVICLNGGICVDGPGHTFDCRCLPGFSGQFCEININECSSSPCLHGANCEDHINGY 
      Pig  (1086) ICSSQSSDTYCEVNISSCAEPVLNTVFWLNGGICVDGHGHTFYCRCLPGFSGKFCEININGCVSSPCVYGANSENHINGY 
  Chicken  (1431) ICLTGYTGKFCEFDIDICNEPTVSSVLCHNGGVCVDGPGRTFHCRCLAGFSGQFCEIEVNECNSSPCLHGSTCEDHVNGY 
Zebrafish  (1436) ICADGFTGKNCDIDQNVCLQTSLNFSLCFNGGTCVDGPGVNFTCSCRPGFMGDFCEVEMNECCSEPCFNGAICQDLINGY 
                  -----------------------------EGF domain----------------------- EGF-CA domain --- 
 
    Human  (1184) VCKCQPGWSGHHCENEL-ECIPNSCVHELCMENEPGS--TCLCTPGFMTCSIGLLCGDEIRRITCLTPIFQRTDPISTQT 
  Macaque  (1184) VCKCQPGWSGHHCEKEL-ECVPNSCVHQLCMENEPGS--TCLCTPGFMTCSIGLLCGDEIRRITCLTPSFQRTDPISTQT 
      Pig  (1166) ICKCQQGKSGRPCEKEL-EWLSNFLVHGTHIGNKTGVGVTCLHTSGIVNFSIGLLCGNEIGRITCLPPVSTRTEANSTKT 
  Chicken  (1511) TCQCQKGWEGLHCELDVDECISNPCIHGICVQSDPSFGYSCFCKPGFVGRSCELNYNDCLIQSCSSGFLCVDGINNITCL 
Zebrafish  (1516) QCHCRPGWTGLHCEDDINECLLQPCNQGMCIQNEPGHGYTCFCRPGFVGENCEYNYDDCLIQSCPETFSCKDGINNVSCV 
                  --------------------------- EGF-like domain ------------------------------------ 
 
    Human  (1261) YTIPPSETLVSSFPSIKATRIPAIMDTYPVDQGPKQTGIVKHDILPTTGLATLRISTPLESYLLQELIVTRELSAKHSLL 
  Macaque  (1261) HTVPPSETLVSSFPSIKATRIPTIMDTYPVDQGPKQTGIVKHDILPTTGLATLRISTPLKSYLLEELIVTRELSAKHSLL 
      Pig  (1245) YTVLTSGISVSTFLFAKATPLWTIMNTSPVYQGPKQTDNFKHEVLPTTGLTALNIGTFFESYLLRELISTGELSAQHSLS 
  Chicken  (1591) PTISQS----------KKTEMAELFPTESLDN-----------------------------DLPSALAVSMELWSKHAIP 
Zebrafish  (1596) PVKTDTS----------------SLPPISVVSWRSTDIS---------------------TELQPTFAPVENLQHTEQPA 
                  -------------------------------------------------------------------------------- 
 
    Human  (1341) SSADVSSSRFLNFGIRDPAQIVQDKTSVSHMPIRTSAATLGFFFPDRRARTPFIMSSLMSDFIFPTQSLLFENCQTVALS 
  Macaque  (1341) SSTDVSSSPFLNFGIHDPAQIVQDKTSVSHMRIRTSAATLGFFFPDRRARTSFIRSSLMSDFIFPTQSLLFENYQTVASS 
      Pig  (1325) SSTDVSSSQFLNFGVHDPAQIVGGKTSIVHMPFQTSADTPGLFSSDKGESTPFIISSLTTNFIFPTQSLLSESSQAIASS 
  Chicken  (1632) DFHTEEVA------------------------------------------------------------------------ 
Zebrafish  (1639) DASFGGYS------------------------------------------------------------------------ 
                  -------------------------------------------------------------------------------- 
 
    Human  (1421) ATPTTSVIRSIPGADIELNRQSLLSRGFLLIAASISATPVVSRGAQEDIEEYSADSLISRREHWRLLSPSMSPIFPAKVI 
  Macaque  (1421) ATPTTSVIRSIPGADIELNRHSLLSRGFLLTAASISATPVVSRGAQEDIKEYSAVSLISRREHWRSLISSMSPIFPAKKI 
      Pig  (1405) APTMSLVISGIPGVGIELNRHSLLSRGFLLSTTSTSAPPVISCGAQEDIEAFSAVSLILRREFQRPLSASTSPISPTKII 
  Chicken  (1640) -------------------------------------------------------------------------------- 
Zebrafish  (1647) -------------------------------------------------------------------------------- 
                  -------------------------------------------------------------------------------- 
    Human  (1501) ISKQVTILNSSALHRFSTKAFNPSEYQAITEASSNQRLTNIKSQAADSLRELSQTCATCSMTEIKSSREFSDQVLHSKQS 
  Macaque  (1501) ISKQVTILNSSALHRFGTKAFIPSEYQAITEASSNQRLTNIKSQAADSLRELSQTCATCSMTEIKSSHEFSDQVLHSKQS 
      Pig  (1485) ISKQVAVLNSSTLHRFTTQASIPSEYQLNTEASSNQRLTNIKPQAADFLSELSQTCATCSMTEIKSSHEFSDEVSHSKQP 
  Chicken  (1640) --------------------------------------------------------------------------QD---- 
Zebrafish  (1647) -------------------------------------------------------------------------------- 
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                -------------------------------------------------------------------------------- 
    Human  (1581) HFYETFWMNSAILASWYALMGAQTITSGHSFSSATEITPSVAFTEVPSLFPSKKSAKRTILSSSLEESITLSSNLDVNLC 
  Macaque  (1581) HFYETFWMNSAILASWYALMGAQTITSGHSFSSATEITPSVAFTEVPSLFPSKKSAKRTILSSSLEESITLSSNLDVNLC 
      Pig  (1565) QFYDTFSMYSAILASWYALMGMQTTTAGHSFPSSEEIMPSVAITEPSSLFPSKKSTKRRILVSSVEEYITQSSNLDANLC 
  Chicken  (1642) -------------------------------------------------------------------------------- 
Zebrafish  (1647) -------------------------------------------------------------------------------- 
                  -------------------------------------------------------------------------------- 
 
    Human  (1661) LDKTCLSIVPSQTISSDLMNSDLTSKMTTDELSVSENILKLLKIRQYGITMGPTEVLNQESLLDMEKSKGSHTLFKLHPS 
  Macaque  (1661) LHKTCLSIVPSQTISSDLMNSDLTSELTTDELSVSENILKLLKIRQYGITTGPTEVLNQDSLLDMEKSKGSHTPFKLHPS 
      Pig  (1645) LNKMCLSIVPSQTVSLDLTNSDLTSKLTKGDPLGSENILKLLKIGHYGITMDPTEMLNQNKLLGVQEHEGSQTPSKLHAR 
  Chicken  (1642) -------------------------------------------------------------------------------- 
Zebrafish  (1647) -------------------------------------------------------------------------------- 
                  -------------------------------------------------------------------------------- 
 
    Human  (1741) DSSLDFELNLQIYPDVTLKTYSEITHANDFKNNLPPLTGSVPDFSEVTTNVAFYTVSATPALSIQTSSSMSVIRPDWPY- 
  Macaque  (1741) DSSLDLELNLRSYPDVTLKTYSEITLANDLKNNLPPLTGSVPDFSEVTTNVAFYTVSATPALPIQTSSSMSVITPDWPY- 
      Pig  (1725) DGSLDFELNLRSHP--------ETMHSSDLKSNLPPSIDSTSDFSEVSSHITFSAVSASQSFPIQTSVPMSVLTPDWTYT 
  Chicken  (1642) -------------------------------------------------------------------------------- 
Zebrafish  (1647) -------------------------------------------------------------------------------- 
                  -------------------------------------------------------------------------------- 
 
    Human  (1820) -FTDYMTSLKKEVKTSSEWSKWELQPSVQYQEFPTASRHLPFTRSLTLSSLESILAPQRLMISDFSCVRYYGDSYLEFQN 
  Macaque  (1820) -FIDYMTSLNKEVKTYSEWSKWELQPSVQYQEFPTASWHLPFTRSLTLSSLESIVAPQQLMISDFSCVCYYGDSYLEFQN 
      Pig  (1797) DYLNLTSYLKENTRTSSEWSKWELQPSGHGQESPAASQRISITRSLSLSSLEPIPASPWLKISDFSCVCYHGESYLEFQN 
  Chicken  (1642) ---------------------------------------------------FSYAR-------------YYGDSYLEFQG 
Zebrafish  (1647) ---------------------------------------------------------------------GN--SFLEFGG 
                  -------------------------------------------------------------------------------- 
 
    Human  (1899) VALNPQNNISLEFQTFSSYGLLLYVKQDSNLVDGFFIQLFIENGTLKYHFYCPGEAKFKSINTTVRVDNGQKYTLLIRQE 
  Macaque  (1899) VVLNPQNNISLEFQTFSSYGLLLYVKQDSNLVDGFFIQLSIENGTLKYHFYCPGEAKFKSINTAIRVDDGQKYTLLIRQE 
      Pig  (1877) VFLNPQNNISLEFQTSNTYGLLLYIKQDPDIADGFFFQLFIENGTLKYHFFCAGEAKLKSINTTIKVDDGQKYTLFIRQE 
  Chicken  (1658) LHLNVQNFIHLEFKTYKPDGLLLYIEESSETIGQFLIQLFIRHGILQYQFVCGKATQVKNITTTARVDDGQWYKVQIRQN 
Zebrafish  (1656) FEVAVPISVTVRFQTESMYGTLLYS--ASAKRSVFFIKLYISNGILQYDFLCNQKQGVQRINTAQWVADGNEHVVIFRQC 
                  ----------------------------Laminin-G domain------------------------------------ 
 
    Human  (1979) LDPCNAELTILGRNTQICESINHVLGKPLPKSGSVFIGGFPDLHGKIQMPVPVKNFTGCIEVIEINNWRSFIPSKAVKNY 
  Macaque  (1979) LDPCKAELTILGRNTQTCESINHVLGKPLPKSGSVFIGGFPDLRGKIQMPVPVKNFTGCIEVIEINNWRSFIPSKAVRNY 
      Pig  (1957) LDPCKAELTILGRTIKASKSINHIYGKPLPDSGTVFVGGIPDLHGVNQISGPVENFTGCIEIIEINNWRSFIPSKAVKKI 
  Chicken  (1738) MKPCEAEMLILEVSAKTGIPSNFSSSPYGLETGSIFVGGLPYSSAIKQIPEPVYNFTGCIQVIEINNVGPFNFSNAVGRR 
Zebrafish  (1734) LFPCVAEVTVSGVRTVRSAPGNYTSALRLQRTDHVFIGGLPRHRSPYKEAEPFHNYTGCIEIIEINKLRRFHMDHAIARN 
                  -------------------------Laminin-G domain--------------------------------------- 
 
    Human  (2059) HINNCRSQGFMLSPTASFVDASDVTQGVDT--MWTSVSPSVAAPSVCQQDVCHNGGTCHAIFLSSGIVSFQCDCPLHFTG 
  Macaque  (2059) HINNCRSQGLMLSPTASFVDASDVTQGVDA--MWTSVSPSVAAPSVCQEDVCHNGGTCRPIFLSSGIVSFQCDCPLHFTG 
      Pig  (2037) HIDSCRSQDSTPTAAANSVAPSRATGLAGS--PGTSLAP-HLAPATCQGPVCRNGGTCRSVLLPGGAFSFQCDCPLHFTG 
  Chicken  (1818) NIDSCRTPVPTHLPTPFPTVSSDVLALPEL--VTPSLSS-PELPSVCQEGLCHNGGTCHPISLPTGAISFECDCQLHFTG 
Zebrafish  (1814) NVDNCRSQWHHEPPTSSTHSPTLLITVETPPGEWVRVLSPTQPAPVCPQGICLNGGTCRPVSLPSGASSFFCDCPLHFTG 
                  ----------------------------------------------------------EGF domain------------ 
 
    Human  (2137) RFCEKDAGLFFPSFNGNSYLELPFLK-------FVLEKEHNRTVTIYLTIKTNSLNGTILYSNGNNCGKQFLHLFLVEGR 
  Macaque  (2137) RFCEKDAGLFFPSFSGNSYLELPFLN-------FVLEKEHNRTVTIYLTIKTNSLNGTILYSNGNNFGKQFLHLFLVEGK 
      Pig  (2114) RFCERDAGLFVPSFSGNSYLELPFFTTQEE-LKFVLEKEHNRIVTIYLTIKTNSLNGTILYSSEKNFGQRFIHLFLVEGR 
  Chicken  (1895) RFCEKDVTLFIPSFNGNSYLELPSLTSVSQ-MRTASGQETSNLTTLYLTVKTTAPSGTILYTSEKNFGEQFLHLYLVEGR 
Zebrafish  (1894) RLCEQDITVFSPRFDGNSFLELPSLTSLFQSDTYFPSRSSEDKRILYLTMKSRTPHGSLLYCREQDLGERFLHVFLQNAR 
                  ---------------------------------------------------Laminin-G domain------------- 
 
    Human  (2210) PSVKYGCGNSQNILTVSANYSINTNAFTPITIRYTTPVGSPGVVCMIEMTADGKPPVQKKDTEISHASQAYFESMFLGHI 
  Macaque  (2210) PSVKYGCGNSQNILTVSANYSINTNAFTPITVRHTMPIGSPGVVCMIEMTADGKPPVQKKDTEISHASQVYFESMFLGHI 
      Pig  (2193) PTVKYGCGSSQNILTLSANYSINRNAFIPVTIRYTMPVGSPGVACMIEMAADGKPLIRKEDVETPQDPQGYFEKMFLGHI 
  Chicken  (1974) PTVRFSCGNSQNILTVSGNQTISKGIFIPIIISYMLPVSSLEGYCMIEMAADRNPPVQHRLHLSYQASQITFGSTFLGNV 
Zebrafish  (1974) AVARLGCG-AAHILTAVAAQNIRIDSLVAITVRYALPSQNNGQLCFIEIAADNGTANQQQKYMDEPVSEVVFGPTFLGGF 
                  ------------------------------Laminin-G domain---------------------------------- 
 
    Human  (2290) PANVQIHKKAGPVYGFRGCILDLQVNNKEFFIIDEARHGKNIENCHVPWCAHHLCRNNGTCISDNENLFCECPRLYSGKL 
  Macaque  (2290) PENVQIHKKAGSVYGFRGCILDLQINNKEFFIIDEARRGKNIENCHVPWCAHHLCRNNGTCLSDSENLFCECPRLYSGKL 
      Pig  (2273) PANVKIYKNAGHIYGFKGCIQELQVNNKEFFIIEEALSGKNIENCLLHGCAHHLCRNNGTCVSESETWFCECPRLYSGKL 
  Chicken  (2054) PVHKEVPECAGQIRGYKGCIRDFQVNNKELFIIDDALGGRNVENCNVPICDYHPCRNGGTCTSDAENWFCECPKLYSGRL 
Zebrafish  (2053) PSVLELHHNSGNVSGFIGCIRELQMGSKELYVVGEAIRGQNIQNCDAAVCQHQPCRNGGTCISDAESWFCACPSLYSGKL 
                  ----Laminin-G domain---------------------------------------EGF domain----------- 
 
    Human  (2370) CQFASCENNPCGNGATCVPKSGTDIVCLCPYGRSGPLCTDAINITQPRFSGTDAFGYTSFLAYSRISDISFHYEFHLKFQ 
  Macaque  (2370) CQFASCENNPCGNGATCVPKSGTDIICLCPYGRSGPLCTDAINITQPRFSGTDAFGYTSFLAYSRISDISFHYEFHLKFQ 
      Pig  (2353) CQFATCENNPCGNGATCVPRSGTDIVCLCPYGRTGLLCTEAVRITQPRLSGTDAFGYTSFLAYSRIPDINFDYEFHVKFQ 
  Chicken  (2134) CQFMTCDESPCGNGATCFPKSRQDVVCLCPYGRSGILCNDVVNISQPSFSGTDVFGYTSFLAYSTIPDITFYYEFHLKFQ 
Zebrafish  (2133) CQFTACERNPCARGATCVPQTQLEAACLCPYGRQGLLCDEAINITRPKFSGLDEFGYSSYVAYPSIPSTGHFYEFHLKLT 
                  -------------EGF domain--------------------------------------------------------- 
 
    Human  (2450) LANNHSALQNNLIFFTGQKGHGLNGDDFLAVGLLNGSVVYSYNLGSGIASIRSEPLNLSLGVHTVHLGKFFQEGWLKVDD 
  Macaque  (2450) LANNHSALQNNLIFFTGQKGHGLNGDDFLAVGLLNGSVVYSYNLGSGIASIRSDPLNLSLGVHTVHLGKFFQEGWLKVDD 
      Pig  (2433) LADDHSAVQDNLLFFTGQKGHGRNGDDFLAVGLRGGRVVYSYNLGSGTASLRSDPLDLSLGIHTIHLGRSFQVGWLKVDD 
  Chicken  (2214) LLNHHSALQDNLIFFTGQKGQGLNGDDFLVLGLCDGRVVYSYNLGSGTATIISKPLDLTLNIHVIHLGRYLQKGWLKVDD 
Zebrafish  (2213) FANNASALRNNLILFSGQKGQGLSGDDFFALGVRNGRIVHKYNLGSGLATIISDRLNPRINIHTVHFGRYLKTGWLKVNG 
                  ------------------------------Laminin-G domain---------------------------------- 
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                -------------------------------------------------------------------------------- 
    Human  (1581) HFYETFWMNSAILASWYALMGAQTITSGHSFSSATEITPSVAFTEVPSLFPSKKSAKRTILSSSLEESITLSSNLDVNLC 
  Macaque  (1581) HFYETFWMNSAILASWYALMGAQTITSGHSFSSATEITPSVAFTEVPSLFPSKKSAKRTILSSSLEESITLSSNLDVNLC 
      Pig  (1565) QFYDTFSMYSAILASWYALMGMQTTTAGHSFPSSEEIMPSVAITEPSSLFPSKKSTKRRILVSSVEEYITQSSNLDANLC 
  Chicken  (1642) -------------------------------------------------------------------------------- 
Zebrafish  (1647) -------------------------------------------------------------------------------- 
                  -------------------------------------------------------------------------------- 
 
    Human  (1661) LDKTCLSIVPSQTISSDLMNSDLTSKMTTDELSVSENILKLLKIRQYGITMGPTEVLNQESLLDMEKSKGSHTLFKLHPS 
  Macaque  (1661) LHKTCLSIVPSQTISSDLMNSDLTSELTTDELSVSENILKLLKIRQYGITTGPTEVLNQDSLLDMEKSKGSHTPFKLHPS 
      Pig  (1645) LNKMCLSIVPSQTVSLDLTNSDLTSKLTKGDPLGSENILKLLKIGHYGITMDPTEMLNQNKLLGVQEHEGSQTPSKLHAR 
  Chicken  (1642) -------------------------------------------------------------------------------- 
Zebrafish  (1647) -------------------------------------------------------------------------------- 
                  -------------------------------------------------------------------------------- 
 
    Human  (1741) DSSLDFELNLQIYPDVTLKTYSEITHANDFKNNLPPLTGSVPDFSEVTTNVAFYTVSATPALSIQTSSSMSVIRPDWPY- 
  Macaque  (1741) DSSLDLELNLRSYPDVTLKTYSEITLANDLKNNLPPLTGSVPDFSEVTTNVAFYTVSATPALPIQTSSSMSVITPDWPY- 
      Pig  (1725) DGSLDFELNLRSHP--------ETMHSSDLKSNLPPSIDSTSDFSEVSSHITFSAVSASQSFPIQTSVPMSVLTPDWTYT 
  Chicken  (1642) -------------------------------------------------------------------------------- 
Zebrafish  (1647) -------------------------------------------------------------------------------- 
                  -------------------------------------------------------------------------------- 
 
    Human  (1820) -FTDYMTSLKKEVKTSSEWSKWELQPSVQYQEFPTASRHLPFTRSLTLSSLESILAPQRLMISDFSCVRYYGDSYLEFQN 
  Macaque  (1820) -FIDYMTSLNKEVKTYSEWSKWELQPSVQYQEFPTASWHLPFTRSLTLSSLESIVAPQQLMISDFSCVCYYGDSYLEFQN 
      Pig  (1797) DYLNLTSYLKENTRTSSEWSKWELQPSGHGQESPAASQRISITRSLSLSSLEPIPASPWLKISDFSCVCYHGESYLEFQN 
  Chicken  (1642) ---------------------------------------------------FSYAR-------------YYGDSYLEFQG 
Zebrafish  (1647) ---------------------------------------------------------------------GN--SFLEFGG 
                  -------------------------------------------------------------------------------- 
 
    Human  (1899) VALNPQNNISLEFQTFSSYGLLLYVKQDSNLVDGFFIQLFIENGTLKYHFYCPGEAKFKSINTTVRVDNGQKYTLLIRQE 
  Macaque  (1899) VVLNPQNNISLEFQTFSSYGLLLYVKQDSNLVDGFFIQLSIENGTLKYHFYCPGEAKFKSINTAIRVDDGQKYTLLIRQE 
      Pig  (1877) VFLNPQNNISLEFQTSNTYGLLLYIKQDPDIADGFFFQLFIENGTLKYHFFCAGEAKLKSINTTIKVDDGQKYTLFIRQE 
  Chicken  (1658) LHLNVQNFIHLEFKTYKPDGLLLYIEESSETIGQFLIQLFIRHGILQYQFVCGKATQVKNITTTARVDDGQWYKVQIRQN 
Zebrafish  (1656) FEVAVPISVTVRFQTESMYGTLLYS--ASAKRSVFFIKLYISNGILQYDFLCNQKQGVQRINTAQWVADGNEHVVIFRQC 
                  ----------------------------Laminin-G domain------------------------------------ 
 
    Human  (1979) LDPCNAELTILGRNTQICESINHVLGKPLPKSGSVFIGGFPDLHGKIQMPVPVKNFTGCIEVIEINNWRSFIPSKAVKNY 
  Macaque  (1979) LDPCKAELTILGRNTQTCESINHVLGKPLPKSGSVFIGGFPDLRGKIQMPVPVKNFTGCIEVIEINNWRSFIPSKAVRNY 
      Pig  (1957) LDPCKAELTILGRTIKASKSINHIYGKPLPDSGTVFVGGIPDLHGVNQISGPVENFTGCIEIIEINNWRSFIPSKAVKKI 
  Chicken  (1738) MKPCEAEMLILEVSAKTGIPSNFSSSPYGLETGSIFVGGLPYSSAIKQIPEPVYNFTGCIQVIEINNVGPFNFSNAVGRR 
Zebrafish  (1734) LFPCVAEVTVSGVRTVRSAPGNYTSALRLQRTDHVFIGGLPRHRSPYKEAEPFHNYTGCIEIIEINKLRRFHMDHAIARN 
                  -------------------------Laminin-G domain--------------------------------------- 
 
    Human  (2059) HINNCRSQGFMLSPTASFVDASDVTQGVDT--MWTSVSPSVAAPSVCQQDVCHNGGTCHAIFLSSGIVSFQCDCPLHFTG 
  Macaque  (2059) HINNCRSQGLMLSPTASFVDASDVTQGVDA--MWTSVSPSVAAPSVCQEDVCHNGGTCRPIFLSSGIVSFQCDCPLHFTG 
      Pig  (2037) HIDSCRSQDSTPTAAANSVAPSRATGLAGS--PGTSLAP-HLAPATCQGPVCRNGGTCRSVLLPGGAFSFQCDCPLHFTG 
  Chicken  (1818) NIDSCRTPVPTHLPTPFPTVSSDVLALPEL--VTPSLSS-PELPSVCQEGLCHNGGTCHPISLPTGAISFECDCQLHFTG 
Zebrafish  (1814) NVDNCRSQWHHEPPTSSTHSPTLLITVETPPGEWVRVLSPTQPAPVCPQGICLNGGTCRPVSLPSGASSFFCDCPLHFTG 
                  ----------------------------------------------------------EGF domain------------ 
 
    Human  (2137) RFCEKDAGLFFPSFNGNSYLELPFLK-------FVLEKEHNRTVTIYLTIKTNSLNGTILYSNGNNCGKQFLHLFLVEGR 
  Macaque  (2137) RFCEKDAGLFFPSFSGNSYLELPFLN-------FVLEKEHNRTVTIYLTIKTNSLNGTILYSNGNNFGKQFLHLFLVEGK 
      Pig  (2114) RFCERDAGLFVPSFSGNSYLELPFFTTQEE-LKFVLEKEHNRIVTIYLTIKTNSLNGTILYSSEKNFGQRFIHLFLVEGR 
  Chicken  (1895) RFCEKDVTLFIPSFNGNSYLELPSLTSVSQ-MRTASGQETSNLTTLYLTVKTTAPSGTILYTSEKNFGEQFLHLYLVEGR 
Zebrafish  (1894) RLCEQDITVFSPRFDGNSFLELPSLTSLFQSDTYFPSRSSEDKRILYLTMKSRTPHGSLLYCREQDLGERFLHVFLQNAR 
                  ---------------------------------------------------Laminin-G domain------------- 
 
    Human  (2210) PSVKYGCGNSQNILTVSANYSINTNAFTPITIRYTTPVGSPGVVCMIEMTADGKPPVQKKDTEISHASQAYFESMFLGHI 
  Macaque  (2210) PSVKYGCGNSQNILTVSANYSINTNAFTPITVRHTMPIGSPGVVCMIEMTADGKPPVQKKDTEISHASQVYFESMFLGHI 
      Pig  (2193) PTVKYGCGSSQNILTLSANYSINRNAFIPVTIRYTMPVGSPGVACMIEMAADGKPLIRKEDVETPQDPQGYFEKMFLGHI 
  Chicken  (1974) PTVRFSCGNSQNILTVSGNQTISKGIFIPIIISYMLPVSSLEGYCMIEMAADRNPPVQHRLHLSYQASQITFGSTFLGNV 
Zebrafish  (1974) AVARLGCG-AAHILTAVAAQNIRIDSLVAITVRYALPSQNNGQLCFIEIAADNGTANQQQKYMDEPVSEVVFGPTFLGGF 
                  ------------------------------Laminin-G domain---------------------------------- 
 
    Human  (2290) PANVQIHKKAGPVYGFRGCILDLQVNNKEFFIIDEARHGKNIENCHVPWCAHHLCRNNGTCISDNENLFCECPRLYSGKL 
  Macaque  (2290) PENVQIHKKAGSVYGFRGCILDLQINNKEFFIIDEARRGKNIENCHVPWCAHHLCRNNGTCLSDSENLFCECPRLYSGKL 
      Pig  (2273) PANVKIYKNAGHIYGFKGCIQELQVNNKEFFIIEEALSGKNIENCLLHGCAHHLCRNNGTCVSESETWFCECPRLYSGKL 
  Chicken  (2054) PVHKEVPECAGQIRGYKGCIRDFQVNNKELFIIDDALGGRNVENCNVPICDYHPCRNGGTCTSDAENWFCECPKLYSGRL 
Zebrafish  (2053) PSVLELHHNSGNVSGFIGCIRELQMGSKELYVVGEAIRGQNIQNCDAAVCQHQPCRNGGTCISDAESWFCACPSLYSGKL 
                  ----Laminin-G domain---------------------------------------EGF domain----------- 
 
    Human  (2370) CQFASCENNPCGNGATCVPKSGTDIVCLCPYGRSGPLCTDAINITQPRFSGTDAFGYTSFLAYSRISDISFHYEFHLKFQ 
  Macaque  (2370) CQFASCENNPCGNGATCVPKSGTDIICLCPYGRSGPLCTDAINITQPRFSGTDAFGYTSFLAYSRISDISFHYEFHLKFQ 
      Pig  (2353) CQFATCENNPCGNGATCVPRSGTDIVCLCPYGRTGLLCTEAVRITQPRLSGTDAFGYTSFLAYSRIPDINFDYEFHVKFQ 
  Chicken  (2134) CQFMTCDESPCGNGATCFPKSRQDVVCLCPYGRSGILCNDVVNISQPSFSGTDVFGYTSFLAYSTIPDITFYYEFHLKFQ 
Zebrafish  (2133) CQFTACERNPCARGATCVPQTQLEAACLCPYGRQGLLCDEAINITRPKFSGLDEFGYSSYVAYPSIPSTGHFYEFHLKLT 
                  -------------EGF domain--------------------------------------------------------- 
 
    Human  (2450) LANNHSALQNNLIFFTGQKGHGLNGDDFLAVGLLNGSVVYSYNLGSGIASIRSEPLNLSLGVHTVHLGKFFQEGWLKVDD 
  Macaque  (2450) LANNHSALQNNLIFFTGQKGHGLNGDDFLAVGLLNGSVVYSYNLGSGIASIRSDPLNLSLGVHTVHLGKFFQEGWLKVDD 
      Pig  (2433) LADDHSAVQDNLLFFTGQKGHGRNGDDFLAVGLRGGRVVYSYNLGSGTASLRSDPLDLSLGIHTIHLGRSFQVGWLKVDD 
  Chicken  (2214) LLNHHSALQDNLIFFTGQKGQGLNGDDFLVLGLCDGRVVYSYNLGSGTATIISKPLDLTLNIHVIHLGRYLQKGWLKVDD 
Zebrafish  (2213) FANNASALRNNLILFSGQKGQGLSGDDFFALGVRNGRIVHKYNLGSGLATIISDRLNPRINIHTVHFGRYLKTGWLKVNG 
                  ------------------------------Laminin-G domain---------------------------------- 
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    Human  (2530) HKNKSIIAPGRLVGLNVFSQFYVGGYSEYTPDLLPNGADFKNGFQGCIFTLQVRTEKDGHFRGLGNPEGHPNAGRSVGQC 
  Macaque  (2530) HKNKSIIAPGRLVGLNVFSQFYVGGYSEYTPDLLPNGADFKNGFQGCIFTLQVRTEKDGHFRGLGNPEGHPNAGRSVGQC 
      Pig  (2513) HKNKSIISPGELVGLNAFSQFYVGGYSEYIPDLLPSEANFKSSFQGCIFTIQVRTKKNGRFRSLGTPEGHPNAGRSVGQC 
  Chicken  (2294) QKNKTTTSPGRLVGLNVFSQFYLGGYHEYTPELLPKGSRFKNGFQGCIFDVQVRTNMNQEFKSPGTPEGHPNSGRSVGQC 
Zebrafish  (2293) QKRRTGTSPGPLMGLNTFSQLYIGGYEEYTPELLPPGSRFQNSFQGCIFDMLFRTRQDGKFHALGGPDIRPLSGRNVGQC 
                  ---------------Laminin-G domain------------------------------------------------- 
 
    Human  (2610) HASPCSLMKCGNGGTCIESGTSVYCNCTTGWKGSFCTETVSTCDPEHDPPHHCSRGATCISLPHGYTCFCPLGTTGIYCE 
  Macaque  (2610) HASPCSLMKCGNGGTCIESGTSVYCNCTTRWKGAFCTETVSICDPEHDPPHHCSRGATCISLPHGYTCFCPLGTTGIYCE 
      Pig  (2593) ETSPCHLMKCDNGGTCMESGSTVYCNCPRGWKGAFCTETVSTCDPEHDPPPHCSKGATCVSLPHGYACHCPLGTTGVYCE 
  Chicken  (2374) KASPCSLIKCRNGGKCMESGSTVYCNCLAGWKGAFCTEMVTVCDPEHDPPHLCKQGGTCVPLPNGYMCHCPLGTSGTYCE 
Zebrafish  (2373) GVNPCSLVFCHNGGTCVDSGSSVYCQCVFGWKGALCSEKVSFCDAEHIPPPFCARGSTCVPLSDGYTCQCPLGSAGLHCQ 
                  -------------EGF domain---------------------------------EGF domain-------------- 
 
    Human  (2690) QALSISDPSFRSNELSWMSFASFHVRKKTHIQLQFQPLAADGILFYAAQHLKAQSGDFLCISLVNSSVQLRYNLGDRTII 
  Macaque  (2690) QALSISDPSFRSSELSWMSFASFHVRKKTHIQLQFQPLAADGILFYAAQHLKAQSGDFLCISLVNGSVQLRYNLGDRTII 
      Pig  (2673) QALSISDPSFKSHELSWMSFASFRIRKKTHIQLQFQPLTADGILFYVAQHLKALSGDFLCISLVNGSVQLRYNLGERTII 
  Chicken  (2454) QDISISDPSFRSNKSSWMSFAPFYIRHKTHIKLQFQPLSPDGILFYTAQRLGTQSGDFLCISLVNGFIQLRYNLGDKTIV 
Zebrafish  (2453) QAITISDPFFSGNQSSWMSFPPINIRHRTHVQLQFQTLSPEGILFYTAQHLSTHSGDFLSISLSAGFLQLRYNLGNQTIV 
                  ---------------------------------------------Laminin-G domain------------------- 
 
    Human  (2770) LETLQKVTINGSTWHIIKAGRVGAEGYLDLDGINVTEKASTKMSSLDTNTDFYIGGVSSLNLVNPMAIENEPVGFQGCIR 
  Macaque  (2770) LETLQKVTINGSTWHIIKAGRVGAEGYLDLDGINVTEKASTKMSSLDTNTDFYIGGVSSLNLVNPMAIENEPVGFHGCIR 
      Pig  (2753) LETPQKVTTNGSTWHVIKAGRDGAEGYLDLDGRNVTEKANSKLSSLDTSTDFYIGGVSSLSLVNPMATANEPVGFQGCIR 
  Chicken  (2534) LQAVQKVHADGQTWHVLKVGRVGNEGYVDLDGINITHTASAGMNVLDTHTDFYVGGVSSLNLVNSMATENEPTGFSGCIR 
Zebrafish  (2533) LQSPKELDVTGVRWHTVKAGREGNSGFLIVDGESVTRNSSEGSTTLDVGANIFIGGISSLNTVSIDAVEKELVGFTGGIR 
                  ------------------------------Laminin-G domain---------------------------------- 
 
    Human  (2850) QVIINNQELQLTEFGAKGGSNVGDCDGTACGYNTCRNGGECTVN-GTTFSCRCLPDWAGNTCNQSVSCLNNLCLHQSLCI 
  Macaque  (2850) QVIINYQELQLTEFGAKGGSNVGDCDGTACGYNTCRNGGECRVN-GTTFSCRCLPDWAGNICNQSAYCLNNLCLHQSLCI 
      Pig  (2833) EVIINNQELQLTELGAKGGSNVGDCDGTACGYSVCKNRGKCIVN-GGTFSCRCLPQWAGDTCDQSVYCLNNLCLHQSLCI 
  Chicken  (2614) EIVINDKELKLTVTDPKGGANIGDCDGTVCGYSVCKNNGTCQVE-SSGFSCSCPQGWIGNTCEESVHCLHNRCRSQALCI 
Zebrafish  (2613) EVVVNGQELELTETGALDGANVGDWDGTACGYKVCKNGGHCHPSGDFSFTCICPSLWTGSRCQQSIQCLNNLCQHNSVCI 
                  ---------------------------------------EGF domain------------------------------- 
 
    Human  (2929) PD-QSFSYSCLCTLGWVGRYCENKTSFSTAKFMGNSYIKYIDPNYRMRNLQFTTISLNFSTTKTEGLIVWMGIAQNEEND 
  Macaque  (2929) PD-QSFSYSCLCTLGWVGRYCENKTSFTTAKFMGNSYIKYIDPNYRMRNLQFTTISLNFSTTKTEGLIIWMGIAQNEEND 
      Pig  (2912) PN-QAFSYNCLCALGWVGRYCKNRTSFSTAKFRGNSYIKYIDPGYRMRNLRFTNVSLHFSSTETEGLITWIGKAQNEEND 
  Chicken  (2693) PQPALLSYTCVCPLGWSGKHCDSKISFFTAKFVGNSYIKYIDPLYGKRDLQYSRISLNFTTNQIEGLMVWLGKAEDEDND 
Zebrafish  (2693) HNSTSASYSCMCSLGWTGTHCDREVTLKTIRFIGNSYLKYKDPKYNSRNLMHTEVSLNFSTSAGDGLIFWMGKAESEDDD 
                  ----EGF domain--------------------------------------------Laminin-G domain------ 
 
    Human  (3008) FLAIGLHNQTLKIAVNLGERISVPMSYNNGTFCCNK-WHHVVVIQNQTLIKAYINNSLILSEDIDPHKNFVALNYDGICY 
  Macaque  (3008) FLAIGLHNQTLKIAVNLGERISVPMSYNNGTFCCNK-WHHVIVIQNQTLIKAYVNNSLILSEDIDPHKNFVALNYEGICY 
      Pig  (2991) FLAIGLYNQTLKIAVNLGESMYVPMIYSPGTFCCNQ-WHHLIVIQNQTLIKAYLNDSLILSEDIDPHKKFVALNYDGISY 
  Chicken  (2773) FLAIGLANGRLKVVINLGERISVPMIHSKDSICTDERWHFVTVIQNQTCIKVYLDEELIIFEDIDPHRKYTALNYGGICY 
Zebrafish  (2773) HLAVGLQDGYLKISVNLGERTALPLVY-QNSFCCNY-WNYLSITHNRTLIQVYVNEERVIFEDIDPFEQYVAVNYGGVIY 
                  ----------------------------Laminin-G domain------------------------------------ 
 
    Human  (3087) LGGFEYGRKVNIVTQEIFKTNFVGKIKDVVFFQEPKNIELIK-LEGYNVYDGDEQNEVT 
  Macaque  (3087) LGGFEYGRKVNIVTQEIFKTNFVGKIKDVVFFQDPKKIELIK-LEGYNVYDGDEQNEVT 
      Pig  (3070) LGGFEYGRKVNTVTQEIFKRGFVGKIKDVFFQDS--KIELIK-SEGYNVYNGDEPD--- 
  Chicken  (2853) FGGFEIGRKVHTATAGLFQKEFIGKIKDIALFQDSKKIQLMK-GEGYNVHNGDHRN--- 
Zebrafish  (2851) LGGFELNRDVASVTSGVFTKGFEGSIKDVFLYQDTKQLQFLQTCEGFNVYQGEE----- 
                  -------Laminin-G domain------------------------------------ 
 
------Signal peptide ------EGF domain ------EGF-like domain 
------Calcium-binding EGF-like domain  ------Laminin A-G domain 
Residues identical in all sequences are white on a black background, whereas similar amino acids are white 
on a gray background. Residues that are present in at least three of the five proteins are indicated in black 
on a light gray background. Accession numbers of the protein sequences used for sequence comparison 
are as follows: human, NM_001142800.1 (RefSeq); macaque, XM_011737495.1 (RefSeq); pig, 
XM_021084496 (RefSeq); chicken, XM_015284845.1 (RefSeq); zebrafish, XM_009307513 (RefSeq). 
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Supplementary Table S1. 
Rules for combining criteria to classify sequence variants.
Pathogenic (i)
(ii)
(iii)
1 Very strong (PVS1) AND
(a) ≥1 Strong (PS1–PS4) OR
(b) ≥2 Moderate (PM1–PM6) OR
(c) 1 Moderate (PM1–PM6) and 1 supporting (PP1–PP5) OR
(d) ≥2 Supporting (PP1–PP5)
≥2 Strong (PS1–PS4) OR
1 Strong (PS1–PS4) AND
(a) ≥3 Moderate (PM1–PM6) OR
(b) 2 Moderate (PM1–PM6) AND ≥2 Supporting (PP1–PP5) OR
(c) 1 Moderate (PM1–PM6) AND ≥4 Supporting (PP1–PP5)
Likely pathogenic (i)
(ii)
(iii)
(iv)
(v)
(vi)
1 Very strong (PVS1) AND 1 moderate (PM1–PM6) OR
1 Strong (PS1–PS4) AND 1–2 moderate (PM1–PM6) OR
1 Strong (PS1–PS4) AND ≥2 supporting (PP1–PP5) OR
≥3 Moderate (PM1–PM6) OR
2 Moderate (PM1–PM6) AND ≥2 supporting (PP1–PP5) OR
1 Moderate (PM1–PM6) AND ≥4 supporting (PP1–PP5)
Benign (i)
(ii)
1 Stand-alone (BA1) OR
≥2 Strong (BS1–BS4)
Likely benign (i)
(ii)
1 Strong (BS1–BS4) and 1 supporting (BP1–BP7) OR
 ≥2 Supporting (BP1–BP7)
Uncertain significance (i)
(ii)
Other criteria shown above are not met OR
The criteria for benign and pathogenic are contradictory
Supplementary Table S2. 
Overview of all EYS variants.
Overview of all EYS variants, with separate tabs for protein-truncating mutations, missense variants, 
splice site variants, silent variants and in-frame indels, and variants detected in the 5’-UTR. The 
following principles are taken into account by scoring the pathogenic evidence as very strong 
(PVS1): A loss of function is a known mechanism of disease, B variants are located upstream of the 
most 3’ truncating variant reported as pathogenic, C the impact of splice-site variants is confirmed 
by functional analysis, D alternate gene transcripts which are biologically relevant do not play a role, 
and E null-alleles are described disease causing in other patients.12 This table is available online via: 
https://doi.org/10.1002/humu.23371.
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Abstract
Inherited retinal diseases (IRDs) are a heterogeneous group of genetic eye diseases. 
Mutations in Eyes shut homolog (EYS) are one of the most common causes of autosomal 
recessive (ar) retinitis pigmentosa (RP), but have also been described in patients with 
cone-rod dystrophy (CRD). The aim of this study was to assess the phenotypic variability 
and natural course of IRDs caused by EYS mutations. We performed a multiethnic cohort 
study (N=30) with biallelic EYS variants from a clinical IRD database (RP (N=27), CRD 
(N=1), and macular dystrophy (N=2)). Medical records were reviewed to extract medical 
history, visual function testing and retinal imaging. An in vitro minigene splice assay was 
performed to determine the effect on EYS pre-mRNA splicing of the c.1299+5_1299+8del 
variant in macular dystrophy patients. We found 27 different EYS variants in RP patients, 
seven of these were novel. Eleven RP patients met low vision criteria (visual field<20°) at 
first examination. The rate of visual field loss of the V4 isopter area was 9% per year. Four 
patients became visually impaired (visual acuity>0.3logMAR), the rate of visual acuity loss 
was 0.75 EDTRS letters/year. An isolated CRD patient carried a homozygous EYS variant 
(c.9405T>A) that was previously identified in RP patients. Two siblings with macular 
dystrophy, carried compound heterozygous EYS variants: c.1299+5_1299+8del and 
c.6050G>T. The former was novel and shown to result in skipping of exon 8, the latter was a 
known RP variant. In conclusion, we report on EYS-associated macular dystrophy, thereby 
extending the spectrum of EYS-associated retinal disease. We observed heterogeneity 
between RP patients in age of onset and disease progression. Identical EYS variants were 
found in cases with RP, CRD, and macular dystrophy. Screening for EYS variants in CRD and 
macular dystrophy patients might increase the diagnostic yield in previously unsolved 
cases.
Key words:
EYS, disease spectrum, retinal dystrophy
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3.1 Introduction
Inherited retinal diseases (IRDs) are a heterogeneous group of genetic eye diseases 
characterized by progressive degeneration of photoreceptor and/or retinal pigment 
epithelium (RPE) cells, leading to severe visual impairment and blindness. Retinitis 
pigmentosa (RP), a rod-cone dystrophy, is the most common subtype of  IRD with an 
estimated prevalence of 1 in 4000 individuals.1 Patients report night blindness, and visual 
field constriction from early adolescence and gradually decreasing visual acuity later in 
life. Over 250 genes have been described to be mutated in IRD, of which several can be 
mutated in different clinical subtypes of IRD.2
Eyes shut homolog (EYS; OMIM: 612424) was first reported in 2008 by two independent 
groups,3,4 and both described this gene as the human ortholog of the Drosophila ‘eyes 
shut’ (eys), also known as Spacemaker (spam). Mutations in EYS account for ~5-35% of 
European and Asian autosomal recessive retinitis pigmentosa (arRP) cases,5-11 but have 
also been described in three patients with autosomal recessive cone-rod dystrophy 
(CRD).4,12,13 EYS is located on chromosome 6p12 (RP25 locus), spans over 2 Mb, and consists 
of 44 exons that together code for a protein that is predicted to harbor 28 epidermal 
growth factor-like (EGF) domains and five Laminin A G-like (LamG) domains. There are 
at least four isoforms, all of which are expressed in the human retina.14 The Drosophila 
ortholog plays an important role in retinal morphogenesis and architecture.15 In zebrafish, 
Eys is expressed in the outer segments and connecting cilium/transition zone (CC/TZ) of 
both rod and cone photoreceptors.16-18 Functional studies in zebrafish suggest Eys helps 
to maintain the stability of the ciliary axoneme in both rods and cones, and the integrity 
of the ciliary pocket in cones.16-18 Eys knockout zebrafish showed a cone-rod pattern of 
retinal degeneration,16 and the Eys protein was assumed to be essential for the structural 
integrity of photoreceptor cells.18 However, the exact function of the EYS protein and the 
role of the different isoforms in the human retina still remains unclear.
We have assessed the spectrum of retinal disease and the course of visual function in 
our multiethnic cohort of 30 patients carrying biallelic EYS mutations to improve patient 
counseling on prognosis, and to provide guidance for the timing of therapeutic intervention 
if available. Twenty-seven patients were diagnosed with RP, one patient was diagnosed 
with cone-rod dystrophy, and two patients with macular dystrophy. To find an explanation 
for the generalized versus more localized retinal dystrophy among our subjects, we 
performed functional testing of a novel splice site variant, and bioinformatically assessed 
the nature of other (presumed) pathogenic variants.
3.2 Materials and Methods
3.2.1 Study subjects
We gathered all available DNA testing results from IRD patients from two tertiary care 
hospitals (the Rotterdam Eye Hospital and Erasmus Medical Center) and selected patients 
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with biallelic EYS mutations. In total, we included 30 IRD patients from 25 families. Four 
patients were previously described by Littink et al.5 Eighteen patients were isolated cases 
with a negative family history of inherited retinal dystrophies. Twenty-seven patients were 
diagnosed with RP, one patient with CRD, and two patients with macular dystrophy based 
on clinical characteristics, retinal imaging, and visual function testing. The study protocol 
adhered to the tenets of the Declaration of Helsinki and was approved by the Institutional 
Review Board and the Ethics Committee of the Erasmus Medical Center (Rotterdam, The 
Netherlands).
3.2.2 Molecular diagnosis
We obtained blood samples and extracted DNA from peripheral blood lymphocytes by 
standard procedures. The molecular diagnosis of EYS variants (NM_001142800.1) was made 
using Sanger sequencing (9 patients), autosomal recessive RP APEX genotyping array (3 
patients) and targeted analysis of 256 IRD-associated genes after exome sequencing (18 
patients). To determine the effect of the c.1299+5_1299+8del variant on EYS pre-mRNA 
splicing, an in vitro minigene splice assay was performed. For this, we generated a wild 
type minigene and a mutant minigene harboring the c.1299+5_1299+8del variant, which 
each contain exon 8 and parts of the flanking introns of EYS (Figure 1a). To investigate 
if the c.1299+5_1299+8del variant leads to alterations in splicing, HEK293T cells were 
transfected with the wild type or mutant minigene constructs, followed by RT-PCR 
analysis. A detailed description of the applied techniques is provided in the Supplemental 
information.
3.2.3 Clinical examination
Retrospective data were collected from our own medical charts and historical data 
were retrieved from referring ophthalmologists to maximize the follow-up period. 
Ophthalmologic examination included best-corrected visual acuity (BCVA), Goldmann 
kinetic visual field testing, full-field electroretinogram (ffERG) according to ISCEV standards 
(Diagnosys, Lowell, MA, United States), multifocal electroretinogram (mfERG) (Diagnosys, 
Lowell, MA, United States), dilated fundus examination, color fundus photography (D300, 
Nikon, Tokyo, Japan and, Topcon, Tokyo, Japan, and Zeiss FF 450 Plus Fundus Camera, 
Carl Zeiss Meditec, Jena, Germany), spectral domain optical coherence tomography (SD-
OCT) (Spectralis, Heidelberg Engineering GmbH, Dossenheim, Germany) and 30° field 
fundus autofluorescence (FAF) (Spectralis, Heidelberg Engineering GmbH, Dossenheim, 
Germany). Visual fields were digitized using a method described by Dagnelie.19 We 
measured the retinal area of the V4-target, because this target was consistently used in 
all examinations. 
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3.2.4 Statistical analysis
Visual impairment was defined as either low vision (BCVA worse than 0.50 LogMAR but 
equal or better than 1.30 LogMAR and/or central visual field (VF) diameter smaller than 
20° but equal or larger than 10° in the better eye) or blindness (BCVA worse than 1.30 
LogMAR and/or central VF diameter smaller than 10° in the better eye) in accordance with 
the WHO criteria. To calculate the annual rate of decline in visual function, we used mixed 
effects linear regression modeling with visual acuity in logMAR and with log-transformed 
area of the V4 isopter expressed in degrees squared (deg2) for visual field, and corrected 
for repeated measurements by entering a fixed effect.20 Patients with a single visit were 
excluded from longitudinal analysis. We used a Student T-test to compare differences in 
age of onset, age at diagnosis, and age at last examination between patients with and 
without constricted visual fields at last examination.
3.3 Results
3.3.1 Cohort characteristics
We have collected clinical data from 30 patients with biallelic EYS variants from 25 families 
with a median follow-up of seven years (range: 0-24 years) (Table 3.1). Twenty-seven 
patients were diagnosed with RP, two siblings had macular dystrophy, and one isolated 
patient was diagnosed with cone-rod dystrophy. Our multi-ethnic cohort consisted of 15 
patients from European, 13 from Asian, and 2 from African descent. The current mean age 
was 45 years (range: 19-75 years), and gender distribution was equal, 16 patients (53%) 
were male.
3.3.2 Molecular diagnosis
Of 27 RP patients, fifteen carried compound heterozygous variants (Table 3.2), and twelve 
patients had homozygous EYS variants, of which eight reported a history of consanguinity. 
We found 27 different variants: eight frame shift, eight nonsense, eight indels, three 
missense, and one splice site variant (Table 3). Seven of these variants were novel. All 
missense variants were classified as pathogenic by SIFT and Polyphen2 algorithms, and 
were located in conserved residues of EYS protein. According to the ACMG classification 
one missense variant, p.(Gly2186Glu), was classified as likely pathogenic, and two variants, 
p.(Arg2604His) and p.(Ile2995Asn), were classified as being of uncertain significance 
(Table 3.3).
In patient XXV, diagnosed with CRD, a homozygous EYS variant, p.(Tyr3135*), was detected 
using whole exome sequencing. Besides this change, no other pathogenic variants were 
found. The p.(Tyr3135*) variant was previously identified homozygously in two Dutch 
siblings: one with CRD and one with RP,4 and three Spanish siblings with RP.6 In our cohort, 
two RP patients were heterozygous carriers of this variant.
Chapter 368   |
For patient XXIV-1, diagnosed with macular dystrophy, ABCA4 was initially screened with 
Sanger sequencing, but no variants were found. Subsequently, targeted whole-exome 
sequencing identified two variants in EYS, c.1299+5_1299+8del and p.(Gly2017Val).21 
Using Sanger sequencing, these EYS variants were detected in his brother, patient XXIV-2. 
Segregation analysis of the offspring of patient XXIV-1 confirmed that both variants were 
located on different alleles. The first variant (c.1299+5_1299+8del) was novel, whereas the 
second variant p.(Gly2017Val) was previously found homozygously in an RP patient.6 This 
missense variant was predicted to be pathogenic by in silico prediction tools (Table 3.3).
Figure 3.1. In vitro splice assay showing that the c.1299+5_1299+8del variant results 
in the skipping of EYS exon 8. 
(A) Schematic overview of the genomic region of EYS exon 7 to 9 including the mutation observed 
in patient XXIV-1 and wild type and mutant minigenes that were generated. (B) RT-PCR analysis of 
Rhodopsin exon 3 (RHO3) to Rhodopsin exon 5 (RHO5), Actin (loading control) and Rhodopsin exon 
5 (transfection control) 48 hours after transfection. The wild type minigene shows a fragment of 
~390 bp, which corresponds to normal splicing (RHO3-EYS8-RHO5). The mutant minigene shows a 
fragment of ~280 bp, which corresponds to RHO3 and RHO5 spliced together without EYS exon 8. 
The mutant minigene showed complete exon skipping of EYS exon 8. (C) Skipping of EYS exon 8 (EYS 
8) in cells transfected with the mutant minigene was validated by Sanger sequencing.
Extending the spectrum of EYS-associated retinal disease to macular dystrophy |   69 
Ch
ap
te
r 3
3.3.3 Minigene splice assay in HEK293T cells
To investigate potential splice defects associated with the novel c.1299+5_c.1299+8del 
variant, wild-type and mutant minigenes harboring this change were generated and 
transfected into HEK293T cells. RT-PCR analysis showed that transfection of the mutant 
minigene resulted in skipping of EYS exon 8, whereas transfection of the wild type 
minigene resulted in normal splicing (Figure 3.1B). Skipping of EYS exon 8 for the mutant 
minigene was validated by Sanger sequencing (Figure 3.1C).
3.3.4 Phenotype and visual function of patients with EYS-associated RP
Most RP patients developed symptoms of night blindness and visual field constriction 
in the second and third decade of life, the mean age at diagnosis was 30 years (range: 
11 – 56 years). Demographic information, and clinical features are available in Table 3.1. 
All RP patients had one or more characteristic fundus feature, such as peripheral retinal 
degeneration, bone spicule pigmentations, attenuated retinal vasculature or pale waxy 
optic disc (Supp. Figure S1). 
We gathered 146 visual acuity measurements, with a mean of six measurements per patient 
(range: 1-22 measurements). Four patients became visually impaired (BCVA worse than 
0.3 logMAR) during follow-up at ages 41, 43, 64, and 70 years, and already had constricted 
visual fields (<20°) at previous examinations. Mixed effects linear regression modeling 
showed an overall increase in LogMAR visual acuity of 0.015 in the best performing eye 
per year, which corresponds to a loss of 0.75 ETDRS letters per year (P<0.001).
Fifty-seven Goldmann visual field examinations were available, ranging from one to eight 
measurements per patient. At first examination, eleven patients were visually impaired 
(central visual field<20°), and five were blind (central visual field<10°). One patient 
became visually impaired during follow-up at age 39. Ten patients had a central visual 
field larger than 20° at last examination. They did not significantly differ from patients that 
were visually impaired in terms of age of onset (p=0.2262), age at diagnosis (p=0.259), or 
age at last examination (p=0.136). All ten patients carried two truncating EYS variants, of 
which nine were located in the N-terminal part of the protein, and eleven in the C-terminal 
part. The rate of visual field loss of the V4 isopter area was 9% per year.
In 23 patients, ffERG was performed: in fifteen patients (mean age: 40 years) no scotopic or 
photopic responses could be elicited, in five patients (mean age: 43 years) both scotopic 
and photopic responses were severely reduced, and in three patients (mean age: 29 years) 
there were no scotopic responses and severely reduced photopic responses. OCT scans of 
24 patients, and autofluorescence imaging of 23 patients were available for analysis. In 19 
patients the ellipsoid
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Figure 3.2. Optical coherence tomography, fundus autofluorescence, fundus 
photography and visual field of three RP patients with different RP phenotypes. 
Patients II-3 (age 23) shows a typical RP phenotype with (A) shortening of the ellipsoid layer 
length and (B) a hyperautofluorescent ring surrounding the fovea, (C) the optic disk appears 
pale and vessels are narrow. Visual field (D) is severely constricted  (~10°). Patient VII-2 (age 41) 
has a milder phenotype, (E) the ellipsoid layer length is longer and there is (F) a ‘crescent-shaped’ 
hyperautofluorescent pattern visible. (G) the optic disk appears pink and vessels are narrow. 
There is decreased sensitivity of the peripheral visual field (H), with an absolute scotoma nasally. 
Patient XX (age 73) has end-stage RP , (I) the ellipsoid zone and other outer segment layers are 
no longer discernible. There is a (J) small relatively hyperautofluorescent patch in the perifoveal 
area, surrounded by hypoautofluorescence, the fovea itself appears hypoautofluorescent as well. In 
fundo (K), the optic disk appears pale, vessels are very narrow, and there is extensive retinal atrophy 
with bone spicule pigmentations. A small island of RPE remains in the macula with RPE-alterations. 
The visual field (L) is severely constricted (<10°) and there is foveal sensitivity loss.
layer length was shortened but continuous in the foveal area, 16 of them had 
an hyperautofluorescent ring (Figure 3.2AB), and three had a crescent shape 
hyperautofluorescence pattern (I, VI-1, VII-2)(Figure 3.2EF). In a single patient (VII-1), the 
ellipsoid layer was continuous over the width of the 4mm single line scan, accompanied 
by a crescent shape pattern on autofluorescence imaging. Four patients (II-2, XV, XVI, XX) 
had foveal abnormalities in at least one eye (Figure 3.2IJ), and it became impossible to 
discriminate between the different outer retinal layers, because retinal architecture in 
the macula, including the fovea, appeared severely distorted. The majority of RP patients 
had epiretinal membranes, but there were no patients with macular holes or tractional 
macular edema. Four patients developed cystoid maculopathy during follow-up; one 
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patient was treated with Acetazolamide tablets, and two with Somatostatin injections. 
In patients with a distinguishable hyperautofluorescent ring, the length of the ellipsoid 
zone was shorter than in patients with a ‘crescent’ autofluorescence pattern as described 
by Sengillo et al. (Figure 3.2).22
3.3.5 Phenotype and visual function of a patient with EYS-associated cone-rod 
dystrophy
One isolated patient (XXV) noted both a decrease in visual acuity and night blindness as 
first symptoms, he previously underwent refractive surgery to correct for high myopia. At 
first examination visual acuity was 0.3 LogMAR in the best eye. On fundoscopy, the optic 
disks appeared pale, and white flecks in the macula were noted, vessels were thin with 
mottling of the RPE in the periphery. OCT imaging showed atrophy of the outer retinal 
layers in the posterior pole, and fundus autofluorescence showed a hyperautofluorescent 
ring with diffuse atrophy in the macula (Figure 3.3).
Figure 3.3. Autofluorescence, SD-OCT and fundus pictures of patient with cone-rod 
dystrophy. 
(A) Fundus autofluorescence of patient XXV shows a hyperautofluorescent ring within the vascular 
arcade, surrounding the macular area, which appears patchy, with diffuse hypoautofluorescent 
lesions. The fovea appears hypoautofluorescent. (B) On OCT, there is a parafoveal cyst, the outer 
retinal layers are distorted and the ellipsoid zone can no longer be distinguished. (C) Atrophy of the 
posterior pole with discernable choroidal vasculature, the retinal vessels are attenuated.
3.3.6 Phenotype and visual function of patients with EYS-associated macular dys-
trophy
The proband (XXIV-2) was the youngest in a family of five siblings; he suffered from 
decreased visual acuity from the age of 7. He was first examined at age 12, binocular 
visual acuity was 1.0 LogMAR with excentric fixation. At age 22, he was diagnosed with 
juvenile macular dystrophy, visual acuity was 0.8 LogMAR and funduscopy revealed a 
bull’s eye maculopathy. Central visual field testing with Humphrey Field Analyzer 10-2 
showed a central scotoma, and color vision testing with Lanthony’s desaturated 15-Hue 
test revealed a tritan defect. ffERG showed normal scotopic and photopic responses. 
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At age 23, pronounced macular atrophy was seen on OCT imaging (Figure 3.4G). His 
older brother (XXIV-1) noted a decrease in visual acuity and color vision problems from 
the age of 18. At age 32, visual acuity was 0.3 LogMAR, funduscopy revealed normal 
foveal reflexes, perimacular RPE alterations and yellow dots, with normal aspect of the 
peripheral retina. OCT imaging showed atrophy of the ellipsoid zone in the fovea, and 
fundus autofluorescence revealed a hyperautofluorescent ring (Figure 3.4A-C). At age 36, 
ffERG rod and cone responses were within normal range, and mfERG showed decreased 
foveal responses (Supplementary Figure 2). At age 38, visual acuity was 0.7 LogMAR 
and OCT imaging showed atrophy of all outer retinal layers and thinning of the RPE. 
Fundus autofluorescence revealed a larger hyperautofluoresent ring surrounding the 
hypoautofluorescent macula (Figure 3.4D-F).
Figure 3.4.  Infrared imaging, OCT imaging and fundus photography in patients with 
macular dystrophy. 
Disease progression of EYS-associated macular dystrophy in patient XXIV-1 using spectral domain 
optical coherence tomography (SD-OCT) scans, fundus autofluorescence (FAF) and fundus images 
of the right eye. (A-C) At age 32, SD-OCT scan shows foveal atrophy with local disruption of the 
ellipsoid zone and thinning of the outer nuclear layer, on FAF a hyperautofluorescent ring is 
discernable surrounding the fovea. Fundus photograph reveals a normal optic disk, normal caliber 
of the retinal vessels and subtle RPE alterations in the foveal region, but no abnormalities in the 
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peripheral retina. (D-F) At age 38 , SD-OCT shows progression of the foveal atrophy with disruption 
of the inner retinal layers, hyperreflective pigment deposits and thinning of the RPE. FAF shows a 
Bull’s eye maculopathy with a hypopigmented fovea and a hyperreflective ring. Fundus photograph 
reveals a hypopigmented fovea surrounded by RPE alterations and RPE atrophy, there were no 
peripheral abnormalities. (G) SD-OCT of patient XXIV-2 at age 23, showing macular atrophy.
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3.4 Discussion
In this study, we have assessed the spectrum of retinal disease and the course of visual 
function in 30 patients carrying biallelic EYS variants. Twenty-seven patients had RP, one 
patient had CRD, and two patients had macular dystrophy, based on clinical characteristics, 
functional testing, and retinal imaging. EYS mutations are one of the most common 
causes of arRP in Asia and Europe. Novel findings included the presence of homozygous 
EYS mutations in CRD patients, and compound heterozygous EYS mutations in patients 
with macular dystrophy.
The age of onset in RP patients ranged from 7 to 51 years, all had one or more typical 
fundus features corresponding with retinitis pigmentosa (Supp. Figure S1). Four patients 
became visually impaired (BCVA worse than 0.3 LogMAR) during follow-up at ages 41, 43, 
64, and 70 years. Mixed effects linear regression modeling showed an overall increase in 
LogMAR visual acuity of 0.015 in the best performing eye per year, which corresponds to 
a loss of 0 .75 ETDRS letters per year (P<0.001). Based on visual field constriction, 11 out 
of 27 RP patients were visually impaired (41%) and five were blind (19%) according to 
WHO-criteria at first examination in our centers. The rate of peripheral visual field loss for 
the V4 target was 9% per year in our cohort, which is markedly slower than 23% per year 
reported by McGuigan et al.23 Ten RP patients had a central visual field larger than 20° at 
last follow-up (mean age: 39 years). They did not differ from RP patients with visual field 
constriction in age of onset, or age at last examination. All ten of these patients carried 
compound heterozygous or homozygous truncating variants. 
Differences in disease manifestation and progression are often attributed to a difference 
in underlying causal variants (e.g. missense versus truncating variants). Three out of 27 RP 
patients carried one heterozygous missense EYS variant, and one truncating EYS variant. 
There were no patients with homozygous missense EYS variants, therefore we could not 
study whether missense variants were associated with milder retinal disease in our cohort. 
Siblings with the same EYS genotype can differ substantially in age of onset, disease 
presentation, and rate of disease progression. Our study was not suited to determine 
genotype-phenotype correlations in detail as many variants were observed only once.
Two-third of RP patients in our cohort had typical hyperautofluorescent rings, and one 
third had a crescent shape hyperautofluorescent pattern, as described by Sengillo et al.22 
The crescent pattern was associated with larger visual fields and therefore milder disease 
progression. Three out of four patients had two mutations near the C-terminal domain, 
which could have a less detrimental impact on protein structure or function. Additional 
studies would be most helpful to study the effect of these mutations on the different 
isoforms. 
Three cases of EYS-associated CRD have been published so far; the first case was a Dutch 
patient that carried the same homozygous variant as our CRD patient, p.(Tyr3135*).4 The 
second case was a Japanese patient, carrying compound heterozygous EYS variants, 
p.(Tyr2935*) and p.(Ser1653fs). Segregation analysis confirmed that these variants were 
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located on different alleles. Each separate variant homozygous, as well as the identical 
compound heterozygous combination of these variants, were previously identified 
as causal in RP patients.9,24-26 The third case, was a French patient with compound 
heterozygous variants, p.(Trp558*), and p.(Asn745Ser). The pathogenicity of the missense 
variant was questionable, as it proved to be not conserved, and the pathogenicity is 
uncertain according to the ACMG classification.18 The homozygous nonsense variant, 
p.(Tyr3135*),  that our CRD patient, as well as the first mentioned CRD case carried, was 
also detected in RP patients,4,5 including in two RP patients of this cohort. The variant 
is located in the last EYS exon and leads to a premature stop codon. Functional assays 
might reveal whether the variant leads to nonsense mediated decay, or the formation 
of a C-terminally truncated EYS protein. It is unclear why identical genotypes can result 
in both RP and CRD phenotypes. The EYS variants found in CRD patients did not cluster 
in a specific domain. Of the 4 known EYS isoforms, only the two long isoforms (isoform 1 
and 4) are predicted to be affected by the mutations, as all CRD-associated variants are all 
located after the 594th amino acid. Unfortunately, this does not help explain the difference 
in phenotype because some of the underlying genotypes were also found in RP patients. 
The presence of genetic and epigenetic modifiers, or environmental factors, could also 
play a role in the observed differences in phenotype in these patients.
Macular dystrophy is an IRD in which the central retina is primarily affected and peripheral 
photoreceptor function is spared. Patients XXIV-1 and XXIV-2 presented with an isolated 
macular dystrophy, with a normal ffERG. Targeted whole exome sequencing identified 
compound heterozygous EYS variants: c.1299+5_1299+8del and c.6050G>T. To assure 
the functional effect of the splice site variant we generated a mutant minigene. RT-PCR 
analysis showed that transfection of the mutant minigene resulted in skipping of EYS 
exon 8, suggesting that similar mis-splicing events can occur in the retina. The second 
variant was previously found homozygous in an RP patient.6 EYS is expressed in the outer 
segments of both rods and cones, and is thought to be crucial for the stability of the ciliary 
axonema and photoreceptor homeostasis in humans. In several mammal lineages, such 
as rodents, EYS is not expressed, which limits the availability of animal models that better 
mimic human anatomy and physiology. EYS zebrafish knockout studies showed cone-rod 
dystrophy pattern of retinal degeneration,16 RP or macular dystrophy phenotypes have 
not been described in animals that are mutant for Eys.
Since molecular testing can uncover pathogenic variants in genes that have not been 
associated with the phenotype of interest, it remains crucial to perform segregation 
analysis and to keep looking for variants in other genes. Reassessing the phenotype might 
be worthwhile; especially in patients with end-stage disease in whom discriminating 
between different subtypes of IRD might prove difficult, as both central and peripheral 
retinal architecture are frequently severely distorted. To better understand the 
pathophysiology of EYS-associated IRDs it is essential to perform functional studies that 
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focus on the effect of mutations on the different EYS isoforms and their effect within the 
retina.
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3.6 Supplemental information
Supplementary Figure S1. Fundus photographs of patients in different stages of RP 
disease.
Supplementary Figure S2. Multifocal electroretinogram of patient XXIV-1 with 
macular dystrophy showing decreased foveal responses.
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Supplementary Table S1. 
Primers used for cloning and RT-PCR.
Primer name Primer sequence (5’ > 3’)
Wild type minigene 
forward in intron 7
5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCAGTCCTATAAGTAGCCCAAC-3’
Wild type minigene 
reverse in intron 8
5’-GGGGACCACTTTGTACAAGAAAGCTGGGTGGTCTCTCTCAGTAAATATCTG-3’
Mutagenesis primer 
forward
5’-GAAGATTCAAAGTAATTTAATACATGGCAAC-3’
Mutagenesis primer 
reverse
5’-GTTGCCATGTATTAAATTACTTTGAATCTTC-3’
Rhodopsin exon 3 forward 5’-CGGAGGTCAACAACGAGTCT-3’
Rhodopsin exon 5 forward 5’-ATCTGCTGCGGCAAGAAC-3’
Rhodopsin exon 5 reverse 5’-AGGTGTAGGGGATGGGAGAC-3’
Actin forward 5’-ACTGGGACGACATGGAGAAG-3’
Actin reverse 5’-TCTCAGCTGTGGTGGTGAAG-3’
Sequences used for Gateway cloning are underlined.
Supplementary methods
Generation of minigenes
PCR primers were designed in intron 7 (forward) and intron 8 (reverse) of the EYS gene 
using Primer3 software1. Fifty nanograms of genomic DNA from a control individual was 
incubated together with 0.5 µM of the forward and reverse primer, 100 µM dNTPs (Roche), 
0.25 U Phusion high fidelity polymerase, 1x Phusion PCR buffer and 1x Q-solution (Qiagen, 
Venlo, the Netherlands) in a total volume of 25 µl. The following program was run in a 
2720 Thermal Cycler (Applied Biosystems): samples were denatured at 98°C for 3 minutes 
followed by 35 cycles of amplification consisting of 30 seconds at 98°C, 30 seconds at 
58°C and 1.5 minutes at 72°C, and a final extension for 5 minutes at 72°C. PCR products 
were separated on a 1% agarose gel and DNA products were excised, and purified on 
Nucleospin Gel and PCR Clean-up columns (Macherey Nagel). 150 ng of the purified insert 
was cloned into the pDONR201 entry vector using the Gateway BP Clonase Enzyme mix 
(Thermo Fisher Scientific). Entry clones were validated by Sanger sequencing.
For generation of the mutant minigene, the c.1299+5_1299+8del mutation was 
introduced via site-directed mutagenesis, using the entry clone containing the wild-type 
construct as a template. Following Sanger sequencing of the mutated construct, both the 
wild-type and mutant entry clone were transferred into the destination vector pCI-NEO-
RHO exon3,5/DEST using the Gateway LR Clonase enzyme mix (Thermo Fisher Scientific). 
The pCI-NEO-RHO exon3,5/DEST vector is a homemade destination vector that allows 
cloning of the fragment of interest between Rhodopsin exon 3 and 5 under the control of 
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the CMV promoter2. Primer sequences used to generate wild type and mutant minigenes 
are listed in Supp. Table S1.
Cell culture and transfection
HEK293T cells were grown in DMEM supplemented with 10% fetal calf serum, 1% penicillin-
streptomycin and 1% sodium pyruvate at 37°C and 5% CO2. Confluent HEK293T cells were 
diluted 1 to 5 and ~400.000 cells per well were seeded in a 12-wells plate and grown for 24 
hours at 37°C in a total volume of 1 ml. For transfection, 750 ng of the minigene vector was 
incubated together with 2.25 µl Fugene® HD Transfection Reagent (Promega, Madison, 
WI, USA) in a total volume of 100 µl Optimem for 20 minutes at room temperature and 
subsequently, the transfection mix was added to the cells. After incubation for 48 hours at 
37°C, cells were harvested for RNA isolation.
RNA isolation and cDNA synthesis
Total RNA from HEK293T cells was extracted using NucleoSpin RNA columns (Macherey-
Nagel, Düren, Germany) according to the manufacturer’s protocols. For cDNA synthesis, 
the iScriptTM cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) was used. One microgram 
of total RNA was incubated with 1 µl iScript Reverse Transcriptase and 1x reaction mix in a 
total volume of 20 µl nuclease free water. For the RT-reaction, the mixture was incubated 
for 5 min at 25°C, 20 min at 46°C and the reaction was stopped by heating at 95°C for 1 
min.
RT-PCR analysis
Two µl of cDNA was incubated together with 0.5 µM of the forward and reverse primer, 
100 µM dNTPs (Roche), 0.25 U Taq polymerase (Roche), 1x PCR buffer + Mg+ (Roche) in a 
total volume of 25 µl milliQ. PCR conditions were 3 minutes at 94°C followed by 35 cycles of 
amplification consisting of 30 seconds at 94°C, 30 seconds at 58°C and 2 minutes at 72°C, 
and a final extension for 5 minutes at 72°C. Primer sequences are listed in Supplementary 
Table 1. PCR products were purified on Nucleospin Gel and PCR Clean-up columns 
(Macherey Nagel). After purification, PCR samples were sent for Sanger sequencing with 
the same primers that were used for the RT-PCR reaction.
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Abstract
Mutations in eyes shut homolog (EYS), a gene predominantly expressed in the photoreceptor 
cells of the retina, are among the most frequent causes of autosomal recessive (ar) retinitis 
pigmentosa (RP), a progressive retinal disorder. Due to the absence of EYS in several rodent 
species and its retina-specific expression, still little is known about the exact function of 
EYS and the pathogenic mechanism underlying EYS-associated RP. We characterized eys in 
zebrafish, by RT-PCR analysis on zebrafish eye-derived RNA, which led to the identification 
of a 8,715 nucleotide coding sequence that is divided over 46 exons. The transcript 
is predicted to encode a 2,905-aa protein that contains 39 EGF-like domains and five 
laminin A G-like domains, which overall shows 33% identity with human EYS. To study the 
function of EYS, we generated a stable eysrmc101/rmc101 mutant zebrafish model using CRISPR/
Cas9 technology. The introduced lesion is predicted to result in premature termination 
of protein synthesis and lead to loss of Eys function. Immunohistochemistry on retinal 
sections revealed that Eys localizes at the region of the connecting cilium and that both 
rhodopsin and cone transducin are mislocalized in the absence of Eys. Electroretinogram 
recordings showed diminished b-wave amplitudes in eysrmc101/rmc101 zebrafish (5 dpf ) 
compared to age- and strain-matched wild-type larvae. In addition, decreased locomotor 
activity in response to light stimuli was observed in eys mutant larvae. Altogether, our 
study shows that absence of Eys leads to a disorganized retinal architecture and causes 
visual dysfunction in zebrafish.
Key words: 
Eyes shut homolog, CRISPR/Cas9, photoreceptors, retinal dysfunction, zebrafish
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4.1 Introduction
Retinitis pigmentosa (RP) is a clinically diverse and genetically heterogeneous disorder with 
a prevalence of approximately 1 in 4,000 individuals. Retinitis pigmentosa is characterized 
by night blindness and visual field constriction, and often leads to total blindness.1 For 
RP, different modes of inheritance including autosomal recessive, autosomal dominant, 
and X-linked,  have been observed. To date, 58 genes are described in which mutations 
can cause arRP (RetNet, http://www.sph.uth.tmc.edu/RetNet/), most of them only being 
responsible for 1-2% of all arRP cases. Mutations in the eyes shut homolog (EYS) gene 
are among the most frequent causes of arRP, accounting for approximately 5-10% of 
all cases.2-4 EYS is located on chromosome 6p12 and is predominantly expressed in the 
retina. Human EYS encodes for the 3,144 amino acid protein eyes shut homolog (EYS) that 
consists of five laminin A G-like (LamG) domains and 28 epidermal growth factor (EGF) or 
EGF-like domains.5,6
Eyes shut homolog is an ortholog of the Drosophila spacemaker (spam) protein, which 
plays a major role in the development of photoreceptors and the maintenance of the 
photoreceptor morphology.7 Since the composition of the Drosophila eye is substantially 
different compared to that of the human eye, it remains questionable whether Drosophila 
can serve as a good model to study EYS-associated RP. Extensive bio-informatic analysis 
showed that Eys is absent from several rodent genomes (e.g. mice),6 which also excludes 
these animals for being used as a model system to study Eys function. In the zebrafish 
genome, several gene predictions encoding EGF-like domains and LamG domains 
are predicted on chromosome 13, including Chr13.1401, Chr13.1402, Chr13.1403, 
ENSDART00000108504 and ENSDART00000122834. This indicates that eys probably is 
present in zebrafish, although its complete sequence was not characterized. Furthermore, 
the zebrafish retina is morphologically similar to that of the human retina, in the sense that 
all the major cell layers found in humans are also present in zebrafish,8 thereby providing a 
promising model to study the function of EYS.
Recently, two independent groups reported degeneration of the photoreceptor cell 
layer in different eys knock-out zebrafish models.9,10 Yu et al. generated an eys mutant 
zebrafish line using CRISPR/Cas9 technology in which degradation of the outer nuclear 
layer was observed. In addition, they revealed that eys localizes near the photoreceptor 
connecting cilium and that it might play a role in maintaining the ciliary pocket.10 In a 
study of Lu et al., TALEN technology was used to generate an eys knock-out zebrafish, 
which showed visual impairment by recording electroretinography (ERG). Furthermore, 
they demonstrated F-actin disruption and mislocalization of the retinal proteins red 
opsin, UV opsin and rhodopsin in the absence of Eys.9 Both studies imply a role of Eys 
in maintaining retinal morphology and visual function, although the exact mechanism 
underlying EYS-associated RP still remains to be elucidated.
In this study, we generated a stable eys-/- mutant zebrafish line, designated eysrmc101/rmc101, 
using CRISPR/Cas9 technology to study the function of Eys in the zebrafish retina. Similar 
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to previous studies,9,10 we observed progressive degeneration of the photoreceptor outer 
segments, mislocalization of rhodopsin and decreased ERG responses in absence of Eys. 
In addition, we show diminished locomotor activity of eysrmc101/rmc101 zebrafish larvae in 
response to light stimuli, which has not been shown before.
4.2 Materials and methods
4.2.1 Animal experiments
The zebrafish experiments were approved by the Centrale Commissie Dierproeven (CCD, 
RU-DEC 2016–0091) and were performed in accordance with the Dutch law (Wet op de 
Dierproeven 1996) and European regulations (Directive 86/609/EEC).
4.2.2 Fish husbandry
We used the in-house bred Tupfel Longfin strain. Adult zebrafish were maintained in 
4.5-liter polyethylene tanks (Tecniplast) in an Aqua Schwarz holding system (Göttingen) 
supplied continuously with circulating filtered tap water (electoral conductivity of 300 uS 
cm-1, 27.5 0C, pH 7.5-8) under cycles providing 14 hrs of light and 10 hrs of dark (14:10 LD; 
lights on 9 AM; lights off 11 PM). The fish were fed with Gemma Micro 300 (Skretting) twice 
a day and living Artemia once a day.   
4.2.3 RNA isolation
Total RNA from adult zebrafish eyes was obtained by snap-freezing isolated eyes in liquid 
nitrogen and subsequently homogenizing the eyes in Trizol (Thermo Fischer Scientific) 
using a pestle and moving through a syringe five times. After incubation on ice for 15 
minutes, 250 µl chloroform was added, incubated for 3 minutes and centrifuged at 4°C at 
12,000xg for 15 minutes. The supernatant was mixed with 1 µl glycogen (5 µg/µl) and 250 
µl isopropanol and stored at -80°C o/n. The RNA was further purified and DNAse treated 
using RNeasy spin columns (Qiagen) according to manufacturer’s protocol.
4.2.4 RT-PCR analysis of eys
For cDNA synthesis, one µg of total RNA was reverse transcribed using the iScriptTM cDNA 
synthesis kit (Bio-Rad) according to the manufacturer’s instructions. For the characterization 
of zebrafish eys, RT-PCR was performed. One microliter cDNA was incubated together with 
0.5 µM of the forward and reverse primer, 100 µM dNTPs (Roche), 0.25 U Taq polymerase 
(Roche), 10x PCR buffer + 15 mM MgCl2 (Roche) and 1x Q solution (Qiagen) in a total volume 
of 25 µl. The following program was run in a 2720 Thermal Cycler (Applied Biosystems): 
the samples were denatured at 94°C for 3 minutes followed by 35 cycles of amplification 
consisting of 94°C for 20 seconds, 58°C for 30 seconds and 72°C for 50 seconds, and a final 
primer extension at 72°C for 5 minutes. Primers targeting all exons of eys were designed, 
based on gene predictions Chr13.1401, Chr13.1402, Chr13.1403, ENSDART00000108504 
Eyes shut homolog is important for the maintenance 
of photoreceptor morphology and visual function in zebrafish |   95 
Ch
ap
te
r 4
and ENSDART00000122834 using the UCSC Genome Browser on Zv9/danRer7 assembly. 
Primer sequences are listed in S1 Table. A number of these primer combinations were 
used for nested PCRs resulting in the amplification of PCR products representing parts 
of the eys transcript expressed in zebrafish eyes. To verify that the amplified products 
indeed correspond to eys, PCR products were purified on Nucleospin Gel and PCR Clean-
up columns (Macherey Nagel) and either directly sequenced or cloned in the pCR4-TOPO 
vector with the use of the TOPO TA Cloning Kit (Invitrogen) for sequencing with T7 and T3 
sequencing primers.
To study the presence of eys transcript in wild-type and eysrmc101/rmc101 larvae, total RNA from 
20 pooled larvae was extracted as described above. RT-PCR was performed using a primer 
pair covering the region in exon 20 of eys where the deletion was located (Supp. Table S1).
4.2.5 Multiple sequence alignment
A multiple sequence alignment of EYS proteins from different species was generated 
using AlignX in the Vector NTI software package (Vector NTI Advance 11). Accession 
numbers of the protein sequences used for sequence comparison are as follows: 
human, NM_001142800.1 (RefSeq); macaque, XM_011737495.1 (RefSeq); chicken, 
XM_015284845.1 (RefSeq); Drosophila, NM_001032399.3 (RefSeq).
4.2.6 Target site selection and gRNA synthesis
Target sites for genome editing were selected by using the online web tool CHOPCHOP 
(https://chopchop.rc.fas.harvard.edu/).11 Guide RNAs (gRNAs) were synthesized as 
described previously.12 Templates for gRNA transcription were generated by annealing 
gene-specific oligonucleotides containing the T7 (5’-TAATACGACTCACTATA-3’) promoter 
sequence, the 20-base target sequence without the PAM, and a complementary region 
to a constant oligonucleotide encoding the reverse complement of the tracrRNA tail. 
T4 DNA polymerase (New England Biolabs) was used to fill the ssDNA overhang and the 
template was then purified using the GenElute PCR clean-up kit (Sigma). Transcription of 
the gRNAs was performed using the T7 MEGAshortscript Kit (Ambion). Oligos used for 
gRNA synthesis are listed in Supp. Table S2.
4.2.7 Microinjections
Zebrafish embryos were collected after natural spawning and injected at the single cell 
stage with one nanoliter of injection mix (4.5 µl gRNA (1µg/µl), 2.5 µl Cas9 protein (2µg/
µl, PNA Bio), 2 µl 1M KCl and 1 µl 0.5% phenol red dye). To screen for genomic lesions, 
genomic DNA was extracted from a pool of 15 embryos at 2.5 days post fertilization (dpf ).
4.2.8 Genotyping
Genomic DNA was extracted from larvae at 2.5 dpf or caudal fin tissue from adult zebrafish. 
Tissue was incubated in 25 µl (larvae) or 75 µl (fin tissue) lysis buffer (40 mM NaOH 0.2 
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mM EDTA) at 95°C for 20 minutes. The lysed samples were diluted 10 times of which 1 µl 
was incubated together with 0.5 µM of the forward and reverse primer, 100 µM dNTPs 
(Roche), 0.25 U Taq polymerase (Roche) and 10x PCR buffer + 15 mM MgCl2 (Roche) in a 
total volume of 25 µl. Samples were denatured at 94°C for 3 minutes followed by 35 cycles 
of amplification consisting of 20 seconds at 94°C, 30 seconds at 58°C and 50 seconds at 
72°C, and a final primer extension of 5 minutes at 72°C. To screen for genomic lesions, PCR 
products were sequenced directly. Primer sequences are listed in Supp. Table S1.
4.2.9 Immunohistochemistry
Dissected adult zebrafish eyes (2 mpf and/or 5 mpf) and larvae (5 dpf ) from eysrmc101/rmc101 
mutants and their age- and strain-matched wild-type controls were cryoprotected with 
10% sucrose in PBS for 10 minutes prior to embedding in OCT compound. Embedded 
samples were snap frozen in liquid nitrogen-cooled isopentane and cryosectioned 
following standard protocols. Cryosections (7 µm) were fixed with 4% paraformaldehyde 
(PFA) at room temperature for 10 minutes, permeabilized with 0.01% PBS-Tween20 and 
hereafter blocked in 10% normal goat serum and 2% BSA in PBS at room temperature for 
1 hour. Subsequently, they were incubated with primary antibodies directed against EYS/
RP25 (rabbit, 1:300, Novus Biological NBP1-90038), Centrin  (mouse, 1:250, Millipore 04-
1624) or GFAP (rabbit, 1:750, Dako) at 4°C overnight. After washing with PBS, cryosections 
were incubated with secondary antibodies (rabbit IgG, Alexa Fluor 488, goat, 1:800, 
Molecular Probes A11008; mouse IgG, Alexa Fluor 568, goat, 1:800, Life Technologies 
A11031) at room temperature for one hour.
For rhodopsin and cone transducin staining, zebrafish eyes were fixed with 4% PFA at 
4°C overnight, followed by incubation in a MeOH gradient. After embedding, freezing 
and cryosectioning, slides were permeabilized with 0.1% PBS-Tween20 and incubated 
in antigen retrieval solution (10 mM sodium citrate pH 8.5) at 121°C for 1 minute. After 
washing, cryosections were blocked in block solution (10% Non Fat Dry Milk in 0.1% PBS-
Tween20) at RT for 1 hour, followed by incubation with the primary antibodies Rhodopsin 
(clone 4D2, mouse, 1:2,000, Novus Biological NBP1-48334) and GNAT2 (rabbit, 1:500, MBL 
PM075) in block solution at 4°C overnight. After washing with 0.1% PBS-Tween20, slides 
were incubated with the secondary antibodies (rabbit IgG, Alexa Fluor 488, goat, 1:800, 
Molecular Probes A11008; mouse IgG, Alexa Fluor 488, goat, 1:800, Invitrogen A11029) 
together with Phalloidin Alexa Fluor 568 (1:100, Molecular Probes, A-12380). 
For staining with boron-dipyrromethene (BODIPY), zebrafish larvae or eyes were fixed in 
4% PFA for 2 hours, cryoprotected in 10% sucrose in PBS for 30 minutes, embedded in 
OCT, snap frozen in melting isopentane and cryosectioned. BODIPY was applied to the 
cryosections at room temperature for 20 minutes.
In all cases, nuclei were counterstained with DAPI (1:8,000). Imaging was performed on 
a ZEISS LSM 880 microscope with Airyscan. Zen software was used for processing the 
images. To analyze the thickness of ONL and INL in 5 dpf, 2 mpf and 5 mpf zebrafish, up 
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to 10 different measurements were taken for each section. Two different sections were 
analyzed for one wild-type fish and one eys mutant fish per time-point.
4.2.10 Optokinetic response (OKR) measurements
Optokinetic response measurements were performed as described previously.13 In brief, 
zebrafish larvae were mounted in 3% methylcellulose in a small Petri-dish, which was 
placed on a platform surrounded by a rotating drum of 8 cm in diameter. A pattern of 
alternating black and white vertical stripes was displayed on the drum interior (each 
stripe subtended an angle of 36°C). Larvae (5 dpf ) were placed in an upright position 
and visualized through a stereomicroscope positioned over the drum and illuminated 
with fiberoptic lights. Eye movements were recorded while larvae were optically 
stimulated by the rotating stripes. Larvae were subjected to a protocol of 30 seconds 5 
rpm counterclockwise rotation, 10 seconds rest, 30 seconds 5 rpm clockwise rotation, 10 
seconds rest, 30 seconds 8 rpm counterclockwise rotation, 10 seconds rest, 30 seconds 8 
rpm clockwise rotation. The amount of eye movements were counted from the recorded 
movies afterwards and plotted using Graphpad Prism (version 5.03).
4.2.11 Electroretinography (ERG)
Electroretinography measurements were performed on isolated larval eyes (5 dpf ) as 
previously described.14 Larvae were dark-adapted for a minimum of  30 minutes prior to 
the measurements, and subsequently handled under dim red illumination. The isolated 
eye was positioned to face the light source. Under visual control via a standard microscope 
(Stemi SV8, Zeiss) equipped with red illumination (KL1500 electronic, Zeiss), the recording 
electrode with an opening of approximately 15  μm at the tip was placed against the 
center of the cornea with a micromanipulator. This electrode was filled with E3 medium (5 
mM NaCl, 0.17 mM KCl, 0.33 mM CaCl, and 0.33 mM MgSO4). A custom-made stimulator 
was invoked to provide light pulses of 100 ms duration, with a 100% light intensity of 6000 
lux. It uses a ZEISS XBO 75W light source and a fast shutter (custom made) driven by the 
self-developed NI Labview program. Electronic signals were amplified 1,000 times by a 
pre-amplifier (P55 A.C. Preamplifier, Astro-Med. Inc, Grass Technology) with a band pass 
between 0.1 and 100 Hz, digitized by DAQ Board NI BNC-2090 (National Instruments) and 
displayed via the self-developed NI Labview program. All experiments were performed at 
room temperature.
4.2.12 Visual motor response
Locomotor activity in response to light-dark conditions, also known as visual motor 
response (VMR), was analyzed using the Danio Vision system (Noldus B.V.). Collected 
embryos were raised in E3 medium (5mM NaCL, 0.17mM KCL, 0.33mM CaCl2, 0.33mM 
MgSO4, supplemented with 0.1% methylene blue) in a 28°C incubator, subsequently 
under 14 hrs of light and 10 hrs of dark. Medium was changed every day and during the 
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process curved and dead larvae were discarded. Behavioral tests were carried out at 5 
dpf. Larvae were transferred to a 48-wells plate filled with 200 µl E3 medium without 
methylene blue. In each run, 24 mutant larvae and 24 age- and strain-matched control 
wild-type zebrafish larvae were tested. During the experiment, the temperature was kept 
constant at 28°C using a heating/cooling system (Noldus B.V.). The protocol consisted of 
20 min acclimation (with lid of the system open; room light: 500-650 lux), closing of the 
lid followed by alternating periods of 10 minutes dark, 10 minutes bright light (about 
3000 lux) and 10 minutes dark (in total 12 cycles). Variables of interest were: distance 
moved (mm) and maximum velocity (Vmax, mm/s), and difference in distance moved and 
difference in Vmax (maximum distance moved/Vmax of first 30 seconds light condition 
minus average distance moved/Vmax last 30 seconds of dark condition) for the change 
from dark to light.
4.2.13 Statistical analysis
Statistical analysis was performed using Graphpad Prism software. For data obtained 
using Danio Vision, RStudio version 1.0.153 (https://www.r-project.org) was used to 
generate graphs and perform statistical analysis. The difference between wild-type and 
mutant zebrafish was analyzed using two-tailed, unpaired Student’s t-test, and p-values 
were corrected for multiple testing using the Benjamini-Hochberg method. Statistical 
significance was set at p< 0.05. The means and standard errors of the mean are shown. 
Exact p-values are shown in Supp. Table S3.
4.3 Results
4.3.1 Characterization of zebrafish eys cDNA
The complete zebrafish eys sequence was not completely identified, however, in the 
UCSC genome browser, several gene predictions for zebrafish eys were present. On 
zebrafish chromosome 13, genes encoding EGF-like domains and LamG domains were 
predicted, including Chr13.1401, Chr13.1402, Chr13.1403, ENSDART00000108504 
and ENSDART00000122834 (Supp. Figure S1). Based on these gene predictions, we 
hypothesized that eys is present in zebrafish. We performed RT-PCR using primers 
targeting eys on RNA derived from adult zebrafish eyes as a template. This resulted in 
the identification of a 8,715 nucleotide long transcript encompassing 46 exons. Most of 
these exons were previously predicted by several gene prediction programs, although 
also a number of new exons were identified (Supp. Figure S1A). The resulting eys transcript 
translates into a protein of 2,905 amino acids that is predicted to harbor 39 EGF-like 
domains and five LamG domains. This domain organization is similar to what is observed 
for the human and Drosophila EYS proteins (Supp. Figure S1B). Interestingly, the zebrafish 
Eys protein appears to lack a so called low-complexity region, as seen for the human and 
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Drosophila protein, in which no domains are predicted. In human, this region is completely 
encoded by exon 26, which is lacking in zebrafish eys.
We performed a multiple sequence alignment of the predicted Eys protein with the 
sequence of Eys from several other species (Supp. Figure S2). From this, we could deduce 
that the amino acids coding for the N-terminal EGF- and EGF-like domains as well as the 
C-terminal LamG domains are conserved over macaque, chicken, Drosophila, human and 
zebrafish. Overall, the predicted zebrafish Eys protein shows a 33% sequence identity 
compared to human EYS.
4.3.2 Generation of an eys-/- zebrafish line by CRISPR/Cas9 technology
To better study the zebrafish Eys protein in the retina, we generated a stable zebrafish 
eys knock-out line using CRISPR/Cas9 technology. By screening zebrafish larvae for 
genetic lesions, several different types of mutations were identified. For subsequent 
experiments, zebrafish carrying a five base pair deletion (c.3488_3492del) in exon 20 were 
selected for the creation of a stable zebrafish line and named eysrmc101/rmc101(Figure 4.1A). 
The deletion is predicted to lead to a frameshift and premature termination of protein 
translation (p.Gly1163Valfs*14) (Figure 4.1C). To determine whether eys mRNA is present 
in homozygous mutant zebrafish or wether this mRNA undergoes nonsense mediated 
decay, RNA was isolated from a pool of larvae (n=15). Subsequently, the presence of eys 
transcripts was determined by RT-PCR analysis. PCR products were observed for both 
wild-type and mutant zebrafish larvae (Figure 4.1B), indicating that mutant eys transcripts 
are not rapidly degraded. Sanger sequencing confirmed that eys knock-out fish express 
the eys mRNA with the five base pair deletion.
4.3.3 Eys is absent from the retina of eysrmc101/rmc101 zebrafish and localizes 
           with the ciliary protein Centrin
To determine the localization of the Eys protein in the zebrafish retina, immuno-
histochemistry with an antibody against Eys was performed on retinal cryosections 
of zebrafish at 5 days post fertilization (dpf ) and 5 months post fertilization (mpf). Co-
staining of wild-type and mutant retinas using the Eys antibody together with an antibody 
against centrin, a marker for the connecting cilium, was performed to determine whether 
Eys localizes near the connecting cilium. Eys expression was observed adjacent to the 
immunoreactive signal of centrin (Figure 4.2A). This suggests that Eys localizes near the 
photoreceptor connecting cilium. Since two puncta of Eys were always observed close 
to the immunofluoresence signal of centrin, it might be that Eys is located in the ciliary 
basal body and the daughter centriole. The Eys signal was completely absent in the retinas 
of eys knock-out zebrafish, indicating that the Eys protein is not properly expressed in 
the mutants and that the immunofluorescence signal observed in the wild-type retinas is 
specific (Figure 4.2A).
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4.3.4 Disorganization of photoreceptor outer segments and mislocalization 
            of outer segments proteins in eysrmc101/rmc101 zebrafish
Next, we evaluated the effect of Eys deficiency on overall photoreceptor outer segment 
morphology by staining with BODIPY. This is a fluorescent dye that stains lipids and allows 
to visualize the outer segments of the photoreceptor cells. In the mutant retinas, the 
outer segments appear to be less in numbers, shorter, thicker and also more disorganized 
compared to outer segments in the wild-type retinas (Figure 4.2B). In addition, a reduction 
in inner and/or outer nuclear thickness was observed in eysrmc101/rmc101 fish of 2 mpf and 5 mpf 
(Supp. Figure S3). As Müller glia activation is a feature of retinal degeneration in zebrafish, 
we investigated the presence of activated Müller glia cells by immunohistochemistry. 
Müller glia cells were detected using an antibody against a specific cytoskeletal 
protein, glial fibrillary acidic protein (GFAP). Glial fibrillary acidic protein is described to 
be upregulated in glial cells in response to injury.15 However, we did not observe any 
differences in GFAP staining between wild-type and eysrmc101/rmc101 zebrafish, at 5 dpf nor at 
Figure 4.1. Characterization of a stable eysrmc101/rmc101 zebrafish line. 
(A) Sanger sequencing identified a five base pair deletion in exon 20 in eysrmc101/rmc101 zebrafish. (B) 
Representative gel image of RT-PCR analysis using RNA from a pool of larvae (n=15), which shows 
that eys transcripts are present in both wild-type and eysrmc101/rmc101 zebrafish (upper panel). Sanger 
sequencing confirmed the presence of the five base pair deletion in the eysrmc101/rmc101 transcript 
(lower panel). (C) Protein domain structures of wild-type Eys and the truncated Eys protein that is 
predicted in eysrmc101/rmc101 zebrafish.
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Figure 4.2. Immunohistochemistry on retinal sections of wild-type and eysrmc101/rmc101 
zebrafish. 
(A) Retinal sections of wild-type and eysrmc101/rmc101 zebrafish at 5 dpf and 5 mpf stained with antibodies 
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against Eys (green) and centrin (red). (B) BODIPY (green) staining showing disorganization of 
photoreceptor outer segments in eysrmc101/rmc101 zebrafish (5 dpf and 5 mpf) compared to age- 
and strain-matched wild-type zebrafish (arrows). (C) Retinal sections of wild-type and eysrmc101/
rmc101 zebrafish at 5 dpf (upper panel), 2 mpf (middle panel) and 5 mpf (lower panel) stained with 
antibodies against rhodopsin (green) and F-actin (red). Asterisks indicate mislocalization of 
rhodopsin to the inner segments and synapses of photoreceptor cells. (D) Retinal sections of wild-
type and eysrmc101/rmc101 zebrafish at 5 dpf, 2 mpf and 5 mpf stained with antibodies against GNAT2 
(green) and F-actin (red). Arrows indicate dysmorphic outer segments in mutant zebrafish. In all 
images, nuclei are counterstained with DAPI (blue). INL: inner nuclear layer; ONL: outer nuclear layer; 
OS: outer segments. Scale: 5 µm.
2 mpf (Supp. Figure S4). In addition, we stained the fish retinas (5 dpf, 2 mpf and 5 mpf) 
with an antibody against F-actin. In contrast to what was observed in the wild-type retinas, 
F-actin expression was disrupted in retinas of eysrmc101/rmc101 zebrafish (Figure 4.2C,D), which 
further illustrates outer segment disorganization and is in agreement with findings by Lu 
et al. 2017.9 Finally, we examined the localization of the photoreceptor proteins rhodopsin 
and cone transducin (GNAT2) in retinas of wild-type and eysrmc101/rmc101 larvae and adult 
zebrafish (5 dpf, 2 mpf and 5 mpf). In the wild-type retinas, rhodopsin localization was 
observed in the outer segments as well as lining the outer segment membranes (Figure 
4.2C). Cone transducin was mainly observed lining the outer segments (Figure 4.2D). 
In retinas of eysrmc101/rmc101 adult zebrafish and larvae, dysmorphic outer segments were 
observed together with aberrant localization of rhodopsin and cone transducin (Figure 
4.2C,D). In the retinas of eys mutant fish at 5 mpf, rhodopsin was partially mislocalized to 
the inner segments and synapses of photoreceptor cells (Figure 4.2C). This suggests that 
the change in outer segment morphology due to absence of Eys also affects the proper 
localization of other photoreceptor-specific proteins.
4.3.5 Visual function is impaired in eysrmc101/rmc101 zebrafish
To assess whether depletion of Eys results in visual dysfunction, we performed behavioral 
and functional assays. All assays were performed with larvae at 5 dpf. First, ERG recordings 
were performed to measure the visual function of wild-type and eysrmc101/rmc101 zebrafish 
larvae at 5 dpf. Mutant larvae showed significantly diminished b-wave amplitudes (640.4 
µV ± 37.31 (mean ± SEM, n=30)) compared to the b-wave amplitude of wild-type zebrafish 
larvae (451.0 µV ± 34.37 (mean ± SEM, n=30)) (Figure 4.3A,C). No difference was observed 
in a-wave amplitude between wild-type (-102.9 µV ± 8.047 (mean ± SEM, n=20))  and 
eysrmc101/rmc101 larvae (-89.06 µV ± 8.040 (mean ± SEM, n=20)) (Figure 4.3B,D). The diminished 
b-wave amplitude in the mutant larvae indicates that the eysrmc101/rmc101 larvae are visual 
impaired already in an early stage of life. Subsequently, optokinetic responses were 
measured using an in-house experimental set-up. The number of saccades was used as 
a measure for the optokinetic response. No significant difference in the number of eye 
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movements between wild-type and eysrmc101/rmc101 larvae was observed (p=0.9710, n=19) 
(Figure 4.3E).
Figure 4.3. Visual function of wild-type and eysrmc101/rmc101 zebrafish larvae. 
(A) ERG measurements of the b-wave of wild-type (black line) and eysrmc101/rmc101 (red line) zebrafish 
larvae at 5 dpf. (B) ERG measurements of the a-wave of wild-type (black line) and eysrmc101/rmc101 
(red line) zebrafish larvae at 5 dpf. (C) Quantification of the ERG b-wave amplitude of wild-type 
and eysrmc101/rmc101 zebrafish larvae at 5 dpf (n=30; p=0.0004). (D) Quantification of the ERG a-wave 
amplitude of wild-type and eysrmc101/rmc101 zebrafish larvae at 5 dpf (n=20; p=0.2324). (E) Optokinetic 
response measurements of wild-type and eysrmc101/rmc101 larvae at 5 dpf (n=19).
4.3.6 Impaired locomotor activity of eysrmc101/rmc101 zebrafish in response to light
Locomotor activity of wild-type and eysrmc101/rmc101 larvae (n=120) in response to a light 
stimulus, the visual motor response (VMR), was examined using the Danio Vision system. 
Larvae were exposed to alternating periods of 10 minutes dark and 10 minutes bright 
light for 12 cycles in total and parameters of interest were the distance moved and 
the maximum velocity (Vmax). We specifically analyzed these parameters during the 
transition from dark-to-light (last 30 seconds of dark period and first 30 seconds of light 
period), since this is described to contain the visual startle response.16,17 Both wild-type 
and mutant larvae start to move at the moment the light is switched on. However, the 
response to light was less pronounced in the eys knock-out larvae compared to the wild-
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Figure 4.4. Visual motor response of zebrafish larvae. 
(A) Distance moved (mm) of wild-type (blue line) and eysrmc101/rmc101 (red line) larvae in response to 
a light stimulus (dark-to-light transition at t=50 minutes). (B) Comparison of difference in distance 
moved between wild-type and eysrmc101/rmc101 larvae at the dark to light transition zones. (C) Maximum 
velocity (Vmax; mm/s) of wild-type (blue line) and eysrmc101/rmc101 (red line) larvae in response to a light 
stimulus (dark-to-light transition at t=50 minutes). (D) Comparison of difference in Vmax between 
wild-type and eysrmc101/rmc101 larvae at the dark to light transition zones. All experiments were done 
with larvae at 5 dpf (n=120). Statistical significance (p<0.05) is indicated with an asterisk.
type larvae (Figure 4.4A,C). Furthermore, we analyzed the change in distance moved and 
the change in Vmax during the transition from dark-to-light, since the baseline activity 
of wild-type and eysrmc101/rmc101 fish were not equal. Overall, our data showed that the 
difference in Vmax was decreased in eysrmc101/rmc101 larvae compared to wild-type larvae and 
that this decreased response was significantly lower at seven out of twelve dark-to-light 
transition zones (Figure 4.4D). Similarly, we observed a major decrease of the difference 
in distance moved in eysrmc101/rmc101 fish compared to wild-type fish for all dark-to-light 
transition zones (Figure 4.4B), though not significantly different. These data show that 
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there is a diminished response to light by eys mutant larvae compared to age- and strain-
matched wild-type larvae.
4.4 Discussion
Mutations in EYS are among the most frequent causes of arRP, yet the exact retinal function 
of EYS and the pathogenic mechanism underlying EYS-associated RP are still poorly 
understood. In this study, we characterized eys in zebrafish and showed that absence of 
Eys leads to disorganization of the photoreceptor cell layer and functional impairment of 
the zebrafish retina. Furthermore, we showed decreased locomotor activity in response 
to light stimuli in eysrmc101/rmc101 knock-out zebrafish larvae compared to wild-type larvae.
The zebrafish Eys protein lacks the low-complexity region as observed in human EYS 
protein, in which no protein domains are predicted. In human, this region is completely 
encoded by exon 26 of EYS. When analyzing the cDNA sequence of zebrafish eys, no 
corresponding exon of human EYS exon 26 could be found. In our multiple sequence 
alignment, one can also observe that this low complexity region is also missing from 
chicken EYS. This might suggest that the low complexity region, as observed in human EYS, 
is not of great importance for EYS to be a functional protein, at least not in all vertebrate 
species. In addition, a blast search with the amino acid sequence of this region only gave 
hits of human EYS protein and a number of EYS orthologs, such as gorilla, macaque, pig 
and dog.
A role of Eys in the morphogenesis of photoreceptors is described in Drosophila.7 In the 
human retina, EYS might play a role in photoreceptor survival, however, certain rodent 
species including mouse, rat and guinea pig completely lack the Eys gene.6 This raises the 
interesting questions on how photoreceptors in these species can survive.
In humans, retinitis pigmentosa is characterized by the progressive degeneration of rod 
photoreceptor cells, and in a later stage also cone photoreceptor cells. In our study, we 
also observed degeneration of photoreceptor outer segments in our zebrafish eysrmc101/
rmc101 knock-out model. It is remarkable that the eysrmc101/rmc101 zebrafish show this clear 
morphological phenotype, since it is known that retinal regeneration can occur in 
zebrafish.18 The Müller glia cells in zebrafish have the capacity to reprogram into retinal 
stem cells in response to injury, in contrast to mammals, where Müller glia cells rarely 
divide.19 We investigated the presence of Müller glia activation in eysrmc101/rmc101 zebrafish 
by immunohistochemistry using an antibody against GFAP. This specific cytoskeletal 
protein is shown to be upregulated in response to different types of retinal injury, such 
as mechanical damage and photoreceptor degeneration.15,20,21 In our study, we did not 
observe any Müller glia activation by immunohistochemistry on retinal sections of wild-
type and eys mutant fish (5 dpf and 2 mpf). It is possible that Müller glia activation occurs 
in later stages when degeneration is more severe. Another explanation could be that at 
the protein level, Müller glia activaton in this stage of degeneration is not detectable yet. 
Studying gene expression levels in Müller glia cells might be a good alternative, since it 
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is shown that these levels change rapidly after photoreceptor loss.22 However, our data 
suggests that the regeneration capacity in the zebrafish is not sufficient to overcome 
outer segment degeneration caused by absence of Eys.
Rhodopsin, which is located in the outer segments of rod photoreceptors, is a light-
sensitive receptor protein and plays a major role in visual phototransduction cascade. In 
the absence of Eys, rhodopsin was mislocalized to the photoreceptor inner segments and 
synapses. An explanation for the mislocalization of rhodopsin might be that the absence 
of Eys directly affects the transport of rhodopsin to the photoreceptor outer segments. 
Another reason could be that rhodopsin is not able to reach the outer segments of the 
photoreceptor as a consequence of the morphological changes within eysrmc101/rmc101 
zebrafish. A previous study by Lu et al. also showed mislocalization of rhodopsin in eys-/- 
zebrafish retinas, as well as mislocalization of two other outer segment proteins, guanine 
nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 (GNB3) and peripherin-2 
(PRPH2).9 Besides the peripheral mislocalization of rhodopsin, we also observed 
mislocalization of cone transducin (GNAT2). Next to that, GNAT2 immunofluorescence was 
decreased in eysrmc101/rmc101 retinas compared to wild-type retinas, indicating mislocalization 
of GNAT2 or degeneration of cone photoreceptors which is in agreement with previous 
studies of both Yu et al. and Lu et al. that show degeneration of cone photoreceptor cells 
in their eys-/- zebrafish lines.9,10
In line with the paper of Yu et al.,10 we showed that Eys localizes in the region of the 
photoreceptor connecting cilium. Two immunofluorescent dots of Eys were observed 
together near the centrin signal, suggesting that Eys might localize in the ciliary basal 
body and the daughter centriole. These data also implicate a possible role of Eys in 
facilitating ciliary transport of proteins towards the base of the cilium. To be able to further 
investigate the function of EYS it will be important to know the exact localization of eys in 
the ciliary zone, for instance by performing electromicroscopy studies.
To determine the effect of eys knock-out on the visual function of the zebrafish larvae 
(5dpf), we performed OKR, ERG and VMR experiments. No differences in OKR were observed 
between wild-type and mutant zebrafish larvae; however, ERG and VMR experiments 
showed that eysrmc101/rmc101 zebrafish were visually impaired. A reason why we did not see 
any difference in OKR between wild-type and mutant zebrafish might be that this assay 
was not sensitive enough. In eysrmc101/rmc101 larvae, the VMR was significantly decreased 
compared to wild-type larvae. When analyzing the data of the VMR experiments, we 
specifically focused on the transition between light and dark, which is shown to be the eye-
specific startle response.16,17 The light-off response is not only driven by photoreceptors in 
the retina, but also deep brain photoreceptors play an important role in this process.23,24 
Electroretinography data showed a significantly diminished b-wave amplitude in eys 
mutant fish compared to age- and strain-matched wild-type fish, however, no difference 
was observed for the a-wave amplitude between mutant and wild-type fish. The a-wave 
is a result of photoreceptor activity, whereas the b-wave mainly reflects depolarization of 
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ON bipolar cells.25 The dimished b-wave amplitude in eysrmc101/rmc101 zebrafish could either 
be the result of a defect of the ON bipolar cells itself, or the signal transduction towards 
the ON bipolar cells. Since in zebrafish of 5 dpf, rod photoreceptors are not fully functional 
yet,26,27 the normal a-wave response indicates that the cone photoreceptors of larvae at 
least partially remain their function in the absence of Eys.
Since EYS is not present in several rodent species, we used zebrafish to study the function 
of Eys in vivo. Furthermore, the morphology of the zebrafish retina is similar to that of the 
human retina, in the sense that all the major cell layers found in humans are also present 
in zebrafish. Another approach to further study the function of EYS and the pathogenic 
mechanism underlying EYS-related RP, would be to make use of patient-derived cells. Due 
to the retina-specific expression of EYS, one would have to use induced pluripotent stem 
cells (iPSCs), which can be differentiated into retinal cells.28,29 Cells derived from patients 
with EYS mutations can be compared to cells derived from controls, by looking at gene 
expression levels, EYS localization, and morphological differences.
In conclusion, we generated an eysrmc101/rmc101 zebrafish line, which showed disorganization 
of the photoreceptor outer segments and impaired visual function. Furthermore, absence 
of Eys leads to a significantly decreased VMR, which was not shown previously. In addition, 
this eysrmc101/rmc101 zebrafish line is a powerful model to further study the pathophysiological 
mechanism underlying EYS-associated RP.
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4.7 Supplemental information
Supplementary Figure S1. Gene predictions, exons and protein domain structure. 
(A) Upper panel: gene predictions present for zebrafish eys in the UCSC Genome Browser on 
chromosome 13. Lower panel: Exon structure of zebrafish eys. (B) Protein domain structure of human 
EYS and zebrafish Eys proteins. Note the conservation of Laminin G domains at the C-terminal part 
of the protein.
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Supplementary Figure S2. Multiple sequence alignment of EYS protein in different 
species.
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Supplementary Figure S2. Multiple sequence alignment of EYS protein in different species. 
 
    Human     (1) --MTDKSIVILSLMVFHSSFIN-GKTCRRQLVEEWHPQPSSYVVNWTLTENICLDFYRDC 
   Macaque     (1) --MTDKSIIILSLMVFHSSFIN-GKTCRRELVEEWHPQPSSHVVNWTLTENICLDYYRDC 
   Chicken     (1) --MTPKSTVHMVVCFLQLCIVKGQIICERQIIAEWRVEPKHVLIEWTLRKNICTDFYSEC 
 Zebrafish     (1) MRNPKLAIIVFLLSCVIYGPVYSQVTCRRATSREWHTQPKNISVRWTLMENTCSSLTQCW 
Drosophila     (1) ------------------------------------------------------------ 
----------     (1)    Signal peptide     -------------------------------- 
 
     Human    (58) WFLGVN-TKIDTSGNQAVPQICPLQIQLGDILVISSEPSLQFPEINLMNVSETSFVGCVQ 
   Macaque    (58) WFLGVN-TKIDTSGNQVVPQICPLQIQLGDILVISSEPSLQFPEINLMNVSETSFIGCVQ 
   Chicken    (59) WNVNKN-ATREDKN-LSVPQICPVQLQLGDTLFISSEPSFQSYGMNLVNVSKEEFINCPK 
 Zebrafish    (61) SSFAETNGHFWTTGPYHFPQLCPLELQLGDLLFVSADGTLEQHGVQLIKVSKEEFDKCAI 
Drosophila     (1) ------------------------------------------------------------ 
 
 
     Human   (117) NTTTEDQLLFGCRLKGMHTVNSKWLSVGTHYFITVMASGPSPCPLGLRLNVTVKQQFCQE 
   Macaque   (117) NTTTEDQLLFGCRLKGMHTVNSKWLSVGTHYFITVMASGPSPCPLGLRLNVTVKQQFCQE 
   Chicken   (117) IGFLQEQQIFVCQIRGLHQVDSTWLGVGTHYFAELHKRGPYLCNMGLRLNVTVKQQFCQE 
 Zebrafish   (121) LEPRKEQLVFASSINGTLQVESKWLMSGLNYFTIINRGSSHLCRFGLRIAVLVKPQLCQS 
Drosophila     (1) ------------------------------------------------------------ 
----------     (1) -------------------------------------------------------- --- 
 
     Human   (177) SLSSEFCSGHGKCLSEAWSKTYSCHCQPPFSGKYCQELDACSFKPCKNNGSCINKR-ENW 
   Macaque   (177) SLSSEFCSGHGKCLSEAWSKTYSCHCQPPFSGKYCQELDACSFKPCKNDGSCINKR-GNW 
   Chicken   (177) TPNAPLCSKHGRCLSRVWEKQYSCHCFSQYSGKFCQKFNVCSTKPCHNNASCTEK--LEG 
 Zebrafish   (181) SPLLRLCSGKGECRTTLKDDSFTCRCHKHFSGRYCENVDGCYEQPCLNGGTCLSEGSAYT 
Drosophila     (1) ------------------------------------------------------------ 
----------     (1) --------EGF domain--------------------------EGF domain------ 
 
     Human   (236) DEQAYECVCHPPFTGKNCSEIIG-QCQPHVCFHGNCSNITSNSFICECDEQFSGPFCEVS 
   Macaque   (236) DEQGYECVCHPPFTGKNCSEIIV-QCQPHVCFHGNCSNITSNSFICECDEQFSGPFCEVS 
   Chicken   (235) IRNSYECTCPPEFSGKNCTEIVG-QCQPHTCFNGNCSNVTPNTFLCECDKGFTGPFCEEP 
 Zebrafish   (241) DLPPYTCLCPAPFTGVNCSEIIGNQNCSKWCKEGACLKVSSTSYRCECFTGYTGTYCERK 
Drosophila     (1) ------------------------------------------------------------ 
----------     (1) -------------------------------------EGF domain------------- 
 
     Human   (295) AKPCVSLLFWKRGICPNSSSAYTYECPKGSSSQNGETDVSEFSLVPCQNGTDCIKISNDV 
   Macaque   (295) TKPCVSLLCWKRGICPNSSSAYTYECPKGPSSQNGETDVSECSLILCENGTDGIKISNDV 
   Chicken   (294) GDPCASQPCLNRGVCQYNQSGYICDCPAGFLGQDCEVDINECSSRPCQNRGTCIDLPNDV 
 Zebrafish   (301) RLFCDSNPCRNDGRCEETANGYVCTCPGGFTGLNCETTAEADSYCKS-SGCQLDEACATD 
Drosophila     (1) ------------------------------------------------------------ 
----------     (1) -------------------------------------EGF domain------------- 
 
     Human   (355) MCICSPIFTDLLCKSIQTSCESFPLRNNATCKKCEKDYPCSCISGFTEKNCEKAIDHCKL 
   Macaque   (355) MCICSPIFTDLLCKSFQTSCESFPLKNNATFKKCEKDYHCSCMSGFTGKNCEKVIDHCKL 
   Chicken   (354) SCSCLPLFTGKFCERILNPCELLPCLNNATCVSEQQNYKCRCMPGFTGKNCEEVIDYCKL 
 Zebrafish   (360) KLNATCICVDPECLEQAEVCGTLPCLNGGICVVPNGQYHCRCRQGFSGKNCEEIIDFCKL 
Drosophila     (1) --------------------------------------------------------MSNV 
----------     (1) ----------------------------EGF-like domain----------------- 
 
     Human   (415) LSINCLNEEWCFNIIGRFKYVCIPGCTKNPCWFLKNVYLIHQHLCYCGVTFHGICQDKGP 
   Macaque   (415) LSINCLNEEWCFNIIGRFKYVCIPGCTKNPFWFLKNVHLIHLHPCYYGITFHGICQDKGP 
   Chicken   (414) LSINCLNEGLCLNIIGGFTCLCAPGWTGEFCQVAENACLIYPKSCSNGSTCIDMSQLGEQ 
 Zebrafish   (420) LNINCLNEGLCLNRVGGYNCLCAPGWTGEFCQYLENACLAYPNRCLNGATCISMSQTTAP 
Drosophila     (5) HQFDTQTMAESPQIRRDMGRLCATWPSKDSEDGAGTALRAATPLTANGATTTGLSVTLAP 
----------     (1) -------EGF-CA domain---------------------------------------- 
 
     Human   (475) AQFEYVWQLGFAGS-----------------------------------EGEKCQGVIDA 
   Macaque   (475) AHFEYVWQLGFTGS-----------------------------------EGEKCQGVIDA 
   Chicken   (474) PLFQCLCPHGFTGEFCKVQIDNCNSNLCENGGTCVNYEDHFKCICPMGFEGERCELDIDV 
 Zebrafish   (480) PHYMCTCLPGYTGPYCEAEVNECDSSPCQHQGTCTDFVGYYKCTCPSGYTGIDCEIDINS 
Drosophila    (65) KDMQRNHLLKMPTAT--------------------------------------------- 
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     Human   (500) YFFLAANCTEDATYVNDPEDNNSSCWFPHEGTKEICANGCSCLSEEDSQEYRYLCFLRWA 
   Macaque   (500) YFFLTANCTEDAIYVNNPEDNNSSCSFPCEGTKEICANGCSCLSEEDNQEYRYLCFLRWT 
   Chicken   (534) CLFYNISCAPGAVCMNKSHGFNYTCLSPCIGKTEVCANGGSCFYDEGNQRSHCVCAHGWT 
 Zebrafish   (540) CWLPNATCPPETLCVDLPGDQLFKCHTPCPHYLQPCANGGHCVLHN-ITSYSCVCAPGWT 
Drosophila    (80) -----IEKPTITATIASS---------------SSTS------TSTTRKSVTATRSLKLN 
----------     (1) ------------------------------------------------------------ 
 
     Human   (560) GNMYLENTTDDQENECQHEAVCKDEINRPRCSCSLSYIGRLCVVNVDYCLGNHSISVHGL 
   Macaque   (560) SNMYLENITDDQENKSQHEAICEDEINRPRCSCSLSYIGRLCVVNVDYCLGNQSISVHGL 
   Chicken   (594) GQTCLENINDCEINQCQHGATCEDEVNKYRCICPLGYTGTFCEIDIDNCIGN-QCSEYGF 
 Zebrafish   (599) GATCLVNINECVQHRCQNRATCVDEVGGYSCLCGHGYTGVHCELDFCSGHQC---SEHAV 
Drosophila   (114) PNILLPTLRILARGLLLPALILAILVG--SSQAGFACLSNPCVFGVCIDGLN---SSYSC 
----------     (1) -------------EGF domain-------------------- 
 
     Human   (620) CLALSHNCNCSGLQRYERNICEIDTEDCKSASCKNG------------------------ 
   Macaque   (620) CLALSHNCNCSDLQKYEGNICEIDIEDCKSVSCKNG------------------------ 
   Chicken   (653) CQDHLHNYSCICMLGYGGPFCEVEINECSSSPCKNGGICMNLIGSFSCHCAEGFKGETCT 
 Zebrafish   (656) CVDQQHNYTCRCMLGYEGTLCELETDECKSAPCTNNATCIDLVAGYQCLCAPGFKGRTCS 
Drosophila   (169) YCIDG----------YTGIQCQTNWDECWSSPCQNG------------------------ 
 
 
     Human   (656) ------------------------------------------------------------ 
   Macaque   (656) ------------------------------------------------------------ 
   Chicken   (713) AHVNECLDRPCWNGGTCEEDINGFKCNCPLGFEGLNCEINFDECTYGFCKNNSTCLDLIA 
 Zebrafish   (716) ESMNECWSRPCNNGGSCIDLVNDYICNCPLGFTGHDCSMPATGCTSNPCNTKGTSMCEEQ 
Drosophila   (195) ------------------------------------------------------------ 
 
 
     Human   (656) ------------------------------------------------------------ 
   Macaque   (656) ------------------------------------------------------------ 
   Chicken   (773) --DYSCVCPPGFTDKNCSTDIDECAFKPCQNGGHCHNLIGEFYCSCLPGFTGQFCEADVA 
 Zebrafish   (776) QDGFKCVCHHGYTGLFCETSINHCVEGLCHHGSECVDLTKGFMCECLPGLRGRLCEVNID 
Drosophila   (195) ------------------------------------------------------------ 
 
 
     Human   (656) ------------------------------------------------------------ 
   Macaque   (656) ------------------------------------------------------------ 
   Chicken   (831) ACLSQPCGASSICKDMSDGYVCFCAPGFIGNNCEIEVDECLSDPCHSGATCIDHLNGFSC 
 Zebrafish   (836) DCLDKPCGALSICKDGINAYDCFCAPGFVGNNCEIEVNECLSQPCQNGASCSDELNSFSC 
Drosophila   (195) ------------------------------------------------------------ 
 
 
     Human   (656) --------------------------TTSTHLRGYFFRKCVPGFKGTQCEIDIDECASHP 
   Macaque   (656) --------------------------TTSIHLRGYFFYKCVPGFKGTRCEIDLDECALHP 
   Chicken   (891) ICQGGFQGTTCETNINECHSSPCLHNATCADFVGGYECICLPGFTGTRCETDIDECASSP 
 Zebrafish   (896) LCLAGTTGSLCEINIDECQSSPCMNNGTCLDLSDGFKCICPSGFSGPECSMDINECVSYP 
Drosophila   (195) --------------------------GTCVDGVAYYNCTCPEGFSGSNCEENVDECMSNP 
----------     (1) ------------------------------------------------------------ 
 
     Human   (690) CKNGATCIDQPGNYFCQCVPPFK------------------------------------- 
   Macaque   (690) CKSGATCIDQPGNYFCQCGPPFK------------------------------------- 
   Chicken   (951) CKNGATCIDQPGNYFCQCMAPFKGLNCEFRPCEASNPCENGAVCTEEMNLDAFPLGFQCQ 
 Zebrafish   (956) CKNGGSCIDQPGNYYCRCLAPFKGLNCELLPCEAVNPCDNGAECVEEADLVLFPLGFQCR 
Drosophila   (229) CQNGGLCRDR-------------------------------------------------- 
----------     (1) -------EGF-CA domain---------------------------------------- 
 
     Human   (713) -----------------------------VVDGFSCLCNPGYVGIRCEQDIDDCILNACE 
   Macaque   (713) -----------------------------VVDGFSCLCNPGYVGTRCEQNIDNCILNAFE 
   Chicken  (1011) CVKGFAGPRCEINVNECSSNPCLHGYCYDIVNGFYCLCNPGYAGLTCEQDIDDCINNACE 
 Zebrafish  (1016) CRKGFTGPRCEVNIDECSSNPCLNGFCYDAVDGFYCLCNPGYAGVRCEQHINDCASNMCE 
Drosophila   (239) ------------------------------TNGYICTCQPGYLGSHCELDVAVCETGTGA 
----------     (1) ------------------------------------------------------------ 
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     Human   (744) ----HNSTCKDLHLSYQCVCLSDWEGNFCEQESNECKMNPCKNNSTCTDLYKSYRCECTS 
   Macaque   (744) ----HNSTYKDLHLSYQCVCLSGWEGNFCEQESNECKMNPCKNNSTCTDLYKSYRCECTS 
   Chicken  (1071) ----HNSTCVDLHLRYQCVCLPGWEGTFCEYESNECDSEPCRNNGTCTDLFNSYRCLCTA 
 Zebrafish  (1076) ----NNSTCVDLHLSYNCLCLPGWEGEYCQRETNECLSNPCKNNATCTDLLNAYRCVCPQ 
Drosophila   (269) RCQHGGECIEGPGLEFTCDCPAGWHGRICQEEINECASSPCQNGGVCVDKLAAYACACPM 
----------     (1) -------EGF-CA domain-------------------EGF-CA domain-------- 
 
     Human   (800) GWTGQNCSEEINECDSDPCMNGGLCHESTIPGQFVCLCPPLYTGQFCHQRYNLCDLLHNP 
   Macaque   (800) GWTGQNCSEEINECDSDPCMNGGLCHESTIPGQFVCLCPPLYTGQFCHQRYNPCDLLNNP 
   Chicken  (1127) GWTGPDCSEDINECDSEPCLNGATCYESVKQGQFVCICPPFYTGDFCHQRFSPCELPYNP 
 Zebrafish  (1132) GWTGLDCDEDVKECSSSPCLNGAHCVESDTPGEFSCTCPPFFTGPLCEQPYDPCELQRNP 
Drosophila   (329) GYTGINCEEEILICADNPCQNNALCLMEEG--VPTCYCVPDYHGEKCEFQYDECQLG--- 
----------     (1) ------------------------EGF domain-------------------------- 
 
     Human   (860) CRNNSTCLALVDANQHCICREEFEGKNCEIDVKDCLFLSCQDYGDCEDMVNNFRCICRPG 
   Macaque   (860) CRNNSTCLALVDGNQHCICREEFEGKHCEIDVKECLFLSCQDYGDCEDMVNNFRCICRPG 
   Chicken  (1187) CINNSTCLAQADGNPMCICKTGYEGTYCEVNSDECISHPCQNEGLCVDGINSYRCFCQHG 
 Zebrafish  (1192) CLHNSTCRAQSDGTALCVCPVGFEGTRCEIDSDDCVSRPCQNRGICVDGVNSYSCFCEPG 
Drosophila   (384) ----------------------------------PRCMNG---GVCIDGVDTFSCSCPPL 
----------     (1) --------EGF domain--------- ------------EGF-domain---------- 
 
     Human   (920) FSGSLCEIEINECSSEPCKNNGTCVDLTNRFFCNCEPEYHGPFCELDVNKCKISPCLDEE 
   Macaque   (920) FSGSLCEIEINECSSEPCKNNGTCVDLTNRFFCNCEPGYHGPFCELEVNKCKISPCLDEE 
   Chicken  (1247) FTGTLCEVEINECLSRPCKNNGTCLDLINRFICNCAPGYYGSLCEIDINECETLPCLNGG 
 Zebrafish  (1252) FSGLHCEEDINECASNPCQNQAVCQDLVNGFQCSCVPGYFGPHCNLDVNECDSSPCLHES 
Drosophila   (407) LTGMLCECLMVGEESLDCNYTAPATQSPPRRTTTTSTMAPPTVRPVTPPETTVSPSR--- 
----------     (1) --------------------EGF-CA domain--------------------------- 
 
     Human   (980) NCVYRTDGYNCLCAPGYTGINCEINLDECLSEPCLHDGVCIDGINHYTCDCKSGFFGTHC 
   Macaque   (980) NCVYRTDRYNCLCAPGYTGINCEINLDECLSEPCLHDGVCIDGINHYTCDCKSGFFGTHC 
   Chicken  (1307) SCINRLGGYQCFCSPGFTGDRCETNTDECISTPCLNNGSCIDDINSYKCHCRSGFIGTNC 
 Zebrafish  (1312) VCINKPGGFACVCSAGFSGKWCELNVDECKSNPCRNNGSCIDGLNGYQCVCSRGFMGDHC 
Drosophila   (464) ---ASEEVEIIVVTTSAPAEVVTSVLSPSSSSSSSEEGVSVEIKTPTVAPPESGSHSISV 
----------     (1) -----EGF domain--------------------EGF-CA domain------------ 
 
     Human  (1040) ETNANDCL-SNPCLHGRCTELINEYPCSCDADGTSTQCKIKINDCTSIPCMNEGF----C 
   Macaque  (1040) ETNANDCL-SNPCLHGRCTEPINEYPCSCDADGTSIQCKIKINDCTSMPCMNEGF----C 
   Chicken  (1367) ETNVNECW-PEPCLHGRCIDLIDGYQCSCEAGWTSSRCEININECESVPCINGGS----C 
 Zebrafish  (1372) ERNTDECS-SGPCVHGSCLDEIDAFSCQCEVGWTGHRCQININECEAHPCLNGGS----C 
Drosophila   (521) EQTTAVPAQPEPESEQEPESKPHPESESASESETETEEEIIPGTTARPPTSRSSSSSEES 
----------     (1) -----------EGF-like domain---------------------------------- 
 
     Human  (1095) QKSAHGFTCICPRGYTGAYCEKSIDNCAEPELNSVICLNGGICVDGPGHTFDCRCLPGFS 
   Macaque  (1095) QKSAHGFTCICPRGYTGAYCEKSIDNCAEPELNSVICLNGGICVDGPGHTFDCRCLPGFS 
   Chicken  (1422) QDLVNEFACICLTGYTGKFCEFDIDICNEPTVSSVLCHNGGVCVDGPGRTFHCRCLAGFS 
 Zebrafish  (1427) VDLLDKYACICADGFTGKNCDIDQNVCLQTSLNFSLCFNGGTCVDGPGVNFTCSCRPGFM 
Drosophila   (581) PSIFTTLPPLPGKPQTSASSESSGEVVTSEEYTTVPHFEVSGSKSESG-SEEVTTVRPTA 
----------     (1) –---EGF domain-----------A ----------EGF domain------------- 
 
     Human  (1155) GQFCEININECSSSPCLHGADCEDHINGYVCKCQPGWSGHHCEN-ELECIPNSCVHELCM 
   Macaque  (1155) GQFCEININECSSSPCLHGANCEDHINGYVCKCQPGWSGHHCEK-ELECVPNSCVHQLCM 
   Chicken  (1482) GQFCEIEVNECNSSPCLHGSTCEDHVNGYTCQCQKGWEGLHCELDVDECISNPCIHGICV 
 Zebrafish  (1487) GDFCEVEMNECCSEPCFNGAICQDLINGYQCHCRPGWTGLHCEDDINECLLQPCNQGMCI 
Drosophila   (640) APSITISVDITSSGSSSSSSESVEVFTTPAPVFVQRVTTIETSISIDYVTPTPLPETTTP 
----------     (1) -----------------EGF-CA domain------------------------------ 
 
     Human  (1214) ENEP--GSTCLCTPGFMTCSIGLLCGDEIRRITCLTPIFQRTDPISTQTYTIPPSETLVS 
   Macaque  (1214) ENEP--GSTCLCTPGFMTCSIGLLCGDEIRRITCLTPSFQRTDPISTQTHTVPPSETLVS 
   Chicken  (1542) QSDPSFGYSCFCKPGFVGRSCELNYNDCLIQSCSSGFLCVDGINNITCLPTISQS----- 
 Zebrafish  (1547) QNEPGHGYTCFCRPGFVGENCEYNYDDCLIQSCPETFSCKDGINNVSCVPVKTDTSSLP- 
Drosophila   (700) RVVPVPRPTFAPEPPLDVVETTASTHHLWTEVPTTAAPFFTEYPAEVLITTHRTSAG--- 
----------     (1) ----EGF-like domain-EGF-CA domain--------------------------- 
 
     Human  (1272) SFPSIKATRIPAIMDTYPVDQGPKQTGIVKHDILPTTGLATLRISTPLESYLLQELIVTR 
   Macaque  (1272) SFPSIKATRIPTIMDTYPVDQGPKQTGIVKHDILPTTGLATLRISTPLKSYLLEELIVTR 
   Chicken  (1597) -----KKTEMAELFPTESLDN-----------------------------DLPSALAVSM 
 Zebrafish  (1606) ----------------------------------------------PISVVSWRSTDIST 
Drosophila   (757) -----------------------------------------------RFTTVQPPAGVTT 
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     Human   (500) YFFLAANCTEDATYVNDPEDNNSSCWFPHEGTKEICANGCSCLSEEDSQEYRYLCFLRWA 
   Macaque   (500) YFFLTANCTEDAIYVNNPEDNNSSCSFPCEGTKEICANGCSCLSEEDNQEYRYLCFLRWT 
   Chicken   (534) CLFYNISCAPGAVCMNKSHGFNYTCLSPCIGKTEVCANGGSCFYDEGNQRSHCVCAHGWT 
 Zebrafish   (540) CWLPNATCPPETLCVDLPGDQLFKCHTPCPHYLQPCANGGHCVLHN-ITSYSCVCAPGWT 
Drosophila    (80) -----IEKPTITATIASS---------------SSTS------TSTTRKSVTATRSLKLN 
----------     (1) ------------------------------------------------------------ 
 
     Human   (560) GNMYLENTTDDQENECQHEAVCKDEINRPRCSCSLSYIGRLCVVNVDYCLGNHSISVHGL 
   Macaque   (560) SNMYLENITDDQENKSQHEAICEDEINRPRCSCSLSYIGRLCVVNVDYCLGNQSISVHGL 
   Chicken   (594) GQTCLENINDCEINQCQHGATCEDEVNKYRCICPLGYTGTFCEIDIDNCIGN-QCSEYGF 
 Zebrafish   (599) GATCLVNINECVQHRCQNRATCVDEVGGYSCLCGHGYTGVHCELDFCSGHQC---SEHAV 
Drosophila   (114) PNILLPTLRILARGLLLPALILAILVG--SSQAGFACLSNPCVFGVCIDGLN---SSYSC 
----------     (1) -------------EGF domain-------------------- 
 
     Human   (620) CLALSHNCNCSGLQRYERNICEIDTEDCKSASCKNG------------------------ 
   Macaque   (620) CLALSHNCNCSDLQKYEGNICEIDIEDCKSVSCKNG------------------------ 
   Chicken   (653) CQDHLHNYSCICMLGYGGPFCEVEINECSSSPCKNGGICMNLIGSFSCHCAEGFKGETCT 
 Zebrafish   (656) CVDQQHNYTCRCMLGYEGTLCELETDECKSAPCTNNATCIDLVAGYQCLCAPGFKGRTCS 
Drosophila   (169) YCIDG----------YTGIQCQTNWDECWSSPCQNG------------------------ 
 
 
     Human   (656) ------------------------------------------------------------ 
   Macaque   (656) ------------------------------------------------------------ 
   Chicken   (713) AHVNECLDRPCWNGGTCEEDINGFKCNCPLGFEGLNCEINFDECTYGFCKNNSTCLDLIA 
 Zebrafish   (716) ESMNECWSRPCNNGGSCIDLVNDYICNCPLGFTGHDCSMPATGCTSNPCNTKGTSMCEEQ 
Drosophila   (195) ------------------------------------------------------------ 
 
 
     Human   (656) ------------------------------------------------------------ 
   Macaque   (656) ------------------------------------------------------------ 
   Chicken   (773) --DYSCVCPPGFTDKNCSTDIDECAFKPCQNGGHCHNLIGEFYCSCLPGFTGQFCEADVA 
 Zebrafish   (776) QDGFKCVCHHGYTGLFCETSINHCVEGLCHHGSECVDLTKGFMCECLPGLRGRLCEVNID 
Drosophila   (195) ------------------------------------------------------------ 
 
 
     Human   (656) ------------------------------------------------------------ 
   Macaque   (656) ------------------------------------------------------------ 
   Chicken   (831) ACLSQPCGASSICKDMSDGYVCFCAPGFIGNNCEIEVDECLSDPCHSGATCIDHLNGFSC 
 Zebrafish   (836) DCLDKPCGALSICKDGINAYDCFCAPGFVGNNCEIEVNECLSQPCQNGASCSDELNSFSC 
Drosophila   (195) ------------------------------------------------------------ 
 
 
     Human   (656) --------------------------TTSTHLRGYFFRKCVPGFKGTQCEIDIDECASHP 
   Macaque   (656) --------------------------TTSIHLRGYFFYKCVPGFKGTRCEIDLDECALHP 
   Chicken   (891) ICQGGFQGTTCETNINECHSSPCLHNATCADFVGGYECICLPGFTGTRCETDIDECASSP 
 Zebrafish   (896) LCLAGTTGSLCEINIDECQSSPCMNNGTCLDLSDGFKCICPSGFSGPECSMDINECVSYP 
Drosophila   (195) --------------------------GTCVDGVAYYNCTCPEGFSGSNCEENVDECMSNP 
----------     (1) ------------------------------------------------------------ 
 
     Human   (690) CKNGATCIDQPGNYFCQCVPPFK------------------------------------- 
   Macaque   (690) CKSGATCIDQPGNYFCQCGPPFK------------------------------------- 
   Chicken   (951) CKNGATCIDQPGNYFCQCMAPFKGLNCEFRPCEASNPCENGAVCTEEMNLDAFPLGFQCQ 
 Zebrafish   (956) CKNGGSCIDQPGNYYCRCLAPFKGLNCELLPCEAVNPCDNGAECVEEADLVLFPLGFQCR 
Drosophila   (229) CQNGGLCRDR-------------------------------------------------- 
----------     (1) -------EGF-CA domain---------------------------------------- 
 
     Human   (713) -----------------------------VVDGFSCLCNPGYVGIRCEQDIDDCILNACE 
   Macaque   (713) -----------------------------VVDGFSCLCNPGYVGTRCEQNIDNCILNAFE 
   Chicken  (1011) CVKGFAGPRCEINVNECSSNPCLHGYCYDIVNGFYCLCNPGYAGLTCEQDIDDCINNACE 
 Zebrafish  (1016) CRKGFTGPRCEVNIDECSSNPCLNGFCYDAVDGFYCLCNPGYAGVRCEQHINDCASNMCE 
Drosophila   (239) ------------------------------TNGYICTCQPGYLGSHCELDVAVCETGTGA 
----------     (1) ------------------------------------------------------------ 
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     Human   (744) ----HNSTCKDLHLSYQCVCLSDWEGNFCEQESNECKMNPCKNNSTCTDLYKSYRCECTS 
   Macaque   (744) ----HNSTYKDLHLSYQCVCLSGWEGNFCEQESNECKMNPCKNNSTCTDLYKSYRCECTS 
   Chicken  (1071) ----HNSTCVDLHLRYQCVCLPGWEGTFCEYESNECDSEPCRNNGTCTDLFNSYRCLCTA 
 Zebrafish  (1076) ----NNSTCVDLHLSYNCLCLPGWEGEYCQRETNECLSNPCKNNATCTDLLNAYRCVCPQ 
Drosophila   (269) RCQHGGECIEGPGLEFTCDCPAGWHGRICQEEINECASSPCQNGGVCVDKLAAYACACPM 
----------     (1) -------EGF-CA domain-------------------EGF-CA domain-------- 
 
     Human   (800) GWTGQNCSEEINECDSDPCMNGGLCHESTIPGQFVCLCPPLYTGQFCHQRYNLCDLLHNP 
   Macaque   (800) GWTGQNCSEEINECDSDPCMNGGLCHESTIPGQFVCLCPPLYTGQFCHQRYNPCDLLNNP 
   Chicken  (1127) GWTGPDCSEDINECDSEPCLNGATCYESVKQGQFVCICPPFYTGDFCHQRFSPCELPYNP 
 Zebrafish  (1132) GWTGLDCDEDVKECSSSPCLNGAHCVESDTPGEFSCTCPPFFTGPLCEQPYDPCELQRNP 
Drosophila   (329) GYTGINCEEEILICADNPCQNNALCLMEEG--VPTCYCVPDYHGEKCEFQYDECQLG--- 
----------     (1) ------------------------EGF domain-------------------------- 
 
     Human   (860) CRNNSTCLALVDANQHCICREEFEGKNCEIDVKDCLFLSCQDYGDCEDMVNNFRCICRPG 
   Macaque   (860) CRNNSTCLALVDGNQHCICREEFEGKHCEIDVKECLFLSCQDYGDCEDMVNNFRCICRPG 
   Chicken  (1187) CINNSTCLAQADGNPMCICKTGYEGTYCEVNSDECISHPCQNEGLCVDGINSYRCFCQHG 
 Zebrafish  (1192) CLHNSTCRAQSDGTALCVCPVGFEGTRCEIDSDDCVSRPCQNRGICVDGVNSYSCFCEPG 
Drosophila   (384) ----------------------------------PRCMNG---GVCIDGVDTFSCSCPPL 
----------     (1) --------EGF domain--------- ------------EGF-domain---------- 
 
     Human   (920) FSGSLCEIEINECSSEPCKNNGTCVDLTNRFFCNCEPEYHGPFCELDVNKCKISPCLDEE 
   Macaque   (920) FSGSLCEIEINECSSEPCKNNGTCVDLTNRFFCNCEPGYHGPFCELEVNKCKISPCLDEE 
   Chicken  (1247) FTGTLCEVEINECLSRPCKNNGTCLDLINRFICNCAPGYYGSLCEIDINECETLPCLNGG 
 Zebrafish  (1252) FSGLHCEEDINECASNPCQNQAVCQDLVNGFQCSCVPGYFGPHCNLDVNECDSSPCLHES 
Drosophila   (407) LTGMLCECLMVGEESLDCNYTAPATQSPPRRTTTTSTMAPPTVRPVTPPETTVSPSR--- 
----------     (1) --------------------EGF-CA domain--------------------------- 
 
     Human   (980) NCVYRTDGYNCLCAPGYTGINCEINLDECLSEPCLHDGVCIDGINHYTCDCKSGFFGTHC 
   Macaque   (980) NCVYRTDRYNCLCAPGYTGINCEINLDECLSEPCLHDGVCIDGINHYTCDCKSGFFGTHC 
   Chicken  (1307) SCINRLGGYQCFCSPGFTGDRCETNTDECISTPCLNNGSCIDDINSYKCHCRSGFIGTNC 
 Zebrafish  (1312) VCINKPGGFACVCSAGFSGKWCELNVDECKSNPCRNNGSCIDGLNGYQCVCSRGFMGDHC 
Drosophila   (464) ---ASEEVEIIVVTTSAPAEVVTSVLSPSSSSSSSEEGVSVEIKTPTVAPPESGSHSISV 
----------     (1) -----EGF domain--------------------EGF-CA domain------------ 
 
     Human  (1040) ETNANDCL-SNPCLHGRCTELINEYPCSCDADGTSTQCKIKINDCTSIPCMNEGF----C 
   Macaque  (1040) ETNANDCL-SNPCLHGRCTEPINEYPCSCDADGTSIQCKIKINDCTSMPCMNEGF----C 
   Chicken  (1367) ETNVNECW-PEPCLHGRCIDLIDGYQCSCEAGWTSSRCEININECESVPCINGGS----C 
 Zebrafish  (1372) ERNTDECS-SGPCVHGSCLDEIDAFSCQCEVGWTGHRCQININECEAHPCLNGGS----C 
Drosophila   (521) EQTTAVPAQPEPESEQEPESKPHPESESASESETETEEEIIPGTTARPPTSRSSSSSEES 
----------     (1) -----------EGF-like domain---------------------------------- 
 
     Human  (1095) QKSAHGFTCICPRGYTGAYCEKSIDNCAEPELNSVICLNGGICVDGPGHTFDCRCLPGFS 
   Macaque  (1095) QKSAHGFTCICPRGYTGAYCEKSIDNCAEPELNSVICLNGGICVDGPGHTFDCRCLPGFS 
   Chicken  (1422) QDLVNEFACICLTGYTGKFCEFDIDICNEPTVSSVLCHNGGVCVDGPGRTFHCRCLAGFS 
 Zebrafish  (1427) VDLLDKYACICADGFTGKNCDIDQNVCLQTSLNFSLCFNGGTCVDGPGVNFTCSCRPGFM 
Drosophila   (581) PSIFTTLPPLPGKPQTSASSESSGEVVTSEEYTTVPHFEVSGSKSESG-SEEVTTVRPTA 
----------     (1) –---EGF domain-----------A ----------EGF domain------------- 
 
     Human  (1155) GQFCEININECSSSPCLHGADCEDHINGYVCKCQPGWSGHHCEN-ELECIPNSCVHELCM 
   Macaque  (1155) GQFCEININECSSSPCLHGANCEDHINGYVCKCQPGWSGHHCEK-ELECVPNSCVHQLCM 
   Chicken  (1482) GQFCEIEVNECNSSPCLHGSTCEDHVNGYTCQCQKGWEGLHCELDVDECISNPCIHGICV 
 Zebrafish  (1487) GDFCEVEMNECCSEPCFNGAICQDLINGYQCHCRPGWTGLHCEDDINECLLQPCNQGMCI 
Drosophila   (640) APSITISVDITSSGSSSSSSESVEVFTTPAPVFVQRVTTIETSISIDYVTPTPLPETTTP 
----------     (1) -----------------EGF-CA domain------------------------------ 
 
     Human  (1214) ENEP--GSTCLCTPGFMTCSIGLLCGDEIRRITCLTPIFQRTDPISTQTYTIPPSETLVS 
   Macaque  (1214) ENEP--GSTCLCTPGFMTCSIGLLCGDEIRRITCLTPSFQRTDPISTQTHTVPPSETLVS 
   Chicken  (1542) QSDPSFGYSCFCKPGFVGRSCELNYNDCLIQSCSSGFLCVDGINNITCLPTISQS----- 
 Zebrafish  (1547) QNEPGHGYTCFCRPGFVGENCEYNYDDCLIQSCPETFSCKDGINNVSCVPVKTDTSSLP- 
Drosophila   (700) RVVPVPRPTFAPEPPLDVVETTASTHHLWTEVPTTAAPFFTEYPAEVLITTHRTSAG--- 
----------     (1) ----EGF-like domain-EGF-CA domain--------------------------- 
 
     Human  (1272) SFPSIKATRIPAIMDTYPVDQGPKQTGIVKHDILPTTGLATLRISTPLESYLLQELIVTR 
   Macaque  (1272) SFPSIKATRIPTIMDTYPVDQGPKQTGIVKHDILPTTGLATLRISTPLKSYLLEELIVTR 
   Chicken  (1597) -----KKTEMAELFPTESLDN-----------------------------DLPSALAVSM 
 Zebrafish  (1606) ----------------------------------------------PISVVSWRSTDIST 
Drosophila   (757) -----------------------------------------------RFTTVQPPAGVTT 
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     Human  (1332) ELSAKHSLLSSADVSSSRFLNFGIRDPAQIVQDKTSVSHMPIRTSAATLGFFFPDRRART 
   Macaque  (1332) ELSAKHSLLSSTDVSSSPFLNFGIHDPAQIVQDKTSVSHMRIRTSAATLGFFFPDRRART 
   Chicken  (1623) ELWSKHAIP--------------------------------------------------- 
 Zebrafish  (1620) ELQPTFAPVEN------------------------------------------------- 
Drosophila   (770) TSPTEDSSVELP------------------------------------------------ 
 
 
     Human  (1392) PFIMSSLMSDFIFPTQSLLFENCQTVALSATPTTSVIRSIPGADIELNRQSLLSRGFLLI 
   Macaque  (1392) SFIRSSLMSDFIFPTQSLLFENYQTVASSATPTTSVIRSIPGADIELNRHSLLSRGFLLT 
   Chicken  (1632) ------------------------------------------------------------ 
 Zebrafish  (1631) ------------------------------------------------------------ 
Drosophila   (782) ------------------------------------------------------------ 
 
 
     Human  (1452) AASISATPVVSRGAQEDIEEYSADSLISRREHWRLLSPSMSPIFPAKVIISKQVTILNSS 
   Macaque  (1452) AASISATPVVSRGAQEDIKEYSAVSLISRREHWRSLISSMSPIFPAKKIISKQVTILNSS 
   Chicken  (1632) ------------------------------------------------------------ 
 Zebrafish  (1631) ------------------------------------------------------------ 
Drosophila   (782) ------------------------------------------------------------ 
 
 
     Human  (1512) ALHRFSTKAFNPSEYQAITEASSNQRLTNIKSQAADSLRELSQTCATCSMTEIKSSREFS 
   Macaque  (1512) ALHRFGTKAFIPSEYQAITEASSNQRLTNIKSQAADSLRELSQTCATCSMTEIKSSHEFS 
   Chicken  (1632) -------------------------------------------------D---FHTEEVA 
 Zebrafish  (1631) ----------------------------------------------------LQHTEQPA 
Drosophila   (782) ----------------------------------------------------TPHTPQIV 
 
 
     Human  (1572) DQVLHSKQSHFYETFWMNSAILASWYALMGAQTITSGHSFSSATEITPSVAFTEVPSLFP 
   Macaque  (1572) DQVLHSKQSHFYETFWMNSAILASWYALMGAQTITSGHSFSSATEITPSVAFTEVPSLFP 
   Chicken  (1640) --QDFS------------------------------------------------------ 
 Zebrafish  (1639) DASFGG------------------------------------------------------ 
Drosophila   (790) VTILDSN----------------------------------------------------- 
 
 
     Human  (1632) SKKSAKRTILSSSLEESITLSSNLDVNLCLDKTCLSIVPSQTISSDLMNSDLTSKMTTDE 
   Macaque  (1632) SKKSAKRTILSSSLEESITLSSNLDVNLCLHKTCLSIVPSQTISSDLMNSDLTSELTTDE 
   Chicken  (1644) ------------------------------------------------------------ 
 Zebrafish  (1645) ------------------------------------------------------------ 
Drosophila   (797) ------------------------------------------------------------ 
 
 
     Human  (1692) LSVSENILKLLKIRQYGITMGPTEVLNQESLLDMEKSKGSHTLFKLHPSDSSLDFELNLQ 
   Macaque  (1692) LSVSENILKLLKIRQYGITTGPTEVLNQDSLLDMEKSKGSHTPFKLHPSDSSLDLELNLR 
   Chicken  (1644) ------------------------------------------------------------ 
 Zebrafish  (1645) ------------------------------------------------------------ 
Drosophila   (797) ------------------------------------------------------------ 
 
 
     Human  (1752) IYPDVTLKTYSEITHANDFKNNLPPLTGSVPDFSEVTTNVAFYTVSATPALSIQTSSSMS 
   Macaque  (1752) SYPDVTLKTYSEITLANDLKNNLPPLTGSVPDFSEVTTNVAFYTVSATPALPIQTSSSMS 
   Chicken  (1644) ------------------------------------------------------------ 
 Zebrafish  (1645) ------------------------------------------------------------ 
Drosophila   (797) ------------------------------------------------------------ 
 
 
     Human  (1812) VIRPDWPYFTDYMTSLKKEVKTSSEWSKWELQPSVQYQEFPTASRHLPFTRSLTLSSLES 
   Macaque  (1812) VITPDWPYFIDYMTSLNKEVKTYSEWSKWELQPSVQYQEFPTASWHLPFTRSLTLSSLES 
   Chicken  (1644) ------------------------------------------------------------ 
 Zebrafish  (1645) ------------------------------------------------------------ 
Drosophila   (797) ------------------------------------------------------------ 
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     Human  (1332) ELSAKHSLLSSADVSSSRFLNFGIRDPAQIVQDKTSVSHMPIRTSAATLGFFFPDRRART 
   Macaque  (1332) ELSAKHSLLSSTDVSSSPFLNFGIHDPAQIVQDKTSVSHMRIRTSAATLGFFFPDRRART 
   Chicken  (1623) ELWSKHAIP--------------------------------------------------- 
 Zebrafish  (1620) ELQPTFAPVEN------------------------------------------------- 
Drosophila   (770) TSPTEDSSVELP------------------------------------------------ 
 
 
     Human  (1392) PFIMSSLMSDFIFPTQSLLFENCQTVALSATPTTSVIRSIPGADIELNRQSLLSRGFLLI 
   Macaque  (1392) SFIRSSLMSDFIFPTQSLLFENYQTVASSATPTTSVIRSIPGADIELNRHSLLSRGFLLT 
   Chicken  (1632) ------------------------------------------------------------ 
 Zebrafish  (1631) ------------------------------------------------------------ 
Drosophila   (782) ------------------------------------------------------------ 
 
 
     Human  (1452) AASISATPVVSRGAQEDIEEYSADSLISRREHWRLLSPSMSPIFPAKVIISKQVTILNSS 
   Macaque  (1452) AASISATPVVSRGAQEDIKEYSAVSLISRREHWRSLISSMSPIFPAKKIISKQVTILNSS 
   Chicken  (1632) ------------------------------------------------------------ 
 Zebrafish  (1631) ------------------------------------------------------------ 
Drosophila   (782) ------------------------------------------------------------ 
 
 
     Human  (1512) ALHRFSTKAFNPSEYQAITEASSNQRLTNIKSQAADSLRELSQTCATCSMTEIKSSREFS 
   Macaque  (1512) ALHRFGTKAFIPSEYQAITEASSNQRLTNIKSQAADSLRELSQTCATCSMTEIKSSHEFS 
   Chicken  (1632) -------------------------------------------------D---FHTEEVA 
 Zebrafish  (1631) ----------------------------------------------------LQHTEQPA 
Drosophila   (782) ----------------------------------------------------TPHTPQIV 
 
 
     Human  (1572) DQVLHSKQSHFYETFWMNSAILASWYALMGAQTITSGHSFSSATEITPSVAFTEVPSLFP 
   Macaque  (1572) DQVLHSKQSHFYETFWMNSAILASWYALMGAQTITSGHSFSSATEITPSVAFTEVPSLFP 
   Chicken  (1640) --QDFS------------------------------------------------------ 
 Zebrafish  (1639) DASFGG------------------------------------------------------ 
Drosophila   (790) VTILDSN----------------------------------------------------- 
 
 
     Human  (1632) SKKSAKRTILSSSLEESITLSSNLDVNLCLDKTCLSIVPSQTISSDLMNSDLTSKMTTDE 
   Macaque  (1632) SKKSAKRTILSSSLEESITLSSNLDVNLCLHKTCLSIVPSQTISSDLMNSDLTSELTTDE 
   Chicken  (1644) ------------------------------------------------------------ 
 Zebrafish  (1645) ------------------------------------------------------------ 
Drosophila   (797) ------------------------------------------------------------ 
 
 
     Human  (1692) LSVSENILKLLKIRQYGITMGPTEVLNQESLLDMEKSKGSHTLFKLHPSDSSLDFELNLQ 
   Macaque  (1692) LSVSENILKLLKIRQYGITTGPTEVLNQDSLLDMEKSKGSHTPFKLHPSDSSLDLELNLR 
   Chicken  (1644) ------------------------------------------------------------ 
 Zebrafish  (1645) ------------------------------------------------------------ 
Drosophila   (797) ------------------------------------------------------------ 
 
 
     Human  (1752) IYPDVTLKTYSEITHANDFKNNLPPLTGSVPDFSEVTTNVAFYTVSATPALSIQTSSSMS 
   Macaque  (1752) SYPDVTLKTYSEITLANDLKNNLPPLTGSVPDFSEVTTNVAFYTVSATPALPIQTSSSMS 
   Chicken  (1644) ------------------------------------------------------------ 
 Zebrafish  (1645) ------------------------------------------------------------ 
Drosophila   (797) ------------------------------------------------------------ 
 
 
     Human  (1812) VIRPDWPYFTDYMTSLKKEVKTSSEWSKWELQPSVQYQEFPTASRHLPFTRSLTLSSLES 
   Macaque  (1812) VITPDWPYFIDYMTSLNKEVKTYSEWSKWELQPSVQYQEFPTASWHLPFTRSLTLSSLES 
   Chicken  (1644) ------------------------------------------------------------ 
 Zebrafish  (1645) ------------------------------------------------------------ 
Drosophila   (797) ------------------------------------------------------------ 
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     Human  (1872) ILAPQRLMISDFSCVRYYGDSYLEFQNVALNPQNNISLEFQTFSSYGLLLYVKQDSNLVD 
   Macaque  (1872) IVAPQQLMISDFSCVCYYGDSYLEFQNVVLNPQNNISLEFQTFSSYGLLLYVKQDSNLVD 
   Chicken  (1644) -YA------------RYYGDSYLEFQGLHLNVQNFIHLEFKTYKPDGLLLYIEESSETIG 
 Zebrafish  (1645) ----------------YSGNSFLEFGGFEVAVPISVTVRFQTESMYGTLLYS--ASAKRS 
Drosophila   (797) ---------EVIPSLITTTGSPTTHHHHHHHPHHEAEGTTLQPLEEDEHHHHHHHDEFTT 
----------     (1) ----EGF-like domain------- ----------Laminin-G domain------- 
 
     Human  (1932) GFFIQLFIENGTLKYHFYCPGEAKFKSINTTVRVDNGQKYTLLIRQELDPCNAELTILGR 
   Macaque  (1932) GFFIQLSIENGTLKYHFYCPGEAKFKSINTAIRVDDGQKYTLLIRQELDPCKAELTILGR 
   Chicken  (1691) QFLIQLFIRHGILQYQFVCGKATQVKNITTTARVDDGQWYKVQIRQNMKPCEAEMLILEV 
 Zebrafish  (1687) VFFIKLYISNGILQYDFLCNQKQGVQRINTAQWVADGNEHVVIFRQCLFPCVAEVTVSGV 
Drosophila   (848) PQPVEITTGHPLQTEDLIGVQEPAVVTTESPFAPAETTVVPVVVPATIAPLGTAAPPATP 
----------     (1) ---------------- Laminin-G domain--------------------------- 
 
     Human  (1992) NTQICESINHVLGKPLPKSGSVFIGGFPDLHGKIQMPVPVKNFTGCIEVIEINNWRSFIP 
   Macaque  (1992) NTQTCESINHVLGKPLPKSGSVFIGGFPDLRGKIQMPVPVKNFTGCIEVIEINNWRSFIP 
   Chicken  (1751) SAKTGIPSNFSSSPYGLETGSIFVGGLPYSSAIKQIPEPVYNFTGCIQVIEINNVGPFNF 
 Zebrafish  (1747) RTVRSAPGNYTSALRLQRTDHVFIGGLPRHRSPYKEAEPFHNYTGCIEIIEINKLRRFHM 
Drosophila   (908) APVPPATTTPPPSPPSLATETPTLPPTLPPVTLPPVTQPPPTIPPTPPSTQSAQTLPPPT 
----------     (1) ---------------- Laminin-G domain--------------------------- 
 
     Human  (2052) SKAVKNYHINNCRSQGFMLSPTASFVDASDVTQGVD---TMWTSVSPSVAAPSVCQQDVC 
   Macaque  (2052) SKAVRNYHINNCRSQGLMLSPTASFVDASDVTQGVD---AMWTSVSPSVAAPSVCQEDVC 
   Chicken  (1811) SNAVGRRNIDSCRTPVPTHLPTPFPTVSSDVLALPE---LVTPSLS-SPELPSVCQEGLC 
 Zebrafish  (1807) DHAIARNNVDNCRSQWHHEPPTSSTHSPTLLITVETPP-GEWVRVLSPTQPAPVCPQGIC 
Drosophila   (968) SAINVYTTPDGPPTASQTKPSVTESSEEVEGTNTVSTGGRGSGGVPEEKAGDVDCIKLGC 
----------     (1) ------------------------------------------------------------ 
 
     Human  (2109) HNGGTCHAIFLSSGIVSFQCDCPLHFTGRFCEKDAGLFFPSFNGNSYLELPFLKFVLEKE 
   Macaque  (2109) HNGGTCRPIFLSSGIVSFQCDCPLHFTGRFCEKDAGLFFPSFSGNSYLELPFLNFVLEKE 
   Chicken  (1867) HNGGTCHPISLPTGAISFECDCQLHFTGRFCEKDVTLFIPSFNGNSYLELPSLTSVSQMR 
 Zebrafish  (1866) LNGGTCRPVSLPSGASSFFCDCPLHFTGRLCEQDITVFSPRFDGNSFLELPSLTSLFQSD 
Drosophila  (1028) YNGGTCVTTSEGS-----RCVCRFDRQGPLCELPIIIRNAAFSGDSYVSHRIYKDIGGHE 
----------     (1) ---------EGF domain----------------------------------------- 
 
     Human  (2169) HN-------RTVTIYLTIKTNSLNGTILYSNGN-NCGKQFLHLFLVEGRPSVKYGCGNSQ 
   Macaque  (2169) HN-------RTVTIYLTIKTNSLNGTILYSNGN-NFGKQFLHLFLVEGKPSVKYGCGNSQ 
   Chicken  (1927) TASGQETS-NLTTLYLTVKTTAPSGTILYTSEK-NFGEQFLHLYLVEGRPTVRFSCGNSQ 
 Zebrafish  (1926) TYFPSRSSEDKRILYLTMKSRTPHGSLLYCREQ-DLGERFLHVFLQNARAVARLGCG-AA 
Drosophila  (1083) SLDAVLP----MHIQLKVRTRATNGLIMLAAAQGTKGGHYMALFLQKGLMQFQFSCGLQT 
----------     (1) ---------------------------- Laminin-G domain--------------- 
 
     Human  (2221) NILTVSAN-----YSINTNAFTPITIRYTTPVGSPGVVCMIEMTADGKPPVQKKDTEISH 
   Macaque  (2221) NILTVSAN-----YSINTNAFTPITVRHTMPIGSPGVVCMIEMTADGKPPVQKKDTEISH 
   Chicken  (1985) NILTVSGN-----QTISKGIFIPIIISYMLPVSSLEGYCMIEMAADRNPPVQHRLHLSYQ 
 Zebrafish  (1984) HILTAVAA-----QNIRIDSLVAITVRYALPSQNNGQLCFIEIAADNGTANQQQKYMDEP 
Drosophila  (1139) MLLSELETPVNTGHEITIRAELDFSRNYTHCNASLLVNDTLAMSGDQPTWLKLLPPRLHT 
----------     (1) ---------------- Laminin-G domain--------------------------- 
 
     Human  (2276) ASQAYFESMFLGHIPANVQIHKKAG----PVYGFRGCILDLQVNNKEFFIIDEARHGKNI 
   Macaque  (2276) ASQVYFESMFLGHIPENVQIHKKAG----SVYGFRGCILDLQINNKEFFIIDEARRGKNI 
   Chicken  (2040) ASQITFGSTFLGNVPVHKEVPECAG----QIRGYKGCIRDFQVNNKELFIIDDALGGRNV 
 Zebrafish  (2039) VSEVVFGPTFLGGFPSVLELHHNSG----NVSGFIGCIRELQMGSKELYVVGEAIRGQNI 
Drosophila  (1199) PEAILNTWLHLGGAPQAPIGLIIELPPAQSGSGFTGCLHTLRINGQAREIFGDALDGFGI 
----------     (1) ---------------- Laminin-G domain--------------------------- 
 
     Human  (2332) ENCHVPWCAHHLCRNNGTCISDNEN-----------LFCECPRLYSGKLCQFASCENNPC 
   Macaque  (2332) ENCHVPWCAHHLCRNNGTCLSDSEN-----------LFCECPRLYSGKLCQFASCENNPC 
   Chicken  (2096) ENCNVPICDYHPCRNGGTCTSDAEN-----------WFCECPKLYSGRLCQFMTCDESPC 
 Zebrafish  (2095) QNCDAAVCQHQPCRNGGTCISDAES-----------WFCACPSLYSGKLCQFTACERNPC 
Drosophila  (1259) TECGSLACLSSPCRNGAACIKIETNDLDENGEKAEKWKCKCPTGYMGPTCEISVCEDNPC 
----------     (1) ---------------- ------EGF domain--------------------------- 
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     Human  (2381) GNGATCVPKSGTDIVCLCPYGRSGPLCTDAINITQPRFSGTDAFGYTSFLAYSRISDISF 
   Macaque  (2381) GNGATCVPKSGTDIICLCPYGRSGPLCTDAINITQPRFSGTDAFGYTSFLAYSRISDISF 
   Chicken  (2145) GNGATCFPKSRQDVVCLCPYGRSGILCNDVVNISQPSFSGTDVFGYTSFLAYSTIPDITF 
 Zebrafish  (2144) ARGATCVPQTQLEAACLCPYGRQGLLCDEAINITRPKFSGLDEFGYSSYVAYPSIPSTGH 
Drosophila  (1319) QYGGTCVQFPGSGYLCLCPLGKHGHYCEHNLEVALPSFSG-SVNGLSSFVAYTVPIPLEY 
----------     (1) -------EGF domain------------------------------------------- 
 
     Human  (2441) HYEFHLKFQLANNHSALQNNLIFFTGQKGHGLNGDDFLAVGLLNGSVVYSYNLGSGIASI 
   Macaque  (2441) HYEFHLKFQLANNHSALQNNLIFFTGQKGHGLNGDDFLAVGLLNGSVVYSYNLGSGIASI 
   Chicken  (2205) YYEFHLKFQLLNHHSALQDNLIFFTGQKGQGLNGDDFLVLGLCDGRVVYSYNLGSGTATI 
 Zebrafish  (2204) FYEFHLKLTFANNASALRNNLILFSGQKGQGLSGDDFFALGVRNGRIVHKYNLGSGLATI 
Drosophila  (1378) SLELSFKILPQTMS---QISLLAFFGQSGYHDEKSDHLAVSFIQGYIMLTWNLGAGPRRI 
----------     (1) ------------------- Laminin-G domain------------------------ 
 
     Human  (2501) RSEP-----LNLSLGVHTVHLGKFFQEGWLKVDDHKNKSIIAPGRLVGLNVFSQFYVGGY 
   Macaque  (2501) RSDP-----LNLSLGVHTVHLGKFFQEGWLKVDDHKNKSIIAPGRLVGLNVFSQFYVGGY 
   Chicken  (2265) ISKP-----LDLTLNIHVIHLGRYLQKGWLKVDDQKNKTTTSPGRLVGLNVFSQFYLGGY 
 Zebrafish  (2264) ISDR-----LNPRINIHTVHFGRYLKTGWLKVNGQKRRTGTSPGPLMGLNTFSQLYIGGY 
Drosophila  (1435) FTQKPIDFRLDAPRVPYEIKVGRIGRQAWLSVDGKFNITGRSPGSGSRMDVLPILYLGGH 
----------     (1) ------------------- Laminin-G domain------------------------ 
 
     Human  (2556) SEYTPDLLPNGADFKNGFQGCIFTLQVRTEKDGHFRGLGNPEGHPNAGRSVGQCHASPCS 
   Macaque  (2556) SEYTPDLLPNGADFKNGFQGCIFTLQVRTEKDGHFRGLGNPEGHPNAGRSVGQCHASPCS 
   Chicken  (2320) HEYTPELLPKGSRFKNGFQGCIFDVQVRTNMNQEFKSPGTPEGHPNSGRSVGQCKASPCS 
 Zebrafish  (2319) EEYTPELLPPGSRFQNSFQGCIFDMLFRTRQDGKFHALGGPDIRPLSGRNVGQCGVNPCS 
Drosophila  (1495) EIANFNTLPHDLPLHSGFQGCIYDVQLKAGQVTVP----LQETRGVRGRGVGQCGTRECH 
----------     (1) ---- Laminin-G domain--------------------------------------- 
 
     Human  (2616) LMKCGNGGTCIESGTSVYCNCTTGWKGSFCTETVSTCDPEHDPPHHCSRGATCISLPHGY 
   Macaque  (2616) LMKCGNGGTCIESGTSVYCNCTTRWKGAFCTETVSICDPEHDPPHHCSRGATCISLPHGY 
   Chicken  (2380) LIKCRNGGKCMESGSTVYCNCLAGWKGAFCTEMVTVCDPEHDPPHLCKQGGTCVPLPNGY 
 Zebrafish  (2379) LVFCHNGGTCVDSGSSVYCQCVFGWKGALCSEKVSFCDAEHIPPPFCARGSTCVPLSDGY 
Drosophila  (1551) RHACQHDGACLQHGATFTCICQEGWYGPLCAQPTNPCDSFNN---KCYEDATCVPLVNGY 
----------     (1) -------EGF domain--------------in---------EGF domain-------- 
 
     Human  (2676) TCFCPLGTTGIYCEQALSISDPSFRSNE-------------------------------- 
   Macaque  (2676) TCFCPLGTTGIYCEQALSISDPSFRSSE-------------------------------- 
   Chicken  (2440) MCHCPLGTSGTYCEQDISISDPSFRSNK-------------------------------- 
 Zebrafish  (2439) TCQCPLGSAGLHCQQAITISDPFFSGNQ-------------------------------- 
Drosophila  (1608) ECDCPVGRTGKNCEEVIRSLSDVSLTGRRSYLAVRWPYLYDGGDKLGAKRSQMVSYRNFT 
----------     (1) ---------------- n-G domain--------------------------- 
 
     Human  (2704) -----------------------------------LSWMSFASFHVRKKTHIQLQFQPLA 
   Macaque  (2704) -----------------------------------LSWMSFASFHVRKKTHIQLQFQPLA 
   Chicken  (2468) -----------------------------------SSWMSFAPFYIRHKTHIKLQFQPLS 
 Zebrafish  (2467) -----------------------------------SSWMSFPPINIRHRTHVQLQFQTLS 
Drosophila  (1668) KKLMPPKPITTPSSHFVMKLLNEVEKQRSFSPVPLMGSKSFEEHHRVQFFFIEFQLRPLS 
----------     (1) ---------------- --------G domain--------------------------- 
 
     Human  (2729) ADGILFYAAQHLKAQSGDFLCISLVNSSVQLRYNLG-DRTIILETLQKVTINGSTWHIIK 
   Macaque  (2729) ADGILFYAAQHLKAQSGDFLCISLVNGSVQLRYNLG-DRTIILETLQKVTINGSTWHIIK 
   Chicken  (2493) PDGILFYTAQRLGTQSGDFLCISLVNGFIQLRYNLG-DKTIVLQAVQKVHADGQTWHVLK 
 Zebrafish  (2492) PEGILFYTAQHLSTHSGDFLSISLSAGFLQLRYNLG-NQTIVLQSPKELDVTGVRWHTVK 
Drosophila  (1728) ERGLLLYFGTLNNNQDKKIGFVSLSLQGGVVEFRISGPSNHVTVVRSVRMLAIGEWHKIK 
----------     (1) ------------------- Laminin-G domain------------------------ 
 
     Human  (2788) AGRVGAEGYLDLDGINVTEKASTKMSSLDTNTDFYIGGVSSLNLVNPMAIENEPVGFQGC 
   Macaque  (2788) AGRVGAEGYLDLDGINVTEKASTKMSSLDTNTDFYIGGVSSLNLVNPMAIENEPVGFHGC 
   Chicken  (2552) VGRVGNEGYVDLDGINITHTASAGMNVLDTHTDFYVGGVSSLNLVNSMATENEPTGFSGC 
 Zebrafish  (2551) AGREGNSGFLIVDGESVTRNSSEGSTTLDVGANIFIGGISSLNTVSIDAVEKELVGFTGG 
Drosophila  (1788) MAQRGRWLTLWVEGSASSALAPSAEVLVEPDSLLYIGGLKDVSKLPHNAISGFPIPFRGC 
----------     (1) ------------------- Laminin-G domain------------------------ 
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     Human  (2381) GNGATCVPKSGTDIVCLCPYGRSGPLCTDAINITQPRFSGTDAFGYTSFLAYSRISDISF 
   Macaque  (2381) GNGATCVPKSGTDIICLCPYGRSGPLCTDAINITQPRFSGTDAFGYTSFLAYSRISDISF 
   Chicken  (2145) GNGATCFPKSRQDVVCLCPYGRSGILCNDVVNISQPSFSGTDVFGYTSFLAYSTIPDITF 
 Zebrafish  (2144) ARGATCVPQTQLEAACLCPYGRQGLLCDEAINITRPKFSGLDEFGYSSYVAYPSIPSTGH 
Drosophila  (1319) QYGGTCVQFPGSGYLCLCPLGKHGHYCEHNLEVALPSFSG-SVNGLSSFVAYTVPIPLEY 
----------     (1) -------EGF domain------------------------------------------- 
 
     Human  (2441) HYEFHLKFQLANNHSALQNNLIFFTGQKGHGLNGDDFLAVGLLNGSVVYSYNLGSGIASI 
   Macaque  (2441) HYEFHLKFQLANNHSALQNNLIFFTGQKGHGLNGDDFLAVGLLNGSVVYSYNLGSGIASI 
   Chicken  (2205) YYEFHLKFQLLNHHSALQDNLIFFTGQKGQGLNGDDFLVLGLCDGRVVYSYNLGSGTATI 
 Zebrafish  (2204) FYEFHLKLTFANNASALRNNLILFSGQKGQGLSGDDFFALGVRNGRIVHKYNLGSGLATI 
Drosophila  (1378) SLELSFKILPQTMS---QISLLAFFGQSGYHDEKSDHLAVSFIQGYIMLTWNLGAGPRRI 
----------     (1) ------------------- Laminin-G domain------------------------ 
 
     Human  (2501) RSEP-----LNLSLGVHTVHLGKFFQEGWLKVDDHKNKSIIAPGRLVGLNVFSQFYVGGY 
   Macaque  (2501) RSDP-----LNLSLGVHTVHLGKFFQEGWLKVDDHKNKSIIAPGRLVGLNVFSQFYVGGY 
   Chicken  (2265) ISKP-----LDLTLNIHVIHLGRYLQKGWLKVDDQKNKTTTSPGRLVGLNVFSQFYLGGY 
 Zebrafish  (2264) ISDR-----LNPRINIHTVHFGRYLKTGWLKVNGQKRRTGTSPGPLMGLNTFSQLYIGGY 
Drosophila  (1435) FTQKPIDFRLDAPRVPYEIKVGRIGRQAWLSVDGKFNITGRSPGSGSRMDVLPILYLGGH 
----------     (1) ------------------- Laminin-G domain------------------------ 
 
     Human  (2556) SEYTPDLLPNGADFKNGFQGCIFTLQVRTEKDGHFRGLGNPEGHPNAGRSVGQCHASPCS 
   Macaque  (2556) SEYTPDLLPNGADFKNGFQGCIFTLQVRTEKDGHFRGLGNPEGHPNAGRSVGQCHASPCS 
   Chicken  (2320) HEYTPELLPKGSRFKNGFQGCIFDVQVRTNMNQEFKSPGTPEGHPNSGRSVGQCKASPCS 
 Zebrafish  (2319) EEYTPELLPPGSRFQNSFQGCIFDMLFRTRQDGKFHALGGPDIRPLSGRNVGQCGVNPCS 
Drosophila  (1495) EIANFNTLPHDLPLHSGFQGCIYDVQLKAGQVTVP----LQETRGVRGRGVGQCGTRECH 
----------     (1) ---- Laminin-G domain--------------------------------------- 
 
     Human  (2616) LMKCGNGGTCIESGTSVYCNCTTGWKGSFCTETVSTCDPEHDPPHHCSRGATCISLPHGY 
   Macaque  (2616) LMKCGNGGTCIESGTSVYCNCTTRWKGAFCTETVSICDPEHDPPHHCSRGATCISLPHGY 
   Chicken  (2380) LIKCRNGGKCMESGSTVYCNCLAGWKGAFCTEMVTVCDPEHDPPHLCKQGGTCVPLPNGY 
 Zebrafish  (2379) LVFCHNGGTCVDSGSSVYCQCVFGWKGALCSEKVSFCDAEHIPPPFCARGSTCVPLSDGY 
Drosophila  (1551) RHACQHDGACLQHGATFTCICQEGWYGPLCAQPTNPCDSFNN---KCYEDATCVPLVNGY 
----------     (1) -------EGF domain--------------in---------EGF domain-------- 
 
     Human  (2676) TCFCPLGTTGIYCEQALSISDPSFRSNE-------------------------------- 
   Macaque  (2676) TCFCPLGTTGIYCEQALSISDPSFRSSE-------------------------------- 
   Chicken  (2440) MCHCPLGTSGTYCEQDISISDPSFRSNK-------------------------------- 
 Zebrafish  (2439) TCQCPLGSAGLHCQQAITISDPFFSGNQ-------------------------------- 
Drosophila  (1608) ECDCPVGRTGKNCEEVIRSLSDVSLTGRRSYLAVRWPYLYDGGDKLGAKRSQMVSYRNFT 
----------     (1) ---------------- n-G domain--------------------------- 
 
     Human  (2704) -----------------------------------LSWMSFASFHVRKKTHIQLQFQPLA 
   Macaque  (2704) -----------------------------------LSWMSFASFHVRKKTHIQLQFQPLA 
   Chicken  (2468) -----------------------------------SSWMSFAPFYIRHKTHIKLQFQPLS 
 Zebrafish  (2467) -----------------------------------SSWMSFPPINIRHRTHVQLQFQTLS 
Drosophila  (1668) KKLMPPKPITTPSSHFVMKLLNEVEKQRSFSPVPLMGSKSFEEHHRVQFFFIEFQLRPLS 
----------     (1) ---------------- --------G domain--------------------------- 
 
     Human  (2729) ADGILFYAAQHLKAQSGDFLCISLVNSSVQLRYNLG-DRTIILETLQKVTINGSTWHIIK 
   Macaque  (2729) ADGILFYAAQHLKAQSGDFLCISLVNGSVQLRYNLG-DRTIILETLQKVTINGSTWHIIK 
   Chicken  (2493) PDGILFYTAQRLGTQSGDFLCISLVNGFIQLRYNLG-DKTIVLQAVQKVHADGQTWHVLK 
 Zebrafish  (2492) PEGILFYTAQHLSTHSGDFLSISLSAGFLQLRYNLG-NQTIVLQSPKELDVTGVRWHTVK 
Drosophila  (1728) ERGLLLYFGTLNNNQDKKIGFVSLSLQGGVVEFRISGPSNHVTVVRSVRMLAIGEWHKIK 
----------     (1) ------------------- Laminin-G domain------------------------ 
 
     Human  (2788) AGRVGAEGYLDLDGINVTEKASTKMSSLDTNTDFYIGGVSSLNLVNPMAIENEPVGFQGC 
   Macaque  (2788) AGRVGAEGYLDLDGINVTEKASTKMSSLDTNTDFYIGGVSSLNLVNPMAIENEPVGFHGC 
   Chicken  (2552) VGRVGNEGYVDLDGINITHTASAGMNVLDTHTDFYVGGVSSLNLVNSMATENEPTGFSGC 
 Zebrafish  (2551) AGREGNSGFLIVDGESVTRNSSEGSTTLDVGANIFIGGISSLNTVSIDAVEKELVGFTGG 
Drosophila  (1788) MAQRGRWLTLWVEGSASSALAPSAEVLVEPDSLLYIGGLKDVSKLPHNAISGFPIPFRGC 
----------     (1) ------------------- Laminin-G domain------------------------ 
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     Human  (2848) IRQVIINNQELQLTEFGAKGGSNVGDCDGTACGYNTCRNGGECTVN-GTTFSCRCLPDWA 
   Macaque  (2848) IRQVIINYQELQLTEFGAKGGSNVGDCDGTACGYNTCRNGGECRVN-GTTFSCRCLPDWA 
   Chicken  (2612) IREIVINDKELKLTVTDPKGGANIGDCDGTVCGYSVCKNNGTCQVE-SSGFSCSCPQGWI 
 Zebrafish  (2611) IREVVVNGQELELTETGALDGANVGDWDGTACGYKVCKNGGHCHPSGDFSFTCICPSLWT 
Drosophila  (1848) VRGLVVSGTRIVLNETNIVESRNIRDCDGTACGGDSCESGGHCWLDEKLQPHCICPEYAK 
----------     (1) ---------------- ------n-G --------------EGF domain--------- 
 
     Human  (2907) GNTCNQSVSCLNNLCLHQSLCIPDQSFS-YSCLCTLGWVGRYCENKTSFSTAKFMG-NSY 
   Macaque  (2907) GNICNQSAYCLNNLCLHQSLCIPDQSFS-YSCLCTLGWVGRYCENKTSFTTAKFMG-NSY 
   Chicken  (2671) GNTCEESVHCLHNRCRSQALCIPQPALLSYTCVCPLGWSGKHCDSKISFFTAKFVG-NSY 
 Zebrafish  (2671) GSRCQQSIQCLNNLCQHNSVCIHNSTSASYSCMCSLGWTGTHCDREVTLKTIRFIG-NSY 
Drosophila  (1908) GDRCEYSETCKLIPCKNNGRCLRSGRCS-----CPNGWGGFYCEIAMSKPTTPSFRGNSY 
----------     (1) ---------------- EGF domain--------------------------------- 
 
     Human  (2965) IKYIDPNYRMRN-----------LQFTTISLNFSTTKTEGLIVWMGIAQNEENDFLAIGL 
   Macaque  (2965) IKYIDPNYRMRN-----------LQFTTISLNFSTTKTEGLIIWMGIAQNEENDFLAIGL 
   Chicken  (2730) IKYIDPLYGKRD-----------LQYSRISLNFTTNQIEGLMVWLGKAEDEDNDFLAIGL 
 Zebrafish  (2730) LKYKDPKYNSRN-----------LMHTEVSLNFSTSAGDGLIFWMGKAESEDDDHLAVGL 
Drosophila  (1963) LILPPPRIPMKDKRRGPSLYVRPREAIQVSLNFSTIEPDGLLLWSEHERSK---FLGLGL 
----------     (1) ---------------- ---------------Laminin-G domain------------ 
 
     Human  (3014) HNQTLKIAVNLGERISVPMSYNNGTFCCNK-WHHVVVIQNQTLIKAYINNSLILSEDIDP 
   Macaque  (3014) HNQTLKIAVNLGERISVPMSYNNGTFCCNK-WHHVIVIQNQTLIKAYVNNSLILSEDIDP 
   Chicken  (2779) ANGRLKVVINLGERISVPMIHSKDSICTDERWHFVTVIQNQTCIKVYLDEELIIFEDIDP 
 Zebrafish  (2779) QDGYLKISVNLGERTALPLVYQNSFCCNYW--NYLSITHNRTLIQVYVNEERVIFEDIDP 
Drosophila  (2020) EAGHLKLASNLLGSTNDTVRAPASGFIADGAWHWTSVLLDRSRLELQLDGEVIFTERLPE 
----------     (1) ------   ---------- Laminin-G domain------------------------ 
 
     Human  (3073) --------------------HKNFVALNYDGICYLGGFEYGRKVNIVTQEIFKTNFVGKI 
   Macaque  (3073) --------------------HKNFVALNYEGICYLGGFEYGRKVNIVTQEIFKTNFVGKI 
   Chicken  (2839) --------------------HRKYTALNYGGICYFGGFEIGRKVHTATAGLFQKEFIGKI 
 Zebrafish  (2837) --------------------FEQYVAVNYGGVIYLGGFELNRDVASVTSGVFTKGFEGSI 
Drosophila  (2080) GGRSLGSTTPRSTLAGRRKNSSKEPTISYEDVFYLGGFPNSDSVSRRTKGRFFDPFKGCL 
----------     (1) ------------------- Laminin-G domain------------------------ 
 
     Human  (3113) KDVVFFQE-PKNIELIK-LEGYNVYDGDEQNEVT--- 
   Macaque  (3113) KDVVFFQD-PKKIELIK-LEGYNVYDGDEQNEVT--- 
   Chicken  (2879) KDIALFQD-SKKIQLMK-GEGYNVHNGDHRN------ 
 Zebrafish  (2877) KDVFLYQD-TKQLQFLQTCEGFNVYQGEE-------- 
Drosophila  (2140) QDIQFGAEPTAIISDFSTYQGENIGSCDLHGDEPLTV 
----------     (1) -------- 
 
------Signal peptide ------EGF domain ------EGF-like domain 
 -----Calcium-binding EGF-like domain  ------Laminin A-G domain 
Residues identical in all sequences are white on a black background, whereas similar amino acids are white 
on a gray background. Residues that are present in at least three of the five proteins are indicated in black 
on a light gray background. Accession numbers of the protein sequences used for sequence comparison 
are as follows: human, NM_001142800.1 (RefSeq); macaque, XM_011737495.1 (RefSeq); chicken, 
XM_015284845.1 (RefSeq); Drosophila, NM_001032399.3 (RefSeq).  
 
 
 
Residues identical in all sequences are white on a black background, whereas similar amino acids 
are white on a gray background. Residues that are present in at least three of the five proteins are 
indicated in black on a light gray background. Accession numbers of the protein sequences used for 
sequence comparison are as follows: human, NM_001142800.1 (RefSeq); macaque, XM_011737495.1 
(RefSeq); chicken, XM_015284845.1 (RefSeq); Drosophila, NM_001032399.3 (RefSeq). 
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Supplementary Figure S3. Measurement of the thickness of outer and inner nuclear 
layers in eysrmc101/rmc101 and wild-type zebrafish. 
(A, C, E) Representative images of wild-type and eysrmc101/rmc101 zebrafish retinas at (A) 5 dpf, (C) 2 
mpf, and (E) 5 mpf. Nuclear layers were stained with DAPI and inverted to grey images. ONL: outer 
nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer; GCL: 
ganglion cell layer. Scale bars (A): 10 µm. Scale bars (C, E): 20 µm. (B, D, F) Measurements of ONL and 
INL thickness in wild-type and eysrmc101/rmc101 zebrafish at (A) 5 dpf, (C) 2 mpf, and (E) 5 mpf. Asterisks 
indicate statistical significance (*** = p<0.0001) using Mann-Whitney U test.
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Supplementary Figure S4. Immunohistochemistry on retinal sections of wild-type 
and eysrmc101/rmc101 zebrafish in order to investigate Müller glia activation. 
Retinal sections of wild-type and eysrmc101/rmc101 zebrafish at 5 dpf and 2 mpf stained with antibodies 
against GFAP (green), as a marker for Müller glia cells. Müller glia cell bodies are located in the inner 
nuclear layer (arrow heads) and project processes (arrows) in either direction to outer limiting 
membrane and inner limiting membrane. Nuclei are counterstained with DAPI (blue). INL: inner 
nuclear layer; IPL: inner plexiform layer; ONL: outer nuclear layer. Scale bar: 20 µm.
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Supplementary Table S1. 
Primers used for PCR analysis.
Purpose Product Sequence (5’ > 3’) Comment
Sequence 
analysis
eys exon 1-6 forward TGAGGGAAGTGCCTACACAG
eys exon 1-6 forward GTCTTTGTCCTGCTCCATTC Nested
eys exon 1-6 reverse GCAAGTAGCTCCGTTCAAGC
eys exon 1-6 reverse GATAGGCTAAGCATGCGTTC Nested
eys exon 6-10 forward CTGCACCCCCGCATTATATG
eys exon 6-10 forward GCACCTGTCTCCCTGGATAC Nested
eys exon 6-10 reverse CCTCATATCCCAGCATGCAG
eys exon 6-10 reverse TAGTTGTGCTGTTGGTCCAC Nested
eys exon 10-17 forward TGATTTGGTGGCAGGATAC
eys exon 10-17 forward ATACCAATGCCTGTGTGCAC Nested
eys exon 10-17 reverse ACACACTCTGCCCCGTTATC
eys exon 10-17 reverse GTTATCGCACGGATTAACAGC Nested
eys exon 18-20 forward TAACCCTGGTTACGCTGGAG
eys exon 18-20 forward TCAATGACTGCGCTAGCAAC Nested
eys exon 18-20 reverse AAACTCCCCTGGGGTATCAG
eys exon 18-20 reverse TCCATCCTTGAGGACACACA Nested
eys exon 20-22 forward GATACCCCAGGGGAGTTTTC
eys exon 20-22 forward ACAGCCCTATGACCCTTGTG Nested
eys exon 20-22 reverse GATGCGCATTCATTGATGTC
eys exon 20-22 reverse ACAGTGCAGGCCTGAAAATC Nested
eys exon 21-25 forward GTGAAATTGATAGCGATGACTG
eys exon 21-25 forward TGGATGGGGTCAACAGCTAC Nested
eys exon 21-25 reverse CAACTCCCATGAACACAGGG
eys exon 21-25 reverse TGTTTCTCTCGCAGTGATCG Nested
eys exon 24-28 forward TCGACGGCCTTAATGGTTAC
eys exon 24-28 forward TCACTGCGAGAGAAACACTG Nested
eys exon 24-28 reverse CAGGCTCATTCTGGATGCAC
eys exon 24-28 reverse ATTCCCTGGTTGCATGGTTG Nested
eys exon 28-32 forward GGGAATGTGCATCCAGAATG
eys exon 28-32 forward TGGCTACACCTGCTTCTGTC Nested
eys exon 28-32 reverse TCCTGACACCACTAACGGTG
eys exon 28-32 reverse TCAGCCACACACGGAAAAAG Nested
eys exon 32-36 forward CCATGTGTTTATTGGAGGTC
eys exon 32-36 forward CTCGTCATCGTTCACCTTAC Nested
eys exon 32-36 reverse CTTGCATTCTGGAGAAACAC
eys exon 32-36 reverse AGAAAACGCTCTCCCAAATC Nested
eys exon 36-39 forward TGGCTGCTCAGAATATTAGGATC
eys exon 36-39 forward GATAGTTTGGTGGCAATTACAGTG Nested
eys exon 36-39 reverse GGCACAGCTTACCGGAGTAG
eys exon 36-39 reverse CATGCACAGAACCAGCTCTC Nested
eys exon 39-40 forward TGGTTCTGTGCATGTCCTTC
eys exon 39-40 forward CGCTCTACTCCGGTAAGCTG Nested
eys exon 39-40 reverse AGGCATTATTGGCAAAGGTG
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eys exon 39-40 reverse GGGCCGAGTGATGTTGATAG Nested
eys exon 40-44 forward TCACCTGAAGCTCACCTTTG
eys exon 40-44 forward TTCTCTTTTCCGGGCAAAAG Nested
eys exon 40-44 reverse CAGAACGACACTTTCTCTGAGC
eys exon 40-44 reverse GCACCTTTCCATCCAAACAC Nested
eys exon 44-46 forward GTGTTTGGATGGAAAGGTGC
eys exon 44-46 forward GCTCAGAGAAAGTGTCGTTCTG Nested
eys exon 44-46 reverse TTGAATGGACTGTTGGCATC
eys exon 44-46 reverse CCCAGATTATAGCGGAGCTG Nested
eys exon 46 forward TAAGGTTTGCAAGAACGGTG
eys exon 46 forward TGATCATCTAGCGGTTGGAC Nested
eys exon 46 reverse ACTCTTCTCCTTGATAGACATTGAAAC
eys exon 46 reverse TGGATGAGAGTCCGATTGTG Nested
RT-PCR analysis eys exon 19-21 forward CTGCACAGACCTCCTCAATG
eys exon 19-21 reverse CACAGCGAGTTCCCTCAAAC
actin forward CAACAGGGAAAAGATGACACAGAT
actin reverse CAGCCTGGATGGCAACGT
Genomic lesions eys exon 20 forward TGGGTAAAGAATGCCCAACT In intron 19
eys exon 20 reverse GCAAACAAAGCCACAGAACA In intron 20
Supplementary Table S2. 
Oligo sequences used for gRNA synthesis.
Oligo name Sequence
Constant oligo
AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTT
ATTTTAACTTGCTATTTCTAGCTCTAAAAC
Gene specific oligo eys exon 20 
TAATACGACTCACTATAGGTGCAGGAAAACTCCCCTGGTTTTAGAGCTA
GAAATAGCAAG
T7 promoter in bold. Gene specific region is red and underlined. Overlapping region is underlined.
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Abstract
Autosomal recessive (ar) retinitis pigmentosa (RP), a subtype of inherited retinal dystrophy, 
is often caused by mutations in Eyes shut homolog (EYS), a gene predominantly expressed 
in the photoreceptor cells of the retina. Currently, there is no treatment for this disorder. 
Due to its large size, developing a gene augmentation therapy for EYS using conventional 
adeno-associated viral (AAV) vectors is challenging. In this study, we aimed to develop EYS 
microgenes encoding functional proteins, as a potential therapy for EYS-associated retinal 
dystrophy. Based on the protein domain conservation of EYS, we generated three EYS 
microgenes, of different sizes, by PCR and Gateway cloning. To investigate their expression, 
HEK293T cells were transfected with plasmids encoding the EYS microgenes and their 
cell lysates were used for western blot analysis in order to determine protein expression. 
Two out of three microgenes appeared to be stable and expressed in HEK293T cells. 
Next, we investigated the localization of the microgenes in hTERT-RPE1 cells. However, 
immunofluorescence data were inconclusive. This study is a first step towards the 
development of a genetic therapy for EYS-associated retinal dystrophy, using microgenes. 
Additional experiments are required to determine whether the microgenes are targeted 
to the right location in the cell and whether the microgenes encode functional proteins.
Key words:
Eyes shut homolog, gene therapy, microgenes, retinitis pigmentosa
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5.1 Introduction
Mutations in Eyes shut homolog (EYS) are amongst the most frequent causes of autosomal 
recessive retinitis pigmentosa (arRP), together accounting for 5-10% of the arRP cases.1-3 
Retinitis pigmentosa is a subtype of inherited retinal dystrophy, with a prevalence of 
approximately 1 in 4,000 individuals, and is characterized by progressive degeneration 
of rod photoreceptors causing constriction of the visual field and eventually, often, total 
blindness.4 Different modes of inheritance including autosomal recessive, autosomal 
dominant, and X-linked, have been observed in the disease.
EYS encodes the 3,144 amino acids long protein eyes shut homolog (EYS) and is 
predominantly expressed in the photoreceptor cells of the retina. It contains 28 epidermal 
growth factor (EGF)-like domains and 5 laminin A G-like (LamG) domains. It has been 
described that EGF domains are important for intracellular signaling and cell adhesion, 
whereas proteins harboring LamG domains can have a wide variety of functions, such as 
cell adhesion, migration and signaling.5,6 EYS is an ortholog of the Drosophila spacemaker 
(spam) protein, which is shown to play a major role in maintenance of the photoreceptor 
morphology.7 In zebrafish, it was demonstrated that EYS localizes near the connecting 
cilium and eys knock-out zebrafish show disruption of the retinal architecture and visual 
impairment.8-10
Currently, there is no therapy for RP that has been proven to prevent the development 
or progression of the disease, or can restore visual function. Drugs currently used in the 
treatment of RP are focused on slowing down the progression of disease or targeting 
secondary complications.11 The retina is an accessible and immune privileged structure, 
which makes it a suitable target for gene augmentation therapy, i.e. the replacement of 
a mutated gene that causes disease with a healthy copy of that gene or its cDNA. Adeno-
associated virus (AAV) vector-mediated delivery of the transgene into the subretinal space 
is considered an effective and safe method to treat some subtypes of inherited retinal 
diseases (IRDs).11-14 Recently, AAV-mediated RPE65 gene therapy for LCA (LUXTURNATM) 
was approved by the US Food and Drug Administration (FDA), which opens the door 
to explore the potential of gene therapy for other IRDs. However, a drawback of AAV-
mediated delivery of transgenes is the limited cargo capacity of AAV vectors, which is 4.7 
kb.15 With a length of 9.4 kb, the EYS cDNA exceeds this cargo capacity. This requires the 
need of a different gene augmentation strategy. One solution can be the use of shorter 
therapeutic constructs, here called microgenes. Microgenes are smaller versions of a 
cDNA, containing only the most important regions, that would still encode a functional 
protein. The use of microgenes as a therapeutic strategy was shown to be promising in 
Duchenne muscular dystrophy (DMD), a disesase caused by mutations in the large DMD 
gene that encodes the dystrophin protein. Several studies showed that AAV-mediated 
micro-dystrophin expression in different mutant mouse models and canine models with 
DMD could effectively mitigate muscle disease.16-19 An example of the use of microgene 
therapy for retinal disease is the study by Zhang et al. They reported the delivery of a 
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miniCEP290 gene into a mouse model of LCA. Mice injected with miniCEP290 significantly 
improved photoreceptor survival, morphology and function compared to control-injected 
mice.20
In this study, we generated three EYS microgenes, that are predicted to encode functional 
proteins, and assessed protein stability and localization. This study is a first step towards 
the development of a genetic therapy for EYS-associated retinal dystrophy.
5.2 Materials and Methods
5.2.1 Cloning of full length EYS cDNA
For cloning of EYS cDNA, PCR primers for the amplification of individual fragments were 
designed using Primer3 software (http://bioinfo.ut.ee/primer3-040). Twenty nanogram 
of human retina marathon-ready cDNA (Clonetech) was incubated with 0.5 µM of 
the forward and reverse primer, 100 µM dNTPs (Roche), 0.25 U Phusion high-fidelity 
polymerase (New England Biolabs), 10x Phusion PCR buffer (New England Biolabs) and 1x 
Q-solution (Qiagen) in a total volume of 25 µl milliQ. Overhang PCR was used to fuse the 
separate fragments to form full length EYS cDNA. The purified sample was cloned into the 
pDONR201 vector (Invitrogen) using the Gateway BP Clonase enzyme mix (Thermo Fisher 
Scientific) to generate entry clones. Entry clones were validated by Sanger sequencing 
and cloned into the destination vector pcDNA520 using the Gateway LR Clonase enzyme 
mix (Thermo Fisher Scientific). Primer sequences used are listed in Supp. Table S1.
5.2.2 Microgene design
To be able to design the microgenes, EYS sequence conservation per amino acid 
position was calculated with the AL2CO program21 using default values from http://
prodata.swmed.edu/al2co/al2co.php. Levels of conservation were averaged for each 
predicted domain, the low complexity region, or the regions between those. Levels of 
conservation per amino acid position were calculated using the entropy per position, and 
were subsequently normalized to zero, mean and unit variance (+1 to -1.5). Based on this 
calculation, conserved regions were selected to be part of one or more of the microgenes.
5.2.3 Cloning of microgenes
PCR primers for amplification of individual fragments were designed using Primer3 
software (http://bioinfo.ut.ee/primer3-0.4.0). Some primers contained 5’ overhangs 
complementary to the 3’ end of the adjacent part of the microgene in order to connect 
the different parts using overhang PCR. Twenty nanogram of the plasmid containing full 
length human EYS cDNA was incubated with 0.5 µM of the forward and reverse primer, 
100 µM dNTPs (Roche), 0.25 U Phusion high fidelity polymerase (New England Biolabs), 
1x Phusion PCR buffer (New England Biolabs) and 1x Q-solution (Qiagen) in a total 
volume of 25 µl milliQ. The following program was run in a 2720 Thermal Cycler (Applied 
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Biosystems): the samples were denatured at 98°C for 3 minutes followed by 35 cycles of 
amplification consisting of 30 seconds at 98°C, 30 seconds at 58°C and 1.5 minutes at 72°C, 
and a final extension for 5 minutes at 72°C. PCR products were run on a 1% agarose gel 
and bands were excised. DNA was purified on Nucleospin Gel and PCR Clean-up columns 
(Macherey Nagel). One hundred fifty nanogram of the purified insert was cloned into the 
pDONR201 vector (Invitrogen) using the Gateway BP Clonase Enzyme mix (Thermo Fisher 
Scientific) to generate entry clones. Entry clones were validated by Sanger sequencing 
and cloned into the destination vector pcDNA520 using the Gateway LR Clonase enzyme 
mix (Thermo Fisher Scientific). Primer sequences used to generate the EYS microgenes are 
listed in Supp. Table S2.
5.2.4 Transfection of HEK239T cells or hTERT-RPE1 cells
HEK293T cells or hTERT-RPE1 cells were grown in DMEM (HEK293T) or DMEM/F12 (1:1, 
hTERT-RPE1) supplemented with 10% fetal calf serum, 1% penicillin-streptomycin and 1% 
sodium pyruvate at 37°C and 5% CO2. Confluent cells were diluted 1 to 6, seeded in a 
12-wells plate and grown for 24 hours at 37°C in a total volume of 1 ml. For transfection, 
2 µg of the full length EYS, EYS microgene or CEP290 expression vector (positive control) 
was incubated together with 6 µl Fugene® HD Transfection Reagent (Promega) in a total 
volume of 100 µl Optimem for 20 minutes at room temperature and subsequently the 
transfection mix was added to the cells. After incubation for 96 hours at 37°C, cells were 
harvested for western blot analysis (HEK293T) or immunocytochemistry (hTERT-RPE1).
5.2.5 Western blot analysis
Medium was removed and cells were collected and washed with PBS. HEK293T cells 
were resuspended in 100 µl RIPA buffer containing protease inhibitors (Roche). After 
sonication of the cells for 30 seconds, cells were centrifuged at 11,000 rpm for 5 minutes 
at 4°C and subsequently supernatant containing protein lysates was collected. Protein 
concentrations were determined via BCA according to the manufacturer’s instructions 
(Pierce). For detection of EYS, samples were subjected to SDS-PAGE (3-5% acrylamide) and 
transferred to PVDF (polyvinylidene difluoride) membrane (Roche, 03010040001) using 
standard techniques. Membranes were blocked in 5% non-fat dry milk (blocking buffer, 
Biorad) in PBS for 6 hours at 4°C and subsequently incubated with primary antibody (rabbit 
anti-EYS, Novus Biological, NBP1-90038, 1:1,000 in blocking buffer or mouse anti-HA, 
Sigma, H3663, 1:1,000 in blocking buffer) for three days at 4°C. Membranes were washed 
three times with PBST (0.2% Tween-20 in PBS), incubated with HRP-conjugated secondary 
antibody (HRP-conjugated goat anti-rabbit, Genscript, A00098, 1:10,000 in blocking buffer 
or HRP-conjugated goat anti-mouse, Jackson ImmunoResearch Laboratories, 115-035-
062, 1:10,000 in blocking buffer) for 1 hour at room temperature, washed and developed 
using SuperSignal™ West Femto Maximum Sensitivity Substrate (Thermo Scientific) and 
scanned on a ChemiDoc Touch Imaging System (Biorad). For the detection of tubulin, 
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samples were subjected to SDS-PAGE (4-12% Bis-Tris, NuPAGE) and transferred to a PVDF 
membrane (GE Healthcare Life Sciences) overnight at 4°C. The membrane was blocked in 
blocking buffer for 1 hour at room temperature and subsequently incubated with primary 
antibody (mouse anti-alpha tubulin, Abcam, ab7291, 1:2,000 in blocking buffer) overnight 
at 4°C. The membrane was washed three times with PBST. After incubation with the 
secondary antibody (goat anti-mouse IRDye800, LI-COR Biosciences, 926-32210, 1:10,000 
in blocking buffer) the membrane was washed and scanned on an Odyssey imaging 
system (LI-COR Biosciences).
5.2.6 Immunocytochemistry
hTERT-RPE1 cells were grown on coverslips in 12-well plates and transfected with 
expression clones containing full length EYS or one of the microgenes as described above. 
After transfection, cells were serum-starved for another 48 hours. Cells were rinsed with 1x 
PBS, fixed in 2% paraformaldehyde for 20 minutes, permealized in PBS supplemented with 
1% Triton-X for 3 minutes, and subsequently blocked in 2% bovine serum albumin in 1x 
PBS (blocking solution) for 30 minutes, all at room temperature. For immunostaining, cells 
were incubated with primary antibody diluted 1:100 in blocking solution for 60 minutes 
at room temperature. Cells were washed 3 times for 5 minutes in 1x PBS, incubated for 45 
minutes with the corresponding secondary antibody diluted 1:500 in blocking solution. 
Cells were washed 3 times 5 min in 1x PBS and rinsed in water. Finally, coverslips were 
mounted in Vectashield with DAPI and imaged on a Zeiss Axio Imager Z1 Fluorescense 
microscope (Zeiss).
Antibodies used were rabbit anti-EYS (Novus Biological, NBP1-90038), mouse anti-
acetylated tubulin (Sigma, T6793), donkey anti-rabbit Alexa Fluor 488 (Life Technologies, 
A21206), and donkey anti-mouse Alexa Fluor 568 (Molecular Probes, A10037).
5.3 Results
5.3.1 Cloning of full length EYS cDNA
First, we cloned the full length EYS cDNA by PCR using human retina marathon-ready 
cDNA as a template. Since EYS is a large gene, it was not possible to obtain the complete 
cDNA by one single PCR. Therefore, the cDNA was divided in ten smaller fragments which 
were more easily amplified by PCR (Figure 5.1). There was an overlapping region of at 
least twenty nucleotides between adjacent fragments. After all the ten fragments were 
obtained, additional annealing PCRs were performed to combine the fragments resulting 
into five fragments and ultimately into the complete EYS cDNA. Finally, the EYS cDNA 
was cloned into an expression vector in frame with an C-terminal HA-tag using Gateway 
cloning. The presence of the correct insert was validated by Sanger sequencing (data not 
shown). This construct formed the basis for the cloning of the EYS microgenes, and served 
as a positive control in expression and localization experiments.
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Figure 5.1. Cloning strategy for full length EYS cDNA. 
Upper panel: exonic structure of EYS. Lower panel: schematic representation of the 10 initial PCR 
fragments for the cloning of the full length EYS cDNA. The forward primer of the first fragment 
and the reverse primer of the last fragment contained an AttB1 or AttB2 tail for Gateway cloning, 
respectively. Primers of intermediate fragments contained tails overlapping with their adjacent 
fragments.
5.3.2 Generation of three EYS microgenes
In order to be able to select the regions for the design of the EYS microgenes, EYS 
sequence conservation per domain was calculated with the AL2CO program.21 Part of the 
EGF domains in the N-terminal part of the protein as well as the LamG domains in the 
C-terminal part of the protein appeared to be most conserved, whereas the intermediate 
region of EYS, where no domains are predicted, showed low conservation scores (Figure 
5.2A). The most conserved regions were selected for the generation of three different EYS 
microgenes named microgene A, microgene B and microgene C (Figure 5.2B). The sizes 
of microgene A, B and C are 3.6 kb, 4.5 kb and 5.8 kb, respectively. Microgene A will fit in 
a single AAV vector, whereas for delivery of microgenes B and C, a dual AAV approach 
could be employed for packaging, as described previously.22 To generate the microgenes, 
separate regions of the microgenes were amplified by PCR on human EYS cDNA, followed 
by an additional PCR to anneal these regions to form a complete microgene. Finally, 
gateway cloning was used to clone the three microgenes in a vector in frame with a 
C-terminal HA-tag.
5.3.3 Expression of EYS microgenes in HEK293T cells after transfection
To test the stability of the microgenes in vitro, HEK293T cells were transfected with HA-
tagged versions of either full length EYS cDNA, or microgene A, B or C for 96 hours. We also 
transfected cells with CEP290-HA as a positive control, known to be properly expressed 
in HEK293T cells after transfection. Microgene protein expression in HEK293T cell 
lysates was determined by Western blot analysis using anti-HA and anti-EYS antibodies. 
Immunoblotting using the anti-EYS antibody revealed that the full length EYS (351 kDa), 
microgene A (137 kDa) and microgene B (171 kDa) proteins were expressed approximately 
at their predicted molecular weights, while no protein expression was observed for 
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Figure 5.2. Sequence conservation of EYS and protein structure of EYS microgenes.
(A) Schematic overview of EYS sequence conservation per domain, which was calculated with the 
AL2CO program. (B) Protein domain structure of EYS and the EYS microgenes A, B and C, based on 
the results of the SMART database (http://smart.embl-heidelberg.de/). Conserved regions of EYS 
that were selected to be part of the microgenes are displayed on a grey background. EGF: epidermal 
growth factor.
microgene C (219 kDa)(Figure 5.3A). Furthermore, no expression was detected in 
non-transfected cells or cells transfected with CEP290, indicating that positive bands 
observed for EYS and the microgenes are specific. In contrast to what was observed after 
immunoblotting using anti-EYS antibody, none of the microgenes or full length EYS was 
detected on the blots treated with the anti-HA antibody, whereas CEP290 (302 kDa) was 
clearly visible, confirming that the procedure worked (Figure 5.3B). All constructs were 
re-sequenced to exclude mutations that could affect the expression of the proteins or 
the epitope, but no variants were found. These results indicate that microgenes A and 
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B are stable proteins. Microgene C could not be detected, suggesting that there is no 
protein formed or that the produced protein is not stable. The fact that the microgenes 
and full length EYS were not observed in the HA-blots, suggests that the HA-tag is lost by 
for instance proteolytic processing.
Figure 5.3. Western blot analysis of HEK293T cells transfected with EYS microgenes.
Western blot analysis was performed after transfection of HEK293T cells with expression vectors 
of full length EYS (351 kDa), microgene A (137 kDa), B (171 kDa), C (219 kDa), or CEP290 (302 kDa), 
which all contained a C-terminal HA-tag. (A) Upper panel: western blot using anti-EYS antibody. 
Lower panel: western blot using anti-alpha tubulin (50 kDa). (B) Western blot using anti-HA antibody. 
NT: non-transfected.
5.3.4 Localization of EYS and EYS microgenes in hTERT RPE1 cells
Next, we examined whether the microgenes were properly localized. Therefore, hTERT-
RPE1 cells were transfected with plasmids containing either the full length EYS cDNA 
or microgene A, B, or C, followed by serum starvation to induce ciliogenesis. Previously, 
in the zebrafish retina, it was namely shown that, EYS localizes near the connecting 
cilium of photoreceptor cells (Chapter 4).10 The localization of EYS was determined by 
immunocytochemistry using the same EYS antibody as used for immunoblotting. In order 
to investigate whether EYS and the microgenes localize near the cilium, cells were co-
stained with an antibody against acetylated tubulin, a ciliary marker. Non-transfected, as 
well as cells transfected with either full length EYS or one of the microgenes all showed 
formation of cilia (Figure 5.4). We barely detected any immunofluorescence signal for 
EYS. Some green spots were observed, however, similar staining was also seen in non-
transfected cells, suggesting that this signal is background staining and not specific for 
EYS or the microgenes. So far, the immunofluorescence data were inconclusive and future 
experiments are needed to analyze the localization of the EYS microgenes.
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Figure 5.4. Immunocytochemistry of hTERT-RPE1 cells transfected with the EYS 
microgenes. 
hTERT-RPE1 cells were transfected with full length EYS or microgene A, B or C. Cells were stained 
with anti-acetylated tubulin (Actubulin, red) and anti-EYS (green). Nuclei were counterstained with 
DAPI (blue). Scale: 20 µm.
5.4 Discussion
In this study, we aimed to develop EYS microgenes that would encode functional proteins, 
as a potential therapy for EYS-associated retinitis pigmentosa. We generated three EYS 
microgenes, of different sizes, based on the protein domain conservation of EYS. Two out 
of three microgenes appeared to be stable and expressed in HEK293T cells. The localization 
of the microgenes was studied in hTERT-RPE1 cells, but did not yield any reliable results. 
Thus the potential of microgene therapy for EYS-associated inherited retinal dystrophy as 
of yet remains elusive.
Recently, Zhang et al. reported on the generation of a miniCEP290 fragment. Injection 
of miniCEP290 into the retina of mouse model of LCA showed delay in photoreceptor 
degeneration.20 This is the first example of the use of a minigene approach for retinal 
disease. The use of microgenes as a therapeutic tool has a large history in the development 
of a genetic therapy for DMD. The full length dystrophin gene is 2.6 Mb in length, with 
a coding sequence of 11.5 kb that encodes a 427 kDa protein.23 The development of a 
microgene therapy for DMD started with the discovery of a highly functional Δ17–48 
mini-dystrophin by England et al.24 Although this 6.2 kb construct was still too large for 
packaging, this initiated an acceleration in the development of mini-dystrophin. In 1997, 
Yuasa et al published a 3.7 kb ΔDysM3 gene that unfortunately appeared not functional.25 
Development of EYS microgenes as a potential 
therapy for EYS–associated retinal dystrophy |   135 
Ch
ap
te
r 5
However, the mini-dystrophin construct evolved quickly and in total over 30 different 
mini-dystrophin constructs are reported to date. Therapeutic potential of mini-dystrophin 
was improved with modifications, such as codon optimization and inclusion of important 
domains.26,27 Many preclinical studies in animal models showed positive results, such as 
reduced pathology, increase of muscle force and enhancement of cardiac function.23 
Positive results of pre-clinical in vivo studies resulted in the initiation of clinical trials in 
DMD patients (ClinicalTrials.gov, NCT03368742, NCT03375164, NCT03362502).23 All 
together, this shows that the development of microgenes for therapeutic purposes is a 
challenging process that easily can take many years.
In this study, three EYS microgenes were designed, based on the protein domain 
conservation of the full length EYS. Conserved regions of EYS were selected to be part of 
one or more of the microgenes. Of course, we are not sure whether the selected regions 
will lead to a functional protein. Also, we directly connected the regions to each other. 
More insights in the function of EYS and the function of the specific protein domains may 
help to improve the microgene design. As has been shown for microgene development 
for DMD, codon optimization and inclusion of specific functional domains may also help 
to increase functionality of the protein.26,27
Western blot analysis of protein lysates of HEK293T cells transfected with the EYS 
microgenes revealed that microgene A and microgene B are expressed, whereas no 
protein expression was observed for microgene C. These results indicate that microgene 
A and B are able to produce stable proteins, while for microgene C, either no protein is 
formed or the protein is not stable and prone to degradation. Expression of the proteins 
was observed using an anti-EYS antibody, however, no staining was observed when using 
the anti-HA antibody. One explanation of this could be that the HA signal is not strong 
enough to be detected by western blot. Another reason could be that the protein is 
somehow proteolytically processed at the C-terminal end and thereby the HA-tag is lost. 
At the moment we started this study, we did not have a suitable antibody against EYS. 
Therefore we decided to clone the EYS constructs within an expression vector containing 
an HA-tag. Since a signal peptide is predicted to be present at the N-terminal part of the 
protein, we decided to place the HA-tag at the C-terminal end to prevent the tag from 
being lost.
The next step of validation of the microgenes is to investigate whether the EYS 
microgene proteins show proper localization. In this study, we transfected hTERT-
RPE1 cells with either full length EYS or one of the microgenes. In order to study their 
localization, immunocytochemistry was performed using anti-EYS and anti-acetylated 
tubulin antibodies. Unfortunately, we were not able to draw any conclusions about 
the localization of the microgenes, since immunofluorescence signal of EYS was barely 
detected. The green spots that were observed were also seen in non-transfected cells. 
This could mean that endogenously expressed EYS protein was detected, however, since 
EYS expression levels in hTERT-RPE1 cells are very low, this is not very likely. We therefore 
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assumed that this is background signal and not specific EYS staining. The poor EYS signal 
that was observed could be due to the fact that the EYS antibody did not work properly. 
However, the same antibody was successfully used before, for the staining of zebrafish 
retinal cryosections using a similar procedure (Chapter 4). Another explanation could 
be that the transfection efficiency was not high enough to be able to detect full length 
EYS or the microgenes. In previous studies, it was observed that EYS localizes near the 
connecting cilium of photoreceptor cells at least in the zebrafish retina (Chapter 4).10,28 
Although in our hands, hTERT-RPE1 have always shown low transfection efficiencies, we 
selected these cells for localization experiments, because they are able to form cilia and 
have a large cytoplasmic compartment. Other cells that also contain cilia and possibly 
can be transfected more easily could be COS-1 cells.29 There is also a possibility that EYS 
localizes outside the cilium in hTERT-RPE1 cells. Or, since a signal peptide is predicted to 
be present at the N-terminus, it might be possible that EYS is excreted.
Once the microgenes are proven to be stable and show proper localization, we need to 
determine whether the microgene proteins are also functional and will be able to rescue 
a disease phenotype. To be able to test protein function in a cellular model, one can make 
use of patient-derived induced pluripotent stem cells (iPSCs). These iPSCs can then be 
differentiated into photoreceptor cells.30 After treatment of the cells with the microgenes, 
the presence of microgene transcripts as well as protein expression should be evaluated. 
Furthermore, treated patient-derived cells should be compared to untreated patient-
derived cells and cells derived from a healthy individual with respect to successful 
differentiation, morphology and expression of retinal genes. The use of iPSCs represents 
an important alternative to in vivo animal studies. However, there are also some limitations 
of the use of iPSCs. Interactions with other cells and organ specific influences, as well as 
the consequences on the surrounding cells cannot be very well studied.
Since Eys is not expressed in several rodent species, such as mouse and rat, they are excluded 
from being suitable animal models.31 However, the zebrafish does express eys8-10 and its 
retina is similar to that of the human retina,32 which makes the zebrafish a good model 
organism to study the effect of EYS microgenes in an in vivo situation. Rescue experiments 
can be performed using a zebrafish eys knock-out model which shows a clear retinal 
phenotype, as described in Chapter 4. There are several methods for testing the effect of 
the microgenes. One option is the injection of mRNA of the human EYS microgenes into 
the eys knockout zebrafish embryos, when they are still in their single-cell stage. When 
the zebrafish larvae are 5 days post-fertilization, expression of the microgenes can be 
studied by immunoblotting and immunohistochemistry, and functional assays, such as 
measuring ERG and visual motor response, could be performed. Mutant zebrafish injected 
with microgenes will be compared to uninjected mutant fish and wild-type fish. Using 
mRNA injections, the time to perform these experiments is limited due to poor stability 
of the mRNA. Furthermore, it is difficult to control how many copies of the microgene 
are present and it is not known whether the RNA will be incorporated in the zebrafish 
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genome and where in the genome that will be. Initial attempts of injections of microgene 
A mRNA into eys knockout zebrafish embryos were not successful.
Another strategy to test EYS microgenes in zebrafish is to make use of the phiC31 integrase 
system as described previously by Mosimann et al.33 There, the eys knock-out zebrafish 
line needs to be outcrossed with a transgenic line containing genomic attP landing sites. 
In addition, the microgene constructs that will be injected in the zebrafish embryos need 
to contain attB sites and a retina specific promoter. In this way, the phi31C integrase 
catalyzes a unidirectional recombination reaction between attP and attB sites and is an 
efficient strategy for site-directed transgenesis.33,34 The advantages of this method are that 
the location of gene incorporation is known and that long-term effects can be studied.
The main reason for generating EYS microgenes is that the full length EYS does not fit in an 
AAV vector for delivery. Microgene A has a size of 3.6 kb and can, together with a promoter 
sequence, still be packaged into a single AAV. However, microgene B and microgene C 
are by its own already 4.5 kb and 5.8 kb, respectively, so for its delivery two AAV vectors 
would be required. This two vector approach has been proven to be effective in restoring 
the retinal phenotype in mouse models of retinal diseases. Trapani et al. reported the use 
of a so-called dual AAV vector approach in which the gene will be divided in two parts, 
which will be simultaneously delivered in separate AAV vectors.22 Since AAVs have the 
ability to concatemerize, dual AAV vectors can reconstitute large genes by either splicing, 
homologous recombination or a combination of the two.
It still remains possible that none of the EYS microgenes generated in this study appears 
to be able to rescue EYS function. In that case, the most promising option left will be the 
delivery of full length EYS. For this, a dual AAV approach will not be sufficient, and a triple 
AAV approach will be required. In addition to the use of AAVs, nanoparticle-based delivery 
strategies for large genes, including ABCA4, are also being investigated.35 
In conclusion, the use of microgenes as a therapeutic approach is promising for the 
delivery of large genes as has been also demonstrated for DMD and CEP290.20,36 Here, we 
showed the generation and initial characterization of EYS microgenes, which is the first 
step towards the development of a genetic therapy for EYS-associated retinal disease.
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5.6 Supplemental information
Supplementary Table S1. 
Primers used for cloning of full length EYS cDNA.
Fragment Forward primer (5’ > 3’) Reverse primer (5’ > 3’)
1 GGGGACAAGTTTGTACAAAAAAGCAGGCT
CCGAAAATGACTGACAAATCAATCG
AGATTCCTGGCAGAACTGC
2 GTGGTCCATCACCTTGTCC CCGATATTCCTGACTGTCTTCTTCACTC
3 ATTTGTGCAAATGGATGCAG GCAGGAAAGGAAGAGGCAGTCTTTCAC
4 GACTGCCTCTTCCTTTCCTG CACATGAGTTGGGAATGCAC
5 GTGCATTCCCAACTCATGTG AGCAGGAAAAATGGGAGACA
6 TGTCTCCCATTTTTCCTGCT TGCAACATTGGTGGTGACTT
7 AAGTCACCACCAATGTTGCA CAGAGGGGCTGACAGAAGTC
8 GACTTCTGTCAGCCCCTCTG TTCCACATGGGTTGTTTTCA
9 TGAAAACAACCCATGTGGAA GCAGGTTGCTCCTCTGCTAC
10 ACCCTCCACACCACTGTAGC GGGGACCACTTTGTACAAGAAAGCTGGGTCTG
TAACCTCATTTTGTTCATCTCC
AttB sites for Gateway cloning are underlined.
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Supplementary Table S2. 
Primers used for the generation of EYS microgenes.
Micro
gene
Part Forward/
reverse primer
Primer sequence (5’ > 3’)
A 1 Forward primer GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGAAAATGACTGACAA
ATCAATCG
Reverse primer cattttacactcattggattcCACCTCACAGAATGGACCT 
A 2 Forward primer aggtccattctgtgaggtgGAATCCAATGAGTGTAAAATG 
Reverse primer gatgatgagcacaccaaggACCTTCAAATTCTTCTCTAC 
A 3 Forward primer tgtagagaagaatttgaaggtCCTTGGTGTGCTCATCATC 
Reverse primer GGGGACCACTTTGTACAAGAAAGCTGGGTCTGTAACCTCATTTTGTTC
ATCTCC 
B 1 Forward primer 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGAAAATGACTGACAAA
TCAATCG 
Reverse primer
cattttacactcattggattcCACCTCACAGAATGGACCT 
B 2 Forward primer aggtccattctgtgaggtgGAATCCAATGAGTGTAAAATG 
Reverse primer gggtcacgaataccaaaattGAAGAGGCAGTCTTTCACAT 
B 3 Forward primer atgtgaaagactgcctcttAATTTTGGTATTCGTGACCC 
Reverse primer gatgatgagcacaccaaggTGTTCTTTTTGCACTCTTTTTA 
B 4 Forward primer taaaaagagtgcaaaaagaacaCCTTGGTGTGCTCATCATC 
Reverse primer GGGGACCACTTTGTACAAGAAAGCTGGGTCTGTAACCTCATTTTGTTC
ATCTCC 
C 1 Forward primer 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGAAAATGACTGACAA
ATCAATCG 
Reverse primer
AAGGAAGAGGCAGTCTTTGACGTCAATTTC 
C 2 Forward primer ttgacgtcaaagactgcctcttccttCCCTCTGTTGCAGCACCCTC 
Reverse primer GGGGACCACTTTGTACAAGAAAGCTGGGTCTGTAACCTCATTTTGTTC
ATCTCC 
Overhangs (lower case letters) were required for the connection of the different parts of the 
microgenes. The primers at the start and end of the microgenes contain AttB sites (underlined), 
necessary for Gateway cloning.
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Abstract
Mutations in Eyes shut homolog (EYS) are one of the most frequent causes of autosomal 
recessive (ar) retinitis pigmentosa (RP). Exon 26 of EYS is a large exon in which many 
frameshift and nonsense mutations are described in patients with this subtype of retinal 
dystrophy. The aim of this study was to develop a therapeutic approach for retinal 
dystrophy patients with mutations in EYS exon 26, using antisense oligonucleotide 
(AON)-mediated exon skipping, predicted to leave the reading frame intact. Western blot 
analysis revealed that Δ26EYS protein is stable and equally expressed compared to full 
length EYS. Transcriptional analysis of AON-treated hTERT-RPE1 cells showed that exon 
26 could be successfully skipped by using a combination of two AONs (AON6 and AON7), 
whereas treatment with only one of these AONs did not affect splicing. Furthermore, 
we differentiated human-derived induced pluripotent stem cells (iPSCs) into three-
dimensional (3D) retinal organoids to generate a cellular disease model. We did not 
observe clear differences between cells derived from a patient or from a healthy control. 
Differentiated cells expressed some retinal markers; however, expression levels were quite 
low. In addition, AON efficacy was tested in this cellular model. In contrast to what was 
observed in hTERT-RPE1 cells, control cells treated with AON6 alone showed skipping 
of part of exon 25 and the majority of exon 26. In conclusion, we showed that Δ26EYS 
is a stable protein, and that AONs have the potential to skip EYS exon 26 in hTERT-RPE1 
cells. However, optimization is required to reproduce this in patient-derived 3D retinal 
organoids.
Key words:
Eyes shut homolog, EYS, antisense oligonucleotides, exon skipping, iPSCs, organoids
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6.1 Introduction
Retinitis pigmentosa (RP) is a group of inherited retinal dystrophies with a prevalence 
of approximately 1 in 4,000 individuals worldwide.1,2 Clinical features of the disease 
are night blindness and visual field constriction, and in later stages of the disease total 
blindness can occur.1,2 There are 62 genes described to date in which mutations can lead 
to autosomal recessive (ar) RP (RetNet http://www.sph.uth.tmc.edu/Retnet). Most genes 
are only responsible for a small proportion of the arRP cases. A few genes, however, are 
known to be more frequently mutated in arRP patients, including eyes shut homolog (EYS). 
Mutations in EYS are responsible for approximately 5-10% of all arRP cases,3 which makes 
EYS one of the most frequently mutated genes in patients with RP.
EYS encodes the protein eyes shut homolog and is predominantly expressed in the retina. 
The EYS protein consists of 28 epidermal growth factor (EGF) like domains, mainly at the 
N-terminal part of the protein, and 5 laminin A G-like (LamG) domains at the C-terminal 
end of the protein.4,5 This domain structure is conserved over species. Besides these 
functional domains, human EYS also harbors a so-called low complexity region in which 
no functional domains are predicted to be present. This region is completely encoded 
by exon 26. The low complexity region in EYS is not present in all species, for instance 
zebrafish and chicken Eys lack this region (Chapter 4).6 The exact function of EYS and its 
role in the pathogenesis of RP is not clear yet. In Drosophila, Eys is shown to be important 
for the maintenance of the morphology of photoreceptors.7 In zebrafish, Eys is described 
to play a major role in the maintenance of retinal architecture and eys deficient zebrafish 
show visual impairment.6,8,9
Currently, there is no treatment for EYS-associated retinal dystrophy. Great progress has 
been made to the development of therapeutic approaches for IRDs, such as gene therapy. 
However, conventional gene therapy has some drawbacks. For instance, delivery most 
often occurs via adeno-associated viruses (AAVs). The cargo capacity for AAVs is 4.7 kb, 
which makes it unsuitable to carry the complete EYS cDNA (9.4 kb). Recently, the use 
of antisense oligonucleotides (AONs) for the treatment of IRDs has shown promising 
results. One of the first examples describing the successful use of AONs for IRD is the 
prevention of pseudo-exon inclusion caused by the recurrent CEP290 c.2991+1655A>G 
mutation.10-15 Recently, a study by Albert et al. showed the successful rescue of splice 
defects in photoreceptor precursor cells caused by two neighboring deep-intronic 
mutations in ABCA4 using AONs.16 Splice-correction using AONs was also shown to be 
successful in proof-of-concept studies for the USH2A c.7595-2144A>G mutation17 and the 
OPA1 c.610+364G>A mutation.18 Besides the correction of the splicing defects caused by 
intronic mutations, AONs can also be used to modulate splicing and therefore skip regular 
exons.19 AON-mediated exon skipping as a therapeutic approach is most developed for 
Duchenne muscular dystrophy (DMD).20 Early phase clinical trials are ongoing in DMD 
patients with promising results.21,22 The purpose of this strategy was to exclude exons 
from the pre-mRNA in order to restore the reading frame leading to a shorter, but mature 
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transcript.23 As a consequence, the translated protein will still contain most of its essential 
domains, thereby retaining some function and reducing severity of disease.
A technology that gained tremendous attraction over the last decade is the use of induced 
pluripotent stem cells (iPSCs)24 for the directed differentiation towards almost all cell 
types, including retinal cells.25 Nakano et al. were the first to show that pluripotent cells 
have the capacity to self-organize into organoids.26 Several groups adapted this approach 
and, with slight changes in the differentiation protocol, were also able to differentiate 
iPSCs in to three-dimensional (3D) retinal organoids.13,27,28 When using cells from patients, 
this technique is a powerful tool to model disease, since these cells will contain the 
genetic mutation and have the exact genomic and molecular context as present within 
the corresponding patient.
In this study, we designed AONs for the skipping of EYS exon 26. Efficacy of AONs was first 
examined in hTERT-RPE1 cells. Next, fibroblast from a RP patient carrying c.4350_4356del, 
which is located in exon 26 of EYS,  in a homozygous state, were reprogrammed to generate 
iPSCs to further differentiated them to 3D retinal organoids. Finally, AON efficacy was also 
tested in this patient-derived cellular model system.
6.2 Materials and methods
6.2.1 Ethics statement
Our research was conducted according to the tenets of the Declaration of Helsinki. The 
procedures for obtaining human skin biopsies to establish primary fibroblasts cell lines 
were approved by the Ethical Committee of the Radboud University Medical Centre 
(Commissie Mensgebonden Onderzoek Arnhem-Nijmegen, 2015-1543). Written informed 
consent was gathered from all participating individuals. All procedures were carried out in 
the Netherlands.
6.2.2 Cloning of Δ26EYS
The entry clone containing the EYS cDNA, that was generated in Chapter 5, was 
used as the basis to obtain the Δ26EYS construct. Site-directed mutagenesis was 
performed using a forward primer that contained 24 nucleotides complementary to 
the end of exon 25 and 15 nucleotides complementary to the beginning of exon 27 
(5’- GACACTTACCCAGTTGATCAAGATTTCAGTTGTGTTC-3’), and a reverse primer that 
contained 22 nucleotides complementary to the beginning of exon 27 and 15 nucleotides 
complementary to the end of exon 25 (5’- CATAATAACGAACACAACTGAAATCTTGAT 
CAACTGGGT-3’). For the site-directed mutagenesis reaction, 50 ng of EYS cDNA entry 
clone was incubated together with 0.5 µM of the forward and reverse primer, 100 µM 
dNTPs (Roche), 0.25 U Phusion high-fidelity polymerase (New England Biolabs), 10x 
phusion PCR buffer (New England Biolabs) and 1x Q-solution (Qiagen) in a total volume of 
50 µl. Samples were denatured for 2 minutes at 94°C, followed by 10 cycles of 30 seconds 
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at 94°C, 30 seconds at 50°C and 15 minutes at 72°C, an additional 10 cycles of 30 seconds 
at 94°C, 30 seconds at 55°C and 15 minutes at 72°C, and a final primer extension of 15 
minutes at 72°C. Entry clones were validated by Sanger sequencing and cloned into the 
destination vector pcDNA520 with an HA-tag at the C-terminus using the Gateway LR 
Clonase enzyme mix (Thermo Fisher Scientific).
6.2.3 Transfection of HEK293T cells or hTERT-RPE1 cells
HEK293T cells or hTERT-RPE1 cells were cultured in DMEM (HEK293T) or DMEM/F12 (1:1, 
hTERT-RPE1) supplemented with 10% fetal calf serum, 1% penicillin-streptomycin and 
1% sodium pyruvate at 5% CO2 at 37°C. Confluent cells were diluted 1 to 6, seeded in a 
12-wells plate and grown for 24 hours at 37°C in a total volume of 1 ml. For transfection, 2 
µg of the expression vector containing full length EYS or Δ26EYS were incubated together 
with 6 µl Fugene HD Transfection Reagent (Promega) in a total volume of 100 µl Optimem 
for 20 minutes at room temperature and subsequently the transfection mix was added 
to the cells. After incubation for 96 hours at 37°C, cells were harvested for western blot 
analysis (HEK293T) or immunocytochemistry (hTERT-RPE1).
6.2.4 Western blot analysis
Medium was removed and cells were collected and washed with phosphate buffered 
saline (PBS1x). HEK293T cells were resuspended in 100 µl RIPA buffer containing protease 
inhibitors (Roche). After sonication of the cells for 30 seconds, cells were centrifuged 
at 11,000 rpm for 5 minutes at 4°C and subsequently supernatant containing soluble 
proteins were collected. Total protein concentrations were determined via BCA according 
to the manufacturer’s instructions (Pierce). For detection of EYS, samples were subjected 
to SDS-PAGE (3-5% acrylamide) and subsequently transferred to a PVDF (polyvinylidene 
difluoride) membrane (Roche, 03010040001) o/n at 4°C. Membranes were blocked in 
5% non-fat dry milk (blocking buffer, Biorad) in PBS for 6 hour at room temperature and 
subsequently incubated with primary antibody (rabbit anti-EYS, Novus Biological, NBP1-
90038, 1:1,000 in blocking buffer) for three days at 4°C. Membranes were washed three 
times with PBST (0.2% Tween-20 in PBS), incubated with HRP-conjugated secondary 
antibody (HRP-conjugated goat anti-rabbit, Genscript, A00098, 1:10,000 in blocking 
buffer) for 1 hour at room temperature, washed and developed using SuperSignal™ West 
Femto Maximum Sensitivity Substrate (Thermo Scientific) and scanned on a ChemiDoc 
Touch Imaging System (Biorad). For the detection of tubulin, samples were subjected to 
SDS-PAGE (4-12% Bis-Tris, NuPAGE) and transferred to a PVDF membrane (GE Healthcare 
Life Sciences) overnight at 4°C. The membrane was blocked in blocking buffer for 1 hour 
at room temperature and subsequently incubated with primary antibody (mouse anti-
alpha tubulin, Abcam, ab7291, 1:2,000 in blocking buffer) overnight at 4°C. The membrane 
was washed three times with PBST. After incubation with the secondary antibody (goat 
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anti-mouse IRDye800, LI-COR Biosciences, 926-32210, 1:10,000 in blocking buffer) the 
membrane was washed and scanned on an Odyssey imaging system (LI-COR Biosciences).
6.2.5 Immunocytochemistry
hTERT-RPE1 cells were grown on coverslips in 12-well plates and transfected with 
expression clones containing full length EYS or Δ26EYS as described above. After 
transfection, cells were serum starved for another 48 hours. Cells were rinsed with 1x PBS, 
fixed in 2% paraformaldehyde for 20 minutes, permeablized in 1x PBS supplemented with 
1% Triton-X for 3 minutes, and subsequently blocked in 2% bovine serum albumin in 1x 
PBS (blocking solution) for 30 minutes, all at room temperature. For immunostaining, cells 
were incubated with primary antibody diluted 1:100 in blocking solution for 60 minutes 
at room temperature. Cells were washed 3 times for 5 minutes in 1x PBS, incubated for 45 
minutes with the corresponding secondary antibody diluted 1:500 in blocking solution. 
Cells were washed 3 times 5 min in 1x PBS and rinsed in water. Finally, coverslips were 
mounted in Vectashield with DAPI (Vector Laboratories) and imaged on a Zeiss Axio 
Imager Z1 Fluorescense microscope (Zeiss).
Antibodies used were rabbit anti-EYS (Novus Biological, NBP1-90038), mouse anti-
acetylated tubulin (Sigma, T6793), donkey anti-rabbit Alexa Fluor 488 (Life Technologies, 
A21206), and donkey anti-mouse Alexa Fluor 568 (Molecular Probes, A10037).
6.2.6 Patient derived fibroblast reprogramming
Skin biopsy samples from an RP patient with a homozygous EYS mutation (c.4350_4356del) 
and from a control individual were collected, washed in PBS (Sigma Aldrich), dissected 
and incubated for 1-3 hours in a solution of 1000 U/ml Collagenase type II (Worthington 
Biochemical Corporation) and penicillin/streptomycin (Sigma Aldrich) in DMEM (Sigma 
Aldrich) at 37°C. The digestion was stopped by adding 20% fetal calf serum (Sigma Aldrich) 
and the cell suspension was incubated in DMEM with 20% fetal calf serum for 7 days at 37°C 
and 5% CO2. After approximately 1 month, a pure culture of fibroblasts was reprogrammed 
as follows. Fibroblasts were transduced with 4 lentiviral vectors containing the stemness-
related genes OCT3/4, NANOG, KLF4, and c-MYC. Transduced cells were incubated at 37˚C 
for 24 hours, lentiviruses were removed and cells were washed three times with PBS. The 
following day, cells were transferred onto murine embryonic fibroblast (MEF)-coated 
plates and cultured for one month at 37˚C and 5% CO2 in a stem cell medium containing 
DMEM/Ham’s F-12 (Sigma Aldrich), 20% knock-out serum replacement (KOSR, Thermo 
Fisher Scientific), MEM Non-essential amino acids (NEAA, Sigma Aldrich), L-glutamine 
(Sigma Aldrich), β-mercaptoethanol (Sigma Aldrich), β-FGF (Sigma Aldrich). One month 
after transduction, iPSC colonies were picked and expanded on vitronectin-coated plates 
(Thermo Fisher Scientific) in Essential E8 medium (Thermo Fisher Scientific).
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6.2.7 Mutation validation
Total DNA was isolated from iPSCs using QIAamp DNA mini kit (Qiagen). PCR analysis 
was performed for mutation detection. Fifty nanogram of DNA was incubated together 
with 0.5 µM of the forward (5’-ATCTGCTACCCCAACGACTT-3’) and reverse primer 
(5’-GAGACATCGAGGGGCTGAG-3’), 100 µM dNTPs (Roche), 0.25 U Taq Polymerase (Roche) 
and PCR buffer + 25 mM MgCl2 (Roche) in a total volume of 25 µl. Samples were denatured 
at 94°C for 3 minutes, followed by 35 cycles of amplification consisting of 30 seconds at 
94°C, 30 seconds at 58°C and 30 seconds at 72°C, and a final primer extension of 5 minutes 
at 72°C. Samples were analyzed by Sanger sequencing.
6.2.8 Differentiation of iPSCs into 3D retinal organoids
Directed differentiation of iPSCs into retinal organoids was based on the protocols by 
Nakano et al.26 and Parfitt et al.13 Briefly, iPSCs were dissociated to single cells using TrypLE 
Express (Invitrogen) and plated at a density of 10,000 cells per well in low-cell-adhesion 96-
well plates with V-shaped bottom in 100 µl EB media (GMEM (Gibco) supplemented with 
20% KORS, 0.1 mM nonessential amino acids, 1 mM GlutaMax, 1 mM sodium pyruvate, 
and 100 µM β-mercaptoethanol) supplemented with 20 µM Y-27632 ROCKi (Millipore) 
and 3 µM IWR1e (Cayman Chemical). After 48 hours, cells were topped up with 100 µl 
EB media supplemented with 20 µM Y-27632 ROCKi, 3µM IWR1e, and 2% Matrigel (EB2 
media). EB2 media was changed every 2 days until day 12, from which the embryonic 
bodies (EBs) were further cultured in EB media with 10% FCS, 1% Matrigel, 20 µM Y-27632 
ROCKi, and 100 nM smoothened agonist (SAG; Enzo Life Sciences). After 3 days, media 
was replaced for EB media with 10% FCS, 1% Matrigel, 20 µM Y-27632 ROCKi, and 100 
nM SAG, and 3 µM CHIR99021 (MACS). Media was refreshed every 2 days until day 20 
when EBs were transferred to non-adherent 24-well plates for further culture in neural 
retinal differentiation (NR) media (DMEM/F12 (Sigma) supplemented with 10% FCS, 1x N2 
supplement (Thermo Fisher), and 0.5 µM retinoic acid (RA, Sigma)). EBs were maintained 
for up to 90 days, changing NR media every 3-4 days.
6.2.9 Quantitative real-time PCR to assess differentiation
Total RNA was isolated using Nucleospin RNA Clean-up Kit (Macherey-Nagel) following the 
manufacturer’s protocol. Reverse transcription was performed using 500 ng of total RNA 
and the iScript cDNA Synthesis Kit (Bio-rad) according to the manufacturer’s instructions.
Quantitative real-time PCR (qPCR) was performed using GoTaq Real Time qPCR Master Kit 
(Promega) and an Applied Biosystem 7900HT fast real-time PCR system (Thermo Fisher 
Scientific). Samples were assayed in triplicate and normalized against the expression of 
the housekeeping gene GUSB. Relative quantification was based on the 2-(ΔΔCt) method. 
Primer sequences are listed in Supp. Table S1.
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6.2.10 AON design
The sequence of EYS exon 26 and the 50 bp upstream and downstream of the exon were 
analyzed as described elsewhere.29 Briefly, the presence of exonic splice enhancer motifs 
was assessed using the ESE finder 3.0 program (http://krainer01.cshl.edu/cgi-bin/tools/
ESE3/esefinder.cgi?process=home) and RNA structure and free energy predictions were 
performed using freely available database tools. Modified AONs were designed with a Tm of 
≥48°C, 40-60% of GC content and a length of 18-23 nt. Subsequently, they were purchased 
from Eurogentec, with a 2’-O-methyl group at the sugar chain and a phosphorothioate 
backbone. Lyophilized AONs were dissolved in 1x PBS. AON characteristics are listed in 
Table 6.1.
6.2.11 AON treatment
hTERT-RPE1 cells were transfected with 0.5 µM of naked AON using FuGene HD (Promega) 
for 48 hours, after which cells were harvested for transcriptional analysis. For treatment of 
differentiated iPSCs, cells were transfected with 2.0 µM of naked AON at day 84. After 96 
hours, medium was removed and cells were again transfected with 2.0 µM naked AON for 
another 96 hours after which cells were harvested for RT-PCR analysis. 
6.2.12 RT-PCR analysis
Total RNA was isolated using Nucleospin RNA Clean-up Kit (Macherey-Nagel) following 
the manufacturer’s protocol. Reverse transcription was performed using 1 µg (hTERT-
RPE1) or 350 ng (iPSC-derived organoids) of total RNA and the SuperScript™ VILO™ Master 
Mix (Invitrogen) according to manufacturer’s instructions. Four microliter cDNA was 
incubated together with 0.5 µM of the forward and reverse primer, 100 µM dNTPs (Roche), 
0.25 U Taq polymerase (Roche), 10x PCR buffer + 15 mM MgCl2 (Roche) and 1x Q-solution 
(Qiagen) in a total volume of 25 µl. The following program was run in a 2720 Thermal 
Cycler (Applied Biosystems): the samples were denatured at 94°C for 3 minutes followed 
by 35 cycles of amplification consisting of 94°C for 20 seconds, 58°C for 30 seconds and 
72°C for 2 minutes, and a final primer extension at 72°C for 5 minutes. Nested PCR was 
performed using 2 µl of PCR product and the same conditions as mentioned for the first 
PCR. PCR products were purified on Nucleospin Gel and PCR Clean-up columns (Macherey 
Nagel) and subsequently Sanger sequencing was performed. Primer sequences are listed 
in Supp. Table S2.
6.3 Results
6.3.1 EYS exon 26 as a target for exon skipping
An interesting target exon for AON-mediated exon skipping as a therapeutic approach for 
EYS-related retinal dystrophy is exon 26 of EYS. Exon 26 is the largest exon of EYS and is 
thereby also one of the most frequently mutated exons in patients with retinal dystrophy. 
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The majority of the mutations described in exon 26 are frameshift or nonsense mutations, 
resulting in premature termination of translation and thereby, assuming the mRNA is not 
degraded, a non-functional protein is formed (Chapter 2).30 Interestingly, exon 26 does 
not encode any functional domains and skipping of this exon does not disrupt the reading 
frame of EYS (Figure 6.1). Skipping of exon 26 will result in a shorter EYS protein, however, 
all its functional domains are predicted to be still present (Figure 6.2A). Therefore, exon 26 
of EYS might be a good candidate for AON-mediated exon skipping.
Figure 6.1. Schematic overview of EYS exon 26 skipping. 
Upper panel: exonic structure of EYS. Colored exons encode for EGF domains (dark green), EGF-like 
domains (light green), calcium binding EGF domains (blue) or laminin A G-like domains (yellow). 
Lower panel: schematic representation of exons 24 till 28 of EYS with and without exon 26. Arrow 
heads indicate the position of the exon related to the reading frame.
6.3.2 EYS lacking exon 26 encodes a stable protein
We first examined whether EYS lacking exon 26 (Δ26EYS) results in a stable protein. 
Therefore, we generated two vectors, one containing the full length EYS cDNA (see 
Chapter 5) and one vector containing Δ26EYS. HEK293T cells were transfected with either 
EYS or Δ26EYS for 96 hours and protein expression was analyzed. Western blot analysis 
revealed that both EYS and Δ26EYS were expressed in HEK293T cells, and the intensity 
of the bands was similar (Figure 6.2B). These results indicate that Δ26EYS encodes for a 
shorter, but stable EYS protein.
To determine the localization of Δ26EYS protein, hTERT-RPE1 cells were transfected with 
either full length or Δ26EYS containing plasmids, and subsequently immunocytochemistry 
with an antibody against Eys was performed. Previous studies showed that EYS localizes 
near the connecting cilium of photoreceptor cells (Chapter 4).9 Co-staining of transfected 
cells with the Eys antibody together with an antibody against acetylated tubulin, a ciliary 
marker, was performed to determine whether the EYS proteins localize near the cilium. 
Cilia were present in non-transfected cells, as well in cells transfected with the full length 
EYS or the Δ26EYS plasmids. We did not observe any specific staining with the EYS antibody 
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in transfected cells. Some green signal could be detected, however, since this was also 
observed in non-transfected cells, we assumed that this was background staining.
6.3.3 AON efficacy in hTERT-RPE1 cells
Next, we evaluated whether we are able to remove exon 26 from the pre-mRNA, using 
AON-mediated exon skipping. Initially, we designed five different AONs (AON1 till 
AON5, Table 6.1) based on parameters used in previous studies, that showed a positive 
correlation between the capability of the AON to induce exon skipping and the presence 
of predicted SC35 splice factor binding motifs in the target region.31 The efficacy of the 
AONs was first assessed in hTERT-RPE1 cells targeting endogenous EYS. Cells were treated 
Figure 6.2. Protein expression of full length EYS and Δ26EYS. 
(A) Protein domain structure of full length EYS and EYS without the protein segment encoded 
by exon 26, according to results of the SMART database (http://smart.embl-heidelberg.de/). EGF: 
epidermal growth factor. (B) Western blot analysis of HEK293T cells transfected with full length EYS 
or EYS lacking exon 26 (Δ26EYS). NT: non-transfected cells. Upper panel: membrane stained against 
EYS. Lower panel: membrane stained against alpha-tubulin. (C) Immunofluorescence images 
of hTERT-RPE1 cells transfected with full length EYS or Δ26EYS. DAPI: blue; AcTubulin: acetylated 
tubulin, red; EYS: green.
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with a final concentration of 0.5 µM of a single AON or a combination of AONs for 48 
hours and subsequently harvested for EYS transcript analysis by RT-PCR. Nested PCR was 
necessary to be able to detect EYS transcripts. We did not observe any clear signs of exon 
skipping after treatment with one of the five AONs (Figure 6.3). An additional, very faint 
band around 177 bp, which corresponds to the skipping of exon 26, was observed in cells 
treated with a combination of AON1, 2 and 3 (Figure 6.3A). However, we were not able to 
confirm exon skipping in this product by Sanger sequencing. These data showed that the 
five AONs designed so far were not able to successfully skip exon 26 of EYS.
Next, two new AONs were designed, named AON6 and AON7 (Table 6.1). The efficacy 
of these two AONs was assessed in the same way as for AON1 till AON5. Wild-type 
EYS transcript was observed in non-treated cells and cells with either AON6 or AON7. 
Interestingly, a lower band, corresponding to the size of the transcript in case exon 26 is 
skipped, was observed for cells treated with a combination of AON6 and AON7 (Figure 
6.4A). Sanger sequencing of this PCR product indeed confirmed the exact skipping of exon 
26 in cells treated with both AONs (Figure 6.4B). However, we were not able to reproduce 
these results in a second experiment. For further experiments, we decided to continue 
only with AON6 and AON7.
6.3.4 Differentiation of patient-derived iPSC into 3D retinal organoids
The promising results of AON treatment in hTERT-RPE1 cells prompted us to investigate 
whether we can also skip EYS exon 26 in patient-derived cells. To answer this question, 
we set-up a patient-derived cellular model for EYS-associated IRD. For this, fibroblasts 
were derived from a dermal skin biopsy of a healthy individual and from an RP patient. 
This patient carried the c.4350_4356del mutation in EYS homozygously. This mutation in 
exon 26 is predicted to lead to a frameshift and thereby premature termination of protein 
translation. Patient and control fibroblasts were reprogrammed to iPSCs by transducing 
Table 6.1. 
Antisense oligonucleotide characteristics.
RNA oligonucleotide Length (nt) GC content Tm (°C)
AON1 22 41% 51.1
AON2 20 45% 49.7
AON3 20 45% 49.7
AON4 20 50% 51.8
AON5 18 50% 48
AON6 20 50% 60
AON7 20 50% 60
SON 20 50% 60
AON: antisense oligonucleotide; SON: sense oligonucleotide, complementary to AON6; nt: 
nucleotide; Tm: melting temperature.
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with 4 lentiviral vectors containing the stemness-related genes OCT3/4, NANOG, KLF4, and 
c-MYC. Colonies of iPSCs were isolated, expanded and selected to generate clonal lines. 
The cells formed colonies that were positive for iPSC markers (Supp. Figure S1).
In order to study the effect of EYS mutations on photoreceptor development, patient 
and control iPSCs were differentiated into 3D retinal organoids using the differentiation 
protocol as previously described by Nakano et al (Figure 6.5).26 First, the presence of the 
mutation in patient-derived cells was validated by PCR analysis on cDNA isolated from 
iPSCs (day 0), followed by Sanger sequencing (Figure 6.6A). Progress of their differentiation 
was monitored using bright field microscopy and qRT-PCR. In general, there were no 
obvious differences between patient and control cells seen during bright field microscopy 
(Figure 6.6B). In patient cells, slightly larger organoids were observed. These were balloon-
like transparent structures, which appeared to be filled with fluid (Figure 6.6C). Pigmented 
cells were observed from ~day 35 onwards in both patient and control cells (Figure 6.6D), 
suggesting the formation of RPE cells.
The expression of pluripotency marker genes was decreased in cells at day 30, 60 and 90 
of differentiation compared to iPSCs (day 0), in both patient and control cells (Supp. Figure 
S1). This indicates that cells are not pluripotent anymore and at least are differentiating 
towards another cell type. We also analyzed the gene expression of several retinal genes 
in order to investigate whether the differentiated cells were moving towards a retinal 
cell fate. In control cells, expression of EYS, CRX, PAX6, PDE6H and RPE65 was detected 
in differentiated cells (Figure 6.6E). Expression of EYS, PAX6, PDE6H and RPE65 was also 
observed in patient-derived cells. In both control and patient cells, SIX6 expression could 
be detected at day 0 (iPSC). However, in general, the expression levels of retinal genes 
were low in both patient and control cells.
Figure 6.3 Efficacy of AON1 till AON5 in hTERT-RPE1 cells. 
(A) RT-PCR analysis of EYS transcripts in hTERT-RPE1 cells treated with 0.5 µM of AON1, AON2, AON3 
or a combination of the three. (B) RT-PCR analysis of EYS transcripts in hTERT-RPE1 cells treated with 
0.5 µM of AON4, AON5, a combination of AON1, 2 and 4, or a combination of AON1, 3 and 5. +: 
positive control; NT: non-treated.
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6.3.5 AON efficacy in patient-derived 3D retinal organoids
To investigate the efficacy of AON6 and AON7 in differentiated patient-derived iPSCs, cells 
were treated with AONs for one week (starting at day 84), after which EYS transcripts were 
analyzed by RT-PCR analysis on day 90. Bands corresponding to the size of the wild-type 
EYS transcript were observed for all samples, except for control cells treated with AON6 
alone. In this sample, a band corresponding to a size of ~177 base pair was observed 
(Figure 6.7A). Sanger sequencing of this band revealed skipping of a 1792-bp fragment. 
However, the skipped fragment did not represent a deletion of the entire exon 26, but the 
end of exon 25 and the majority of exon 26 instead (Figure 6.7B). Skipping of this fragment 
is predicted to disrupt the reading frame and lead to a truncated protein. Remarkably, we 
Figure 6.4. AON-mediated skipping of EYS exon 26 in hTERT-RPE1 cells. 
(A) RT-PCR analysis of EYS transcripts. hTERT-RPE1 cells with treated with AON6, AON7 or a 
combination of the two AONs (AON6 and AON7). Bands visible for non-treated (NT), AON6 treated, 
or AON7 treated cells correspond to normal EYS transcript. The band visible for cells treated with 
AON6 and AON7 corresponds to EYS transcript lacking exon 26. MQ: negative control of the PCR. (B) 
Sanger sequencing of the PCR product of hTERT-RPE1 cells treated with AON6 and AON7 confirmed 
skipping of exon 26.
Figure 6.5. Schematic overview of the differentiation protocol. 
AONs: antisense oligonucleotides; FCS: fetal calf serum; ROCKi: inhibitor of Rho-associated protein 
kinases; SAG: smoothened agonist.
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Figure 6.6. Characterization of patient-derived 3D retinal organoids. 
(A) Sanger sequencing of genomic DNA confirmed the presence of the c.4350_4356del mutation 
in patient-derived iPSCs. (B) Bright field microscopy images of iPSCs (day 0) and differentiated cells 
at day 30, day 60 and day 90. (C) Large balloon-like organoids were observed in patient-derived 
cells. (D) Pigmented cells (arrow) were seen in control and patient organoids. (E) Absolute gene 
expression of retinal markers in control and (F) patient cells. Values were normalized to GUSB. 
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did not observe this in patient cells treated with AON6. In addition, in contrast to what was 
observed in hTERT-RPE1 cells, treatment of control or patient cells with a combination of 
AON6 and AON7 did not result in the skipping of exon 26.
Figure 6.7. Efficacy of AONs in differentiated iPSCs. 
(A) RT-PCR analysis of EYS and actin transcripts in differentiated iPSCs from patient and control 
treated with AONs. SON: sense oligonucleotide (negative control); MQ: negative control of the PCR. 
(B) Sanger sequencing results of the band of control iPSCs treated with AON6. Parts of the exons that 
are covered by the sequence are depicted in the schematic overview in red.
6.4 Discussion
In this chapter, we aimed to study whether AON-mediated skipping of EYS exon 26 
could be a potential therapeutic approach for the treatment of retinal dystrophy caused 
by mutations in exon 26 of this gene. We showed that Δ26EYS is stable and equally 
expressed compared to full length EYS in HEK293T cells. We differentiated iPSCs into 3D 
retinal organoids in order to generate a cellular disease model. Some retinal markers were 
expressed in differentiated cells; however, overall expression levels were low. We did not 
observe clear differences between cells derived from a healthy control or from a patient. 
Furthermore, we showed that a combination of two AONs has the potential to skip exon 
26 in hTERT-RPE1 cells; however, we were not able to reproduce these results in patient-
derived 3D retinal organoids.
Antisense oligonucleotide-mediated exon skipping has shown to be successful in the 
treatment of DMD. The disease is caused by mutations in the DMD gene that affect the 
production of dystrophin protein. AONs have been designed for the skipping of each 
DMD exon or multiple exons.23 So far, skipping of one single exon of DMD seems to be 
the most promising strategy. Several AONs for single exon skipping of exon 53 (212 bp), 
exon 51 (233 bp), exon 45 (176 bp), or exon 44 (148 bp) are investigated in clinical trials.32 
These early phase clinical studies for the use of AON-mediated exon skipping as a therapy 
for DMD showed promising results.21,22 Aartsma-Rus et al. showed the successful joint 
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exon skipping of DMD exons 43+44, exons 45+51 and exons 45+51 in patient-derived 
myotubes.33 In vitro proof of concept studies for AON-mediated exon skipping were also 
reported for NOTCH3. Mutations in NOTCH3 are known to cause cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). 
Rutten et al. reported the successful skipping of exon 2-3 (222 bp), exon 4-5 (462 bp) or 
exon 6 (234 bp) in CADASIL patient-derived vascular smooth muscle cells.34 Compared to 
exon 26 of EYS (1767 bp), these fragments are all relatively small.
Before applying this strategy for the treatment of EYS-associated retinal dystrophy, we 
first evaluated whether the skipping of EYS exon 26 will lead to a stable protein. HEK293T 
cells were transfected with either full length EYS or Δ26EYS. Western blot analysis of the 
cell lysates revealed that Δ26EYS protein is stable and almost equally expressed compared 
to full length EYS. We also aimed to determine whether the Δ26EYS protein was localized 
correctly inside the cell. However, the immunocytochemistry data were inconclusive. The 
EYS signal that was observed in transfected cells was also detected in non-transfected 
cells, suggesting that this was background signal. Another explanation could be that this 
was endogenously expressed EYS, however, this is not very likely since expression levels 
are very low. The low immunofluorescence signal for EYS might be due to the fact that the 
antibody was not working properly for this purpose. The same antibody was also used 
for staining of zebrafish retinal sections using a similar procedure, with positive results 
(Chapter 4). Probably, the transfection efficiency was not high enough to be able to detect 
either full length EYS or Δ26EYS. We chose hTERT-RPE1 cells for localization experiments, 
because these cells have a large cytoplasmic compartment and do form cilia after serum 
starvation. It might be helpful to repeat this experiment using other cell types that also 
form cilia, but are easier to transfect compared to hTERT-RPE1 cells, such as COS-1 cells.35
The next step will be to determine whether the Δ26EYS protein is also functional. Since 
Eys is not present in several rodent species, like mouse and rat, they are not suitable as 
an animal model.4,5 Zebrafish might be a good alternative, since eys is expressed in this 
species and its retina is quite similar to that of the human retina. However, zebrafish does 
not have an equivalent of exon 26 of human EYS. As a consequence, functionality of the 
human Δ26EYS protein in zebrafish is not directly translatable towards humans.
Therefore, we aimed to model retinal dystrophy in a patient-specific genomic context by 
differentiating iPSCs into photoreceptors. In this study, direct differentiation of iPSCs was 
based on the differentiation protocol by Nakano et al.26 We followed the cells during the 
differentiation process by bright field microscopy and took samples at serial time-points 
for qRT-PCR analysis. Both patient and control cells formed organoids and size and shape 
were similar during the 90 days of differentiation. In the patient cell line we observed 
slightly larger organoids with a balloon-like structure presumably filled with fluid. At the 
start of differentiation, iPSCs derived from patient and control looked similar, although 
the patient line started at passage 9 and the control line at passage 28. It has been shown 
that extended passaging of iPSCs increases the differentiation efficiency into neural cell 
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types.36 This has to be taken into account when performing similar experiments in the 
future.
During differentiation, some morphological changes were observed, indicating 
differentiation. We could observe quite some pigmented cells, suggesting that some cells 
differentiated towards RPE cells. In addition, expression of RPE65 was also observed at 
different time points of differentiation. Therefore, we assumed that the differentiation 
went into the proper direction. However, other cell types, like melanocytes, could 
also show pigments. In our cultures we did not observe any evaginating transparent 
neuroretinal vesicles. Nakano et al. observed these evaginations after around two weeks 
of differentiation.26 In general, we believe that the differentiation of both cell lines was not 
very efficient. Several recent studies indicated already that the percentage of successful 
cultures resulting in neuroretinal vesicles is quite low.28,37 It is also known that there can 
be quite some variation not only between different cell lines, but also between different 
organoids derived from the same iPSC line. This is also what we observed and therefore 
complicated the analysis of the organoids. We did not select organoids based on size or 
morphology upon analysis, but organoids were randomly picked.
No clear expression of neuroretinal markers, such as CRX, NRL and OPN1SW, was observed 
after 90 days of differentiation. Some markers were expressed, however, in general, the 
expression of these genes was quite low. This could suggest that differentiation is not 
going fully towards neural retinal cell types. Another explanation could be that longer 
differentiation is required to be able to detect these markers. However, there are studies 
that report the expression of photoreceptor markers already around 12 weeks post-
differentiation.28,38
The successful differentiation towards photoreceptors depends on many factors. First 
of all the choice of cell type can influence the differentiation. We used iPSCs derived 
from human fibroblast, as what was described in a paper by Parfitt et al.13 Other groups 
use human embryonic stem cells (hESCs) for the differentiation into photoreceptors.26 
Looking at the transcriptional profile of iPSCs and ESCs, it appears that both cell types are 
almost identical, with a small number of genes that is differentially expressed between 
iPSCs and ESCs.39 However, due to epigenetic memory, some ESC genes are not highly 
induced in iPSCs. Furthermore, gene expression patterns from the somatic cell source are 
not always completely silenced in iPSCs.39-41 Another factor that influences the efficiency 
of the differentiation, is the culture medium used for differentiation. From day 20 onwards 
we used neuroretinal (NR) media, which contains retinoic acid (RA). It is described that RA 
promotes terminal differentiation of photoreceptors.42 However, it has also been shown 
that continuous RA supplementation suppresses cone maturation.43 Therefore, it might 
be helpful to optimize the protocol by using different concentration and durations of RA 
supplementation to the medium. Third, the duration of differentiation is an important 
factor. Some papers reported the successful differentiation of photoreceptor cells after 
~100 days. Others reported that 120-150 days were needed to obtain retinal cells. In our 
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study, we used a 90-days differentiation protocol that probably might be relatively short, 
especially when interested in protein expression and morphological differences between 
cell lines. Furthermore, to be able to monitor whether cells are going towards the right 
direction, an experienced person has to judge which organoids should continue in the 
differentiation process and which can be discarded.
Our study showed that a combination of two AONs was able to completely skip exon 26, 
at least in hTERT-RPE1 cells. However, these results could not be reproduced in further 
experiments with hTERT-RPE1 cells, nor in patient-derived iPSCs differentiated into 3D 
retinal organoids. In both cell types, we are working on the limit of detection, as for both 
cell types, nested PCR was necessary to be able to detect the EYS transcript. In addition, 
qPCR data of the differentiated iPSCs showed that EYS is expressed at day 90 in both control 
and patient cells, however, expression levels were very low. Furthermore, the discrepancy 
between the results observed in hTERT-RPE1 cells and iPSCs might be due to efficiency of 
AONs to enter the organoids. A study by Dulla et al. showed successful use of AONs in a 
3D retinal organoid model of LCA.15 Wild-type transcript levels of CEP290 were increased 
in a dose-dependent manner, with reaching 90% of the total transcript using an AON 
concentration of 10 µM. The levels of cryptic-exon including transcripts were reduced and 
the maximum reduction was already reached using an AON concentration of 3 µM.15
In iPSCs derived from a control, treatment with AON6 alone resulted in partly skipping 
of exon 25 and skipping of the majority of exon 26. Although we aimed to skip exon 26, 
this could still be a good result if the skipped part would not disrupt the reading frame. 
However, in total, 1792 base pairs are skipped, which means that this results in a frameshift 
and premature termination of protein translation. Remarkably, in patient cells, treatment 
with AON6 did not affect splicing.
A more robust experimental set-up should be used to indeed confirm that these AONs 
are able to skip exon 26 before continuing. A way to do this is to make use of a so-called 
midigene. Therefore, an EYS construct with flanking introns and exons needs to be cloned. 
This construct can then be transfected in HEK293T cells, which do not endogenously 
express EYS. Subsequently, cells are transfected with the AON and the effect on splicing 
can be evaluated by RT-PCR analysis. This experiment can be used to test proof-of-concept. 
A drawback of using the minigene approach is that no functional protein will be formed.
Once AON-mediated skipping of EYS exon 26 is proven to be efficacious, the next challenge 
is how to deliver the AONs to the photoreceptor cells. This will eventually also be important 
for the delivery of AONs in humans. Systemic delivery of AONs has been shown successful 
in a DMD mouse model.44 However, for treatment of retinal cells high doses are required, 
since it has to pass the blood-retina barrier. An alternative will be the direct delivery of 
the AON into the human eye via injections, either as naked AON or packaged into an 
AAV. Naked AONs are small and therefore able to reach and penetrate the photoreceptors 
more easily upon intravitreal injections, compared to AAVs that are injected subretinally. 
A drawback of naked AONs is their limited stability, which requires repeated injections. 
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In contrast, the use of AAVs could give long-time therapeutic benefit. Recently, ProQR 
published positive interim results of a first-in-human clinical trial (NCT03140969) of AONs 
(QR-110) in LCA patients. The majority of subjects demonstrated rapid and sustained 
improvement of vision, measured by visual acuity and mobility course. No serious adverse 
events were reported. (https://ir.proqr.com/news-releases/news-release-details/proqr-
announces-positive-interim-results-phase-12-clinical-trial). 
In conclusion, we showed that Δ26EYS encodes a stable protein. However, proper 
localization of the Δ26EYS protein still has to be investigated. Furthermore, we showed 
that a combination of two AONs targeting exon 26 are able to skip the complete exon 
in hTERT-RPE1 cells. However, quite some optimization is required to reproduce AON-
mediated skipping of EYS exon 26 in patient-derived 3D retinal organoids.
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6.6 Supplemental information
Supplementary Figure S1. Expression of stem cell markers in iPSCs. 
Undifferentiatied iPSCs derived from (A) control and (B) patient stained for the nuclear markers 
NANOG and OCT4 and surface antigens SSEA4 and TRA-1-81.
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Supplementary Figure S2. Gene expression of pluripotency markers during 
differentiation. 
Relative gene expression of pluripotency markers OCT3/4 and NANOG to iPSCs in patient and control 
cells. Normalized to GUSB.
Supplementary Table S1. 
Primers used for qPCR.
 Gene name Forward primer (5’ > 3’) Reverse primer (5’ > 3’)
SIX6 CCAGGCAACCGGACTGAC TGTGACAGGACCTGCTGCT
CRX ATGATGGCGTATATGAACCC TCTTGAACCAAACCTGAACC
OPN1SW GCTTCATTGTGCCTCTCTCC TTCAGCCTTCTGGGTCGTAG
ARR3 GGTGTTGTCCTGGTTGATCC GTCACAGAACAGGGCAGGTT
PDE6H CTCCCAAGTTCAAGCAGAGG ATCTGTTCCTAGCCCCTCCA
PDE6C TTGGGAACAAGGAGATCTGG AACAAAATCAATAAATCCAACTTGA
EYS TGTGGCAATTGGGATTTGCA GGATCGTTCACATAGGTTGCA
OCT3/4 GTTCTTCATTCACTAAGGAAGG CAAGAGCATCATTGAACTTCAC
NANOG TTCTTCCACCAGTCCCAAAG TTGCTCCACATTGGAAGGTT
PAX6 TCTAATCGAAGGGCCAAATG TGTGAGGGCTGTGTCTGTTC
NRL GTTTAGGTGCGCGACGGG ACAGACATCGAGACCAGCG
RHO CAACTACATCCTGCTCAACCTAGC GTGTAGTAGTCGATTCCACACGAG
RPE65 CGTGAGAACTGGGAAGAGGT AATTCTTGCCTGTGTCAGCC
GUSB AGAGTGGTGCTGAGGATTGG CCCTCATGCTCTAGCGTGTC
Supplemental Table S2. 
Primers used for RT-PCR analysis.
Fragment name Forward primer (5’ > 3’) Reverse primer (5’ > 3’)
EYS exon 25-27 PCR 1 TGCTCCATTGGGCTTCTTTG GCTTGACATACAGCAGAAGTCC
EYS exon 25-27 nested PCR ACTTTGGTCAGCAGCTTTCC GCTGAAGGTCTGAAATTCTAGGG
Actin ACTGGGACGACATGGAGAAG TCTCAGCTGTGGTGGTGAAG
Chapter 7
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Mutations in EYS are responsible for approximately 5-10% of all the autosomal recessive 
RP cases. In addition, there are also macular dystrophy and CRD patients described who 
harbor causative EYS mutations. Currently, there is no treatment for EYS-associated 
retinal dystrophy available and still very little is known about the underlying pathogenic 
mechanism. In this doctoral thesis, I have aimed to unravel the function of EYS and the 
pathogenic mechanism underlying EYS-associated retinal dystrophy, and to take the first 
steps towards a therapy for this disease. This chapter reviews our main discoveries and 
discusses future directions and challenges for the development of therapeutic approaches 
for retinal dystrophy caused by mutations in EYS.
7.1 The role of EYS in photoreceptors
Since the discovery of EYS in 2008 by two independent groups,1,2 many groups have 
reported on RP patients carrying mutations in EYS. However, limited data were, and still 
are, available about the function of EYS protein and its role in the development of retinal 
dystrophy. Therefore, I have aimed to unravel the function of EYS, in order to be able to get 
a better understanding of the pathogenic mechanism underlying EYS-associated retinal 
dystrophy.
When looking at the domain structure of the EYS protein, many epidermal growth factor 
(EGF)-like domains, mainly N-terminal, and five laminin A G-like (LamG) domains are 
predicted at the C-terminus (Chapter 1, section 1.5).1,2 The EGF domains are around 30-
40 amino acids long and are found in a large variety of, predominantly, animal proteins. 
These domains are mainly found in the extracellular parts of membrane-bound proteins 
or in proteins that are secreted.3 It has been described that EGF domains might be 
involved in cell signaling and adhesion, although the exact function of the EGF domain 
is not fully clear.4 The LamG domain is around 180 amino acids long and is found in 
one to six copies in various proteins of the laminin family as well as in a large number 
of other extracellular proteins. Laminin A G-like domains can vary in their function, and 
a variety of binding functions has been described for different LamG modules. Proteins 
containing LamG domains appear to have roles in a wide variety of processes, such as cell 
adhesion, cell signaling, migration, adhesion and differentiation.5 Another retinal protein 
described to have both EGF and LamG domains is CRB1. The CRB1 protein contains a short 
intracellular domain, a trans-membrane domain, and a large extracellular portion that 
includes EGF and LamG domains.6 Human CRB1 is expressed in the fetal brain, Müller cells 
and inner segments of photoreceptors and is considered to be crucial for photoreceptor 
morphogenesis.7-10 Furthermore, CRB1 has been described to play a role in mechanisms 
that control cell adhesion, polarity and intracellular communication.11 In addition to the 
EGF and LamG domains, a signal peptide is predicted to be present at the N-terminal end 
of the EYS protein. This might indicate that the protein is translocated to the (cellular) 
membrane, where it can be potentially cleaved and excreted. All together, this suggests 
that EYS is a protein with extracellular domains or a protein that is secreted.
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In Drosophila, the ortholog of EYS, also known as spam or spacemaker, is located in 
the inter-rhabdomere space of the compound eye of the fly. Here, it is shown to play a 
major role in proper formation of the inter-rhabdomere lumen, since in eys deficient flies 
the inter-rhabdomeral space was closed or collapsed.12 In Chapter 4, we describe the 
generation of an eys knock-out zebrafish line using CRISPR/Cas9 technology that allowed 
us to study EYS function in zebrafish. We showed that EYS localizes near the connecting 
cilium in wild-type zebrafish, whereas in eys mutant fish no EYS protein was observed. This 
was in line with the observation of Yu et al., who reported the localization of EYS in the 
region of the connecting cilium/transition zone in zebrafish. In the primate retina, EYS was 
not only located near the connecting cilium but also in the outer segments of rods and 
cones, and cone terminals.13 Another study by Alfano et al. reported localization of EYS in 
the ciliary axoneme in Y79 cells, and in macaque retinal sections, EYS was located in the 
photoreceptor ciliary axoneme of both rods and cones.14 Together, these results indicate 
that, in photoreceptor cells, EYS could be a protein involved in structural organization of 
the outer segments and/or maintaining the stability of the ciliary axoneme.
In Drosophila, Eys localizes extracellular in the inter-rhabdomere space, whereas in 
zebrafish and human it appears to be intracellular. This might suggest that the signal 
peptide is not cleaved in zebrafish and human. However, differences in localization 
between Drosophila and vertebrates might also be due to the morphological differences 
between the rhabdomeres and photoreceptors. Yu et al. suggest that EYS, like in 
Drosophila, is secreted into the lumen of the ciliary pocket, because they observed that 
in EYS deficient photoreceptors the ciliary pocket is collapsed or filled with vesicles.13 
Despite these morphological and localization differences, Drosophila and human EYS 
could possibly still have similar roles in the maintenance of photoreceptors, since their 
domain structures are very similar.
It will be essential to determine the precise location of the EYS protein with respect to 
the connecting cilium in order to explore the function of EYS, for example, by employing 
electron microscopy studies. In addition, co-localization with other ciliary proteins can be 
investigated, as well as the effect of the absence of EYS protein on ciliary trafficking of other 
ciliary proteins. Furthermore, it will be interesting to investigate whether EYS interacts with 
other ciliary proteins, in order to get more insights into its function. Techniques that can 
be used to study protein-protein interactions are the yeast two-hybrid system and protein 
complex affinity purification followed by mass spectrometry.15,16 With the yeast two-hybrid 
system, direct, binary interactions between two proteins that are ectopically expressed in 
a yeast cell can be identified, whereas with mass-spectrometry entire interacting protein 
complexes can be mapped without detailed information on their direct interactions.
Remarkably, Eys is not present in rodent species, such as mouse and rat. When looking 
at the morphology of photoreceptors, an important difference between rodents and 
other species is the absence of calyceal processes in rodents.17,18 These are axially oriented 
microvilli-like structures, near the connecting cilium, which form a collar around the base 
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of the outer segment in rods and cones. Calyceal processes have been suggested to play 
a role in the shaping and growing of the rod outer segments.17 It has also been predicted 
that calcium within the calyceal processes controls mechanical tension by regulating 
plus-directed motor myosin VIIa.19,20 Possibly, in humans, EYS function might be somehow 
related to these calyceal processes.
7.2 Spectrum of EYS-associated retinal dystrophy
In Chapter 2, we collected all reported EYS variants present in 377 arRP index cases 
published before June 2017. We also described 36 additional index cases, carrying 26 
novel variants. In the meantime, as expected since the discovery of EYS was only 10 years 
ago, several additional papers were published to report on retinal dystrophy patients that 
carry EYS variants.21-25 Novel EYS variants that were not included in Chapter 2 or Chapter 
3 are listed in Table 7.1.
In Chapter 3, we describe the phenotypic data in a cohort of 30 patients with EYS 
mutations. In addition to RP, there was one patient with cone-rod dystrophy (CRD) and 
two siblings with macular dystrophy. Cone-rod dystrophy patients with EYS mutations 
were also reported previously (Chapter 2),1,26 whereas EYS mutations in macular dystrophy 
patients were not reported before. Recently, Sun et al. reported an Usher syndrome patient 
with EYS mutations (p.(Asn773Lysfs*2) and p.(Gly2186Glu)). The patient complained about 
hearing loss since his middle age, but pure-tone audiometry examination showed normal 
results after his molecular testing.24 So it is not completely clear whether this patient has 
indeed Usher syndrome or just RP. Screening patients diagnosed with other IRDs than RP, 
such as macular dystrophy or CRD, for EYS variants might increase the diagnostic yield in 
currently unsolved cases.
Sengillo et al. described that variants occurring in positions closer to the C-terminus of 
EYS are more common in patients presenting with hyperautofluorescent rings on fundus 
autofluorescence imaging.23 In both Chapter 2 and Chapter 3, we were not able to draw 
any conclusions regarding the relationship between EYS variants and disease phenotype, 
nor could we identify obvious indications that individuals with protein-truncated variants 
had a more severe phenotype compared to patients with missense variants. The main 
reason for this is probably the small sample size in both studies. For example, in the cohort 
used in Chapter 3, many variants were observed only once. Furthermore, sometimes 
phenotypic data were not always clearly reported or not available. In addition, there is 
a lack of consistency in reporting disease manifestation and methods used for diagnosis 
between different clinical centers.
In Chapter 2, we described that many variants had to be classified as of uncertain 
significance, mainly because there was not enough evidence to meet one of the four 
pathogenicity criteria. This group consisted mainly of missense variants, but also some 
intronic variants and variants at the 5’-UTR were reported as of uncertain significance. One 
of the things that will help by the classification of these variants, but is not yet available, is 
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Table 7.1. 
EYS (NM_001142800.1) variants not described previously in this thesis.
Exon/
intron
DNA change Protein effect ACMG 
classification
Reference
Exon 6 c.963_979del p.(Pro321Profs*4) Pathogenic Sengillo23
Exon 7 c.1155T>A p.(Cys385*) Pathogenic McGuigan,21 
Sengillo23
Intron 7 c.1184+1G>A p.? Pathogenic Mucciolo25
Exon 9 c.1308C>A p.(Cys436*) Pathogenic Sengillo23
Exon 11 c.1641_1644del p.(Ser547Argfs*62) Pathogenic Sengillo23
Exon 11 c.1645G>T p.(Glu549*) Pathogenic Sengillo23
Exon 11 c.1682_1686del p.(Asn561Ilefs*7) Pathogenic Mucciolo25
Exon 12 c.1961dup p.(Asn654Lysfs*5) Pathogenic Sengillo23
Intron 13 c.2137+1G>A p.? Pathogenic McGuigan21
Intron 
14-18
c.2260-1437_2847-
6134del
p.(Ser754Ilefs*4) Pathogenic McGuigan21
Exon 15 c.2318dup p.(Asn773Lysfs*2) Pathogenic Sun24
Exon 16 c.2542C>T p.(Gln848*) Pathogenic Mucciolo25
Exon 19 c.2889T>A p.(Cys963*) Pathogenic McGuigan21
Intron 19 c.2992+1G>A p.? Pathogenic Sengillo23
Exon 23 c.3555C>G p.(Cys1185Trp) US Sengillo23
Exon 26 c.4152del p.(Pro1385Leufs*14) Pathogenic Mucciolo25
Exon 29 c.5928del p.(Arg1976Serfs*11) Pathogenic Sengillo23
Exon 29 c.5976T>A p.(Asn1992Lys) US Mucciolo25
Exon 31 c.6198_6201del p.(Gln2066Hisfs*16) Pathogenic Mucciolo25
Exon 32 c.6528C>A p.(Tyr2176*) Pathogenic McGuigan21
Intron 32 c.6571+5G>A p.? US Sengillo23
Intron 38 c.7578+1G>A p.? Pathogenic Sengillo23
Exon 42 c.8133_8137del p.(Phe2712Cysfs*33) Pathogenic Mucciolo25
Exon 42 c.8111T>G p.(Leu2704*) Pathogenic Sengillo23
Exon 43 c.8338_8342delinsa p.(Gly2780_Ser2781delinsTyrLysLeu*) Pathogenic McGuigan21
Exon 43 c.8411_8412insTT p.(Thr2805*) Pathogenic McGuigan21
Exon 43 c.8413dup p.(Thr2805Asnfs*7) Pathogenic Sengillo23
Exon 43 c.9178A>C p.(Ile3060Leu) US Mucciolo25
Exon 43 c.9317_9336del p.(Thr3106Lysfs*13) Pathogenic Sengillo23
Exon 43 c.9383_9387del p.(Lys3128Argfs*7) Pathogenic Sengillo,23 
Mucciolo25
ainserted sequence: TATAAACTATAAACTATAAACTATAAACTATAAACTATAAACTATAAACTATAAACTATA 
US: uncertain significance.
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experimental evidence. In Chapter 3, we showed how the effect of a variant on EYS pre-
mRNA splicing could be determined by using an in vitro minigene splice assay. This is a 
manageable method that also has been shown useful by others.27,28 Ideally, one would like 
to make use of patient-derived cells, from which RNA can be extracted to subsequently 
investigate EYS mRNA composition and levels. However, since EYS is predominantly 
expressed in the photoreceptor cells of the retina, alternative in vitro or in vivo systems 
that have sufficient EYS expression are needed. These models will be discussed in section 
7.3. 
7.3 Disease models for EYS-associated retinal dystrophy
The use of disease models can also help to give more insights into the function of EYS and 
its role in the pathogenesis of RP. One can either make use of in vivo models or cellular 
models. In Chapter 4, we described the generation of a zebrafish eys knock-out line 
using CRISPR/Cas9 technology, which allowed us to investigate EYS function in zebrafish. 
We showed that in eys deficient fish, the photoreceptor outer segments were highly 
disorganized. In addition, photoreceptor specific proteins such as rhodopsin and cone 
transducin, were mislocalized in eys-/- fish. Furthermore, these fish were visually impaired, 
showing a decreased ERG b-wave amplitude and a diminished VMR response. Two 
other groups reported on the generation of a zebrafish model for EYS-associated retinal 
dystrophy.13,29 The study by Yu et al. also generated mutations in the zebrafish using CRISPR/
Cas9 technology, and demonstrated a progressive loss of rod and cone photoreceptors, 
and disruption of the ciliary pocket of cones.13 Lu et al. used TALEN technology to create 
their eys knock-out line. Using ERG recordings, they showed that these fish were visually 
impaired. Furthermore, they reported F-actin disruption and mislocalization of retinal 
proteins in the absence of Eys.29 So far, these and our own zebrafish model are the only 
in vivo disease models reported for EYS-related retinal dystrophy. Since Eys is not present 
in mouse and rat, they are excluded from being used as a model.1,2 Alternative animal 
models could be for instance dog or pig (Chapter 1), which both do express Eys. The 
porcine retina is cone-rich, has an area centralis dorsal to the optic nerve,30 and lacks a 
tapetal zone,31 which makes it a good model to study IRDs, although the EYS gene is not 
completely annotated yet in pig. The dog retina is rod-dominated in most parts, but it 
does have a central area with a high density of cones.32 Drawbacks of the use of pig or 
dog as a model for retinal dystrophy are the ethical aspects, long regeneration time and 
housing.33
Since the discovery of reprogramming factors by the groups of Yamanaka and 
Thomson,34,35 the use of iPSCs for the differentiation into any cell type of interest became 
booming, leading to the rapid generation of disease-specific cellular models. We aimed to 
differentiate human-derived iPSCs into 3D optic cups using the differentiation protocol 
adapted from Nakano et al.,36 as described in Chapter 6. Using qRT-PCR analysis, we 
showed the expression of some retinal markers, indicating differentiation towards a retinal 
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fate. However, expression levels were very low. In addition, we observed the presence of 
pigmented cells, suggesting the development of RPE cells, although also other cells, like 
melanocytes, do form pigments. By using the experience we have from this differentiation 
together with protocols published by other groups, lessons can be learned to improve 
the differentiation in the future. Playing with the differentiation factors or extending 
differentiation time are examples of how the differentiation can be optimized (Chapter 
6). Besides the use of patient-derived iPSCs, it is also possible to use wild-type iPSCs 
and introduce a mutation manually by the use of CRISPR/Cas9 technology. In this way, 
variability between lines could be reduced.
In general, differentiation of iPSCs into retinal organoids is not easy and the challenges 
are manifold. The generation of retinal organoids takes at least several months and 
is largely dependent on manual manipulation and subjective selection criteria at 
initial stages. In addition, there is high variability among different human-derived iPSC 
lines37 and between iPSCs and ESCs.38 Hence, this results in variability in differentiation 
efficiency, structural features and expression of cell specific markers at a particular stage. 
Photoreceptors generated via iPSC differentiation reported so far, do not show fully 
mature outer segments. This could be due to the fact that the photoreceptors are not in 
direct contact with RPE cells, as in the human retina. It has been shown that aberrant RPE 
could affect photoreceptors by lack of outer segment morphogenesis.39 Further research 
is required to lead to the generation of better retinal organoids, including contact 
between photoreceptor cells and RPE cells and interactions between cell populations. 
Another challenge will be to include vascularisation in the retinal organoids. In this way, 
a more humanized model is created that can be used to study molecular mechanism 
underlying retinal dystrophy. Finally, it might be useful to introduce standardized, robust 
differentiation protocols, thereby increasing translational impact. In addition, there is a 
need for quantitative methods for the analysis of the retinal organoids.
The above mentioned disease models can also be used to study the effect of missense 
mutations. Since most of the missense variants described in Chapter 2 had to be classified 
as of uncertain significance, experimental evidence might help by their classification. 
Human-derived iPSCs can be used to determine the effect of missense mutations on 
the development and morphology of photoreceptors. Differentiated iPSCs derived from 
a patient can be compared to iPSCs derived from a healthy control. A huge drawback 
of the differentiation of human-derived iPSC is that this will be very time-consuming 
and labour-intensive. In addition, there is lot of variation in protocols currently used for 
the differentiation, leading to high variation in differentiation outcome. To be able to 
implement these techniques in clinical diagnostics, protocols have to be standardized. 
Moreover, robust quantitative methods are required for the analysis of these differentiated 
cells. We (Chapter 4) and others,13,29,40 previously reported on the disruption of eys in 
zebrafish using CRISPR/Cas9 or TALEN, leading to a retinal phenotype. In a similar way, 
missense mutations can be introduced and the effect of these mutations can be studied by 
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a variety of assays, such as immunohistochemistry, ERG and VMR measurement. However, 
due to differences between human EYS and its ortholog in zebrafish, not all variants can 
be tested. For instance, zebrafish eys is lacking an equivalent of exon 26 of human EYS, 
therefore mutations located in this exon are excluded from analysis. Similar as for iPSC, 
the use of in vivo models for the screening of EYS mutations will be expensive, labour 
intensive and time-consuming. Taken together, experimental evaluation of EYS variants 
for diagnostic purposes remains to be very challenging.
7.4 Potential therapies for EYS-associated retinal dystrophy
The retina is an accessible and immune-privileged structure, which makes it suitable 
for therapeutic intervention, including gene augmentation therapy. Previous studies 
already have shown that gene therapy for retinal disease can be effective and safe, both in 
animal models and clinical trials.41-44 In addition, the first gene therapy for retinal disease 
caused by mutations in RPE65, named LuxturnaTM, is recently approved by the US Food 
and Drug Administration (FDA). Most of the successful examples of gene therapy for 
retinal disease make use of AAV-mediated gene delivery into the retina.44,45 However, the 
limited cargo capacity of an AAV makes it unsuitable for delivery of the large EYS cDNA. 
Therefore, as described in Chapter 5, we generated EYS microgenes encoding proteins 
that will fit into an AAV. We have shown that at least two out of three EYS microgenes 
encode stable proteins. However, many different aspects of the EYS microgenes need 
to be evaluated in order to decide whether the microgenes are functional, and thus 
can be used for therapeutic purposes. First, localization studies need to be performed 
to assess whether the EYS microgene proteins are hosted at the right location in the 
cell. Unfortunately, we were not able to draw any conclusions on the localization of the 
microgenes based on our localization studies in hTERT-RPE1 cells. This was probably 
due to the low transfection efficiency of the cells. The use of other cell types that also 
contain cilia, such as COS-1 cells, might circumvent this problem. Second, it needs to be 
evaluated whether the EYS microgenes encode for functional proteins. To study this in a 
cellular model, one can make use of patient-derived iPSCs. To study the functionality of 
the microgenes in vivo, a zebrafish eys knock-out model with a clear retinal phenotype 
(as described in Chapter 4) will be a suitable model. Third, a suitable delivery strategy 
for the EYS microgenes needs to be developed. Microgene A can, together with a retinal 
specific promoter, be packaged into a single AAV vector. However, for the packaging of 
microgene B, two AAV vectors will be required. A dual-AAV vector approach was reported 
by Trapani et al., in which the gene was divided in two parts, and simultaneously delivered 
in separate AAV vectors.46 To be able to deliver larger genes, such as full length EYS, a triple 
AAV approach would be required. Additionally, lentiviral and nanoparticle-based delivery 
strategies for large genes, including ABCA4 and genes mutated in Usher syndrome, are 
also being investigated.47,48 However, for the full length EYS cDNA, a lentivirus will also 
not be sufficient, and a disadvantage of the use of lentiviruses is that they integrate 
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into the genome of the host cell, thereby running the risk of insertional mutagenesis. In 
addition, they do not efficiently target photoreceptor cells which are the primary target 
for EYS gene augmentation therapy. Another challenge of the use of gene augmentation 
therapy is that expression levels of the protein cannot be regulated, thereby risking that 
expression levels exceed those of endogenous protein, which in turn can lead to toxicity.
Besides gene therapy, the use of AONs as a therapeutic strategy for IRDs has also emerged 
over the last years. An advantage of the use of AONs over gene augmentation therapy is 
that they can be more easily delivered, since the small sequences fit in an AAV or can be 
delivered as naked AONs. In addition, AONs target the endogenous mRNA and therefore 
the maximum expression levels of the protein will never exceed that of the endogenous 
protein. The successful use of AONs for IRD has been shown for a deep-intronic variant 
in CEP290 (c.2991+1655A>G),49-51 and proof-of-concept studies for the use of AONs to 
correct splicing were published for deep-intronic variants in USH2A (c.7595-2144A>G) 
and OPA (c.610+364G>A).52,53 Recently, a study by Albert et al. showed AON-mediated 
splice correction of two neighboring deep-intronic mutations in ABCA4 causing Stargardt 
disease using iPSC technology.54 The use of AONs is proven not only to be effective for 
correction of intronic mutations, it also can be used for the skipping or inclusion of regular 
exons. AON-mediated exon skipping is currently one of the most promising therapeutic 
tools for DMD and promising results have also been reported for the treatment of 
CADASIL caused by mutations in NOTCH3.55,56 As a therapy for spinal muscular atrophy, 
AONs are used for the inclusion of exon 7 in SMN2 leading to the production of a 
functional protein.57 In Chapter 6, we aimed to investigate whether this AON-mediated 
exon skipping approach might also work as a therapy for EYS-related retinal dystrophy. We 
designed AONs for the skipping of EYS exon 26, a large exon which does not encode any 
functional domains. Skipping of this exon will not disrupt the reading frame. In addition, 
many protein truncated variants are located in this exon, including the most frequently 
reported p.(Ser1653Lysfs*2) variant in the Japanese population as described in Chapter 
2. We showed that EYS lacking exon 26 is translated into a stable protein by western blot 
analysis. As for the microgenes, patient-derived iPSCs can be used to investigate whether 
EYS protein lacking exon 26 (Δ26EYS ) is functional. Since there is no corresponding 
exon of human EYS exon 26 in zebrafish eys, functionality of the Δ26EYS protein cannot 
be studied in this animal model. As discussed in Chapter 4, the low complexity region 
encoded by exon 26 is also missing from chicken EYS. This might suggest that this region 
is not of great importance for the functionality of the EYS protein, at least not in vertebrate 
species. A blast search with the amino acid sequence of the low complexity region only 
gave hits of the human EYS protein and a small number of EYS orthologs, such as gorilla, 
macaque, pig and dog. We tested different AONs in hTERT-RPE1 cells and in iPSCs. The 
outcome of the two experiments was not consistent. In both experiments we worked at 
the limit of detection, since nested PCR was necessary to detect the EYS transcripts. An 
alternative for testing AONs is to make use of a so-called minigene, which contains at 
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least exon 26 and parts of the flanking introns. HEK293T cells can be transfected with the 
minigene and then treated with the AONs. The effect on splicing can then be evaluated 
by RT-PCR analysis. Eventually,  the AONs need to be tested in an in vivo model before they 
can be applied to human subjects. Unfortunately, there is no equivalent of human EYS 
exon 26 present in the zebrafish, which makes it unsuitable to test the AON approach in 
zebrafish. As mentioned before, dog and pig do show a low complexity region as seen in 
human EYS, which might be alternatives for the testing of AONs in vivo.
Figure 7.1. Schematic representation of candidate exons of EYS for AON-mediated 
skipping. 
Candidate exons for AON-mediated exon skipping are depicted in red. Colored lines underneath 
the exons represent functional domains. Dark green: epidermal growth factor (EGF) domain; light 
green: EGF-like domain; blue line: EGF calcium; yellow line: laminin A G-like domain.
In Chapter 6, we selected exon 26 of EYS as a target exon for AON-mediated exon skipping. 
In addition, there are several other candidate exons for AON-mediated exon skipping. In 
total, there are seven other EYS exons that, when skipped, do not lead to a frameshift 
(Figure 7.1). Besides the skipping of single exons, skipping of two or more exons, could 
also be a possible strategy. For instance, skipping of exon 7 or exon 8 alone will lead to 
disruption of the reading frame, whereas skipping of both exons together will leave the 
reading frame intact (Figure 7.1). The same holds true for exon 9 and exon 10, and even 
skipping of exons 7 until 10 could be a possibility. The fact that exons 8, 9 and 10 do not 
encode for any functional domains, makes this region even more interesting to target. In 
Chapter 2, we found eleven patients reported with retinal dystrophy carrying a protein 
truncating variant (eight unique variants) in one of these four exons of EYS. In papers 
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published after June 2017, an additional five patients were described to carry EYS variants 
(4 novel variants) in one of those exons (Table 7.1).
It has been recently discovered that prokaryotic immune components known as 
clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated 
nucleases, such as Cas9, are able to mediate genome editing in mammalian cells.58-60 
This CRISPR/Cas9 technology can be used to correct disease-causing mutations while 
leaving the gene under control of its endogenous regulation. The Cas9 nuclease cleaves 
double-stranded DNA at a specific target in the genome. These double-strand breaks 
are repaired by either the non-homologous end joining (NHEJ) pathway, introducing 
insertions and/or deletions at the target locus, or by the homology-directed repair (HDR) 
pathway, which allows precise genome editing using a donor DNA template for repair. 
For the treatment of retinal diseases, direct silencing of dominant negative mutations 
via the NHEJ pathway is most commonly used. For example, Bakondi et al. showed the 
allele specific disruption of Rhodopsin containing the p.(Ser334*) mutation in rats using 
CRISPR/Cas9.61 Next to inactivation of mutations, it is also possible to insert DNA to restore 
wild-type function of a gene using the HDR pathway.62,63 Preferably, therapeutic targets 
using CRISPR/Cas9 and the HDR pathway are selected based on the frequency of the 
variant. In this way, many patients can be treated with the same therapy, which makes 
it more cost-effective. Although EYS variants are found to be located across the entire 
gene, and no real mutational hotspot can be identified, there are some variants reported 
in quite some patients. As mentioned before, the p.(Ser1653Lysfs*2) variant is reported 
in 79 index patients, and thereby the most frequently reported variant in the Japanese 
population. In addition, the p.(Tyr2935*), p.(Tyr3135*) and p.(Ile2239Serfs*17) variants are 
reported in 38, 12, and 9 patients, respectively (Chapter 2). Interestingly, 21 patients with 
the p.(Tyr2935*) variant carried the p.(Ser1653Lysfs*2) variant on the other allele. When in 
the future a therapy will be developed using CRISPR/Cas9 in combination with HDR, these 
variants would be interesting candidates to target.
Although the results of using CRISPR/Cas9 as a therapeutic strategy are promising, still 
quite some challenges have to be overcome before it can be applied in the clinic, such as 
reduction of off-target effects and increasing the efficiency of gene editing and the rates 
of HDR in the eye.64,65 Besides the use on CRISPR/Cas9 technology on its own, it can also be 
combined with iPSCs to create a powerful therapeutic strategy for IRDs which can be used 
regardless of the disease state. Using CRISPR/Cas9, mutations can be corrected in patient-
derived iPSCs, which in turn can be differentiated into retinal cells and re-implanted into 
the eye.
Most of the above mentioned potential therapeutic strategies are only effective if they 
are applied in early stages of disease, when there is still retinal activity left. In later stages 
of disease, alternative treatment options such as retinal prosthesis, optogenetics and cell 
transplantation (as described in Chapter 1) can be the solution.
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7.5 Concluding remarks
Since the discovery of EYS in 2008, many retinal dystrophy patients have been reported 
to carry mutations in EYS, however, little was known about its exact function. With this 
thesis we provided more insights into EYS-related retinal dystrophy in relation to disease 
spectrum and development of a genetic therapy. There is still a lot to discover about 
EYS, especially about its exact localization, protein function and interactions with other 
proteins. Further studies may lead to a better understanding of the role of EYS in the 
pathogenesis underlying retinal dystrophy and photoreceptor degeneration and will 
progress the development of therapies for EYS-related retinal dystrophies. Gene therapy 
and other genetic therapeutic approaches are focused on the treatment of one specific 
disease. As a consequence, these therapies are only applicable to a small proportion of 
the IRD patients and thereby making it not very cost-effective. In the future, more effort 
should be made on the development of therapies that target a broader range of IRDs.
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Inherited retinal diseases (IRDs) are a heterogeneous group of blinding disorders 
characterized by progressive degeneration of retinal cells (Chapter 1, section 1.4). 
Mutations in Eyes shut homolog (EYS) are one of the most common causes of autosomal 
recessive (ar) retinitis pigmentosa (RP), an IRD characterized by the degeneration of 
photoreceptors (section 1.5). Since the discovery of EYS in 2008, numerous EYS variants 
have been found in patients with retinal dystrophy. However, there is a lack of studies 
that investigate the function of the gene and the EYS protein. Furthermore, there is no 
treatment available for EYS-related retinal dystrophy. With this thesis, we aimed to unravel 
the pathogenic mechanism underlying EYS-associated retinal dystrophy, which can serve 
as the basis for the development of therapeutic approaches for the disease.
Chapter 2 gives an overview of all 271 reported and 26 novel EYS variants reported 
in patients with retinal dystrophy. All these patients and their variants, together with 
phenotypic information (when available) were uploaded to the Leiden Open Variation 
Database (www.LOVD.nl/EYS). In addition, in silico assessment of all EYS variants was 
performed, as well as classification of all the variants according to their pathogenicity 
following the American College of Medical Genetics and Genomics (ACMG) guidelines. 
The variants covered the complete pathogenicity spectrum from likely benign to likely 
pathogenic, although the majority of the missense variants had to be classified as of 
uncertain significance. In this chapter, we highlight the need of functional assays to 
assess the pathogenicity of EYS variants, in order to improve molecular diagnostics and 
counseling of patients with EYS-related retinal dystrophy.
In Chapter 3, we describe the spectrum of retinal dystrophy and the course of visual 
function in a cohort of 30 patients carrying bi-allelic EYS variants. The majority of the 
patients were diagnosed with RP, and one patient had cone-rod dystrophy (CRD). In 
addition, two siblings diagnosed with macular dystrophy carried heterozygous EYS 
variants: c.1299+5_1299+8del and c.6050G>T (p.(Gly2017Val)). We showed that the 
c.1299+5_1299+8del mutation affects splicing using an in vitro minigene splice assay. This 
study indicates that screening of CRD and macular dystrophy patients for EYS variants 
might increase diagnostic yield in previously unsolved cases.
Chapter 4 describes the generation of an eys knock-out zebrafish line using CRISPR/Cas9 
technology to allow us to study Eys function in zebrafish. We showed that Eys localizes 
at the region of the connecting cilium. In the absence of Eys, photoreceptor architecture 
was disorganized and photoreceptor specific protein rhodopsin and cone transducin 
were mislocalized. Furthermore, electroretinogram (ERG) recordings showed diminished 
b-wave amplitudes in eys deficient zebrafish (5 dpf ) compared to wild-type zebrafish. 
In addition, a decrease in visual motor response (VMR) was observed in the eys mutant 
fish. In conclusion, this chapter showed that Eys is important for maintenance of the 
photoreceptor architecture and visual function in zebrafish.
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Chapter 5 describes the generation of three EYS microgenes that can be used as a potential 
therapeutic approach for the treatment of EYS-associated retinal dystrophy. Based on 
conservation analysis of the EYS domains, we selected the most conserved regions of EYS 
to be part of one or more microgenes. Western blot analysis showed that at least two out 
of three microgenes are stable. Further research is necessary to investigate whether the 
EYS microgenes localize properly in the cell, whether the microgenes are functional, and 
how they can be delivered to the photoreceptors. 
In Chapter 6, we describe the design of AONs for skipping of EYS exon 26 as a therapeutic 
approach for retinal dystrophy cause by mutations in this exon. Western blot analysis 
revealed that EYS lacking exon 26 (Δ26EYS) encodes a stable protein. AON efficacy was 
tested in hTERT-RPE1 cells. Transcriptional analysis of cells treated with AONs showed that 
a combination of two AONs resulted in skipping of exon 26, whereas the use of one of the 
AONs alone had no effect. In order to investigate the potential of AON-mediated exon 
skipping in patients, we differentiated patient-derived iPSCs into 3D optic cups. Treatment 
of these 3D cups with the AONs did not show any effect on EYS transcripts except in 
control cells treated with AON6. Sanger sequencing confirmed partial skipping of exon 
25 and exon 26 in those samples, in contrast to what was observed in hTERT-RPE1 cells. 
This chapter is a first attempt towards the development of AON-mediated exon skipping 
therapy for retinal dystrophy patients with mutations in EYS exon 26.
In Chapter 7, the main findings of this thesis are discussed. The role of EYS in the 
photoreceptor and the future prospects on how to get more insight in its exact function 
are discussed in section 7.1. We analyze the spectrum of EYS-associated retinal dystrophy 
in section 7.2 and discuss how the pathogenicity of variants can be experimentally 
assessed in the future. In section 7.3, we discuss the available animal and cellular disease 
models to study EYS-associated retinal dystrophy. Finally, potential therapies for EYS-
associated retinal dystrophy, such as AON-mediated therapy, (micro)gene therapy, and 
CRISPR/Cas9 technology, are discussed in section 7.4. 
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Erfelijke netvliesaandoeningen vormen een heterogene groep van blindheid die 
gekenmerkt wordt door progressieve degeneratie van cellen in het netvlies (Hoofdstuk 
1, paragraaf 1.4). Retinitis pigmentosa (RP) is een vorm van erfelijke blindheid waarin 
de fotoreceptorcellen afsterven. Mutaties in het gen Eyes shut homolog (EYS) zijn één van 
de meest voorkomende oorzaken van autosomaal recessief overervende RP (paragraaf 
1.5). Het EYS gen is ontdekt in 2008 en sindsdien zijn er veel RP patiënten gevonden 
met mutaties in dit gen. Er is echter nog maar weinig bekend over de daadwerkelijke 
functie van het gen en het gecodeerde EYS eiwit. Op dit moment is er nog geen therapie 
beschikbaar voor patiënten met netvliesaandoeningen die veroorzaakt zijn door EYS 
mutaties. Het doel van dit proefschrift was om meer inzicht te verkrijgen in de rol die EYS 
speelt bij het ontstaan van netvliesdegeneratie en om een eerste stap te zetten richting 
het ontwikkelen van mogelijke therapieën.
In Hoofdstuk 2 geven we een overzicht van alle 271 EYS varianten die zijn gerapporteerd 
in patiënten met netvliesdegeneratie. Daarnaast bespreken we ook 26 nieuwe varianten 
die nog niet eerder gerapporteerd waren. Alle beschikbare informatie over het 
ziektebeeld van deze patiënten met hun varianten zijn opgenomen in de Leiden Open 
Variation Database (www.LOVD.nl/EYS). Alle varianten zijn geclassificeerd op basis van 
hun pathogeniciteit met behulp van de richtlijnen van de American College of Medical 
Genetics and Genomics (ACMG). De varianten bekleedden alle mogelijke klassen van 
oorzakelijk tot niet oorzakelijk. Een groot deel van de (met name) missense varianten kon 
niet met zekerheid worden ingedeeld in een van de pathogeniciteitsklassen. Om deze 
varianten toch goed te kunnen classificeren zijn er functionele experimenten nodig. Een 
beter inzicht in de ernst van de EYS varianten zorgt ervoor dat een betere diagnose gesteld 
kan worden bij patiënten, waardoor ze beter geholpen kunnen worden.
Het complete ziektebeeld van 30 patiënten met bi-allelische EYS varianten wordt 
beschreven in Hoofdstuk 3. Het merendeel van de patiënten was gediagnosticeerd met 
RP en er was één patiënt met kegel-staaf dystrophy. Daarnaast waren er twee broers met 
macula degeneratie die drager waren van twee heterozygote EYS varianten, namelijk 
c.1299+5_1299+8del en c.6050C>T (p.(Gly2017Val)). Met behulp van een in vitro minigen 
splice assay hebben we aangetoond dat de c.1299+5_1299+8del variant een effect 
heeft op mRNA splicing. Screening van patiënten met macula degeneratie of kegel-staaf 
dystrophy voor EYS varianten zou kunnen helpen bij het stellen van de juiste diagnose.
Om de functie van EYS te kunnen bestuderen in de zebravis hebben we een zebravis eys 
knock-out model gemaakt met behulp van CRISPR/Cas9 technologie. Dit staat beschreven 
in Hoofdstuk 4.  Lokalisatie studies lieten zien dat Eys zich bevindt in de regio van het 
connecting cilium. De morfologie van fotoreceptorcellen was afwijkend in de afwezigheid 
van Eys. Ook hebben we aangetoond dat de fotoreceptor specifieke eiwitten rhodopsin 
en cone transducin niet goed gelokaliseerd worden in eys mutanten. Verder lieten ERG 
opnames een kleinere b-golf amplitude zien in mutanten in vergelijking met wild-type 
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larves. Tenslotte zagen we ook dat de visuele motor respons in eys knock-out zebravissen 
was afgenomen. Hieruit kunnen we concluderen dat Eys belangrijk is voor de morfologie 
van fotoreceptorcellen en de visuele functie in zebravissen.
In Hoofdstuk 5 hebben we een eerste stap gezet in de richting van het ontwikkelen van 
een microgentherapie voor patiënten met netvliesdegeneratie veroorzaakt door EYS 
mutaties. We hebben hiervoor drie verschillende EYS microgenen ontworpen die zijn 
opgebouwd uit de belangrijkste geconserveerde domeinen van het EYS eiwit. Met behulp 
van western blot hebben we aangetoond dat twee van de drie microgenen stabiele 
eiwitten kunnen vormen. Verder onderzoek is nodig om te bepalen of de microgenen op 
de juiste plek in de cel lokaliseren, of ze ook daadwerkelijk functioneel zijn en hoe ze de 
fotoreceptoren het beste kunnen bereiken.
Het doel van Hoofdstuk 6 was om exon 26 van EYS te excluderen van het mRNA met 
behulp van antisense oligonucleotiden (AONs), zodat we een potentiële therapie kunnen 
ontwikkelen voor patiënten met EYS mutaties die gelegen zijn in dit exon. Met behulp 
van western blot hebben we aangetoond dat EYS zonder exon 26 (Δ26EYS) codeert voor 
een stabiel eiwit. De werkzaamheid van de AONs werd eerst getest in hTERT-RPE1 cellen. 
Analyse van EYS transcripten van behandelde cellen liet zien dat behandeling met een 
combinatie van twee AONs kan leiden tot skipping van exon 26. Om te onderzoeken of 
we exon 26 ook kunnen uitsluiten in patiënten cellen hebben we pluripotente stamcellen 
afkomstig van een patiënt met een mutatie in exon 26 gedifferentieerd in netvlies cellen. 
In het merendeel van de cellen zagen we geen effect van de AON behandeling op de EYS 
transcripten. Een uitzondering hierop waren controle cellen die behandeld waren met 
AON-6. Sanger sequencing bevestigde dat in deze cellen een deel van exon 25 en het 
grootste deel van exon 26 afwezig waren. Dit in tegenstelling tot wat we eerder zagen 
in de hTERT-RPE1 cellen. Dit hoofdstuk beschrijft een eerste poging tot het ontwikkelen 
van exon exclusie therapie met behulp van AONs voor netvliesdegeneratie patiënten met 
mutaties in exon 26 van EYS.
De meest belangrijke bevindingen van dit proefschrift werden bediscussieerd in Hoofdstuk 
7. In paragraaf 7.1 bediscussiëren we de mogelijke rol van EYS in de fotoreceptorcellen, 
alsmede hoe verder onderzoek kan zorgen dat de exacte functie van EYS beter in kaart 
kan worden gebracht. Het ziektebeeld van patiënten met netvliesdegeneratie dat 
veroorzaakt wordt door EYS mutaties wordt besproken in paragraaf 7.2. Ook gaan we 
hier dieper in op de mogelijke experimenten die uitgevoerd kunnen worden, zodat er 
meer duidelijkheid komt over de ernst van de varianten. In paragraaf 7.3 beschrijven we 
welke dier- en celmodellen er beschikbaar zijn om EYS-gerelateerde netvliesdegeneratie 
te bestuderen. Als laatste bespreken we in paragraaf 7.4 hoe AONs, (micro)gentherapie 
en CRISPR/Cas9 technologie mogelijk kunnen worden ingezet als therapie voor patiënten 
met netvliesdegeneratie en EYS mutaties.
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204   | Donders Graduate School for Cognitive Neuroscience
Donders Graduate School for Cognitive Neuroscience
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Data management
Type of data Subject 
to 
privacy 
(yes/no)
Way of 
anonymization
Storage
Antibodies No n.a. Antibodies were registered in the antibody 
database from the Department of Human Genetics 
in Labguru: https://radboudumc.labguru.com/
biocollections/antibodies. Antibodies were stored 
with a traceable number in the assigned freezer/
fridge at the Department of Human Genetics, 
according to the manufacturer’s instructions.
Fluorescence 
images
No n.a. Fluorescence imaging data was stored on the 
private network of the Blindness Genetics Therapy 
group at the Department of Human Genetics: T:\
PIgroup-Rob-Collin\02 Microscopy images\09 
Muriel Messchaert.
Plasmids No n.a. Plasmids were registered in the Blindness Genetics 
Therapy database and assigned to a pGT-number. 
H:\GR Theme groups\10 PI Group Rob Collin\05 
Vector_AAV_AON Database. Plasmids were stored in 
the assigned freezer at -80°C at the Department of 
Human Genetics.
Patient-derived 
cell lines
Yes All patients 
received an 
untraceable 
number, the 
identity of 
the patient is 
only known by 
the treating 
physician.
Cell lines received a traceable number and 
were registered at the cell culture facility of the 
Department of Human Genetics. Cell lines were 
frozen in liquid nitrogen and stored in the assigned 
freezer at -80°C at the Department of Human 
Genetics. The number of the cell lines used can 
be found in the labjournal of Muriël Messchaert, 
stored at the Department of Human Genetics or in 
Labguru in the EYS project: https://radboudumc.
labguru.com/knowledge/projects/701. Contact 
person to find the cell lines in the assigned freezer: 
Saskia van der Velde-Visser.
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Other cell lines No n.a. Cell lines were stored with a traceable number 
at the cell culture facility at the Department of 
Human Genetics, according to the manufacturer’s 
instructions. The number of the cell lines used can 
be found in the labjournal of Muriël Messchaert, 
stored at the Department of Human Genetics or in 
Labguru in the EYS project: https://radboudumc.
labguru.com/knowledge/projects/701. Contact 
person to find the cell lines in the assigned freezer: 
Saskia van der Velde-Visser.
n.a.: not applicable.
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